Solid forms of heteroaromatic macrocyclic ether compounds, pharmaceutical compositions and preparation

By providing solid forms of ROS1 and ALK inhibitors, the problems of limited CNS activity and resistance mutation in the prior art are solved, effective inhibition of ROS1 and ALK and drug stability are achieved, and suitable for commercial scale production.

CN119072481APending Publication Date: 2024-12-03NUVALENT INC

Patent Information

Application Number
CN202380035934.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-07
Filing Date
2023-04-06
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing ROS1 and ALK inhibitors have problems with limited CNS activity and insufficient activity against resistant mutations in the treatment of ROS1-positive or ALK-positive patients, resulting in adverse reactions and difficulty in preparing safe, scalable and economically feasible for commercial scale drug form.

Method used

Provided is a solid form comprising a compound of formula (I), including its crystalline form, amorphous form and free base form, to prepare a pharmaceutical composition by a specific preparation method for the treatment of cancer, including the use of Compound 1 and its pharmaceutically acceptable. Accepted salts and excipients to ensure the stability and effectiveness of the drug.

Benefits of technology

Effective inhibition of ROS1 and ALK is achieved, adverse reactions in CNS are reduced, the safety and expansion of drugs are improved, the physical and chemical stability of drugs are ensured, and suitable for commercial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072481A_ABST
    Figure CN119072481A_ABST
Patent Text Reader

Abstract

Provided herein are solid forms comprising a compound of Formula (I) or a stereoisomer or a mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing compounds of Formula (I), pharmaceutical compositions comprising compounds of Formula (I), and methods of treating, preventing, and managing various conditions using the compositions provided herein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to U.S. Serial No. 63 / 328,609, filed April 7, 2022, which is incorporated herein by reference in its entirety. Background Technology

[0002] Receptor tyrosine kinases (RTKs) are cell surface enzymes that receive external signals, such as whether to grow and divide, and transmit those signals within the cell through kinase activity. Many RTKs are proto-oncogenes; abnormal RTK activity can drive cell survival, growth, and proliferation, leading to cancer and related conditions. This abnormal kinase activity can be caused by mutations, such as activating mutations in the kinase domain, gene rearrangements leading to fusion proteins containing intact kinase domains, amplification, and other mechanisms. RTK proto-oncogenes include ROS1, anaplastic lymphoma kinase (ALK), NTRK1 (encoding TRKA), NTRK2 (encoding TRKB), and NTRK3 (encoding TRKC).

[0003] ROS1 is an RTK proto-oncogene, and ROS1 rearrangements have been detected in non-small cell lung cancer (NSCLC), glioblastoma, inflammatory myofibroblastic tumor (IMT), cholangiocarcinoma, ovarian cancer, gastric cancer, colorectal cancer, angiosarcoma, and spitzoid melanoma. Oncogenic ROS1 gene fusions contain the kinase domain (3' region) of ROS1 fused to the 5' region of various partner genes. Examples of ROS1 fusion partner genes observed in NSCLC include SLC34A2, CD74, TPM3, SDC4, EZR, LRIG3, KDELR2, CEP72, CLTL, CTNND2, GOPC, GPRC6A, LIMA1, LRIG3, MSN, MYO5C, OPRM1, SLC6A17 (presumed), SLMAP, SRSF6, TFG, TMEM106B, TPD52L1, ZCCHC8, and CCDC6. Other fusion partners include CAPRIN1, CEP85L, CHCHD3, CLIP1 (presumed), EEF1G, KIF21A (presumed), KLC1, SART3, ST13 (presumed), TRIM24 (presumed), ERC1, FIP1L1, HLAA, KIAA1598, MYO5A, PPFIBP1, PWWP2A, FN1, YWHAE, CCDC30, NCOR2, NFKB2, APOB, PLG, RBP4, and GOLGB1.

[0004] ALK is an RTK proto-oncogene that has been detected in many cancers, including NSCLC, anaplastic large cell lymphoma (ALCL), IMT, diffuse large B-cell lymphoma (DLBCL), esophageal squamous cell carcinoma (ESCC), renal medullary carcinoma, renal cell carcinoma, breast cancer, colon cancer, serous ovarian cancer, papillary thyroid carcinoma, and Spitz nevus-like tumors. ALK activating mutations have also been detected in neuroblastoma. Oncogenic ALK gene fusions contain an ALK kinase domain (3' region) fused to the 5' region of more than 20 different partner genes, the most common of which are EML4 in NSCLC and NPM in ALCL. Other partner genes include TMP1, WDCP, GTF2IRD1, TPM3, TPM4, CLTC, LMNA, PRKAR1A, RANBP2, TFG, FN1, KLC1, VCL, STRN, HIP1, DCTN1, SQSTM1, TPR, CRIM1, PTPN3, FBXO36, ATIC, and KIF5B kinases.

[0005] NTRK1, NTRK2, and NTRK3 are RTK proto-oncogenes encoding TRK family kinases, among which NTRK1, NTRK2, and NTRK3 chromosomal rearrangements are detected at low frequencies in many cancers. However, for the treatment of ROS1-positive or ALK-positive patients, TRK inhibition has caused adverse reactions, particularly in the central nervous system (CNS), including dizziness / ataxia / gait disturbances, paresthesia, weight gain, and cognitive changes.

[0006] Prior art agents for treating oncogenic ROS1 and ALK have significant drawbacks. These drawbacks may represent one or more of the following: associated TRK inhibition, limited CNS activity, and insufficient activity against resistant mutations. Treatment of ROS1-positive or ALK-positive patients with TRK inhibition results in adverse reactions, particularly in the CNS, including dizziness / ataxia / gait disturbances, paresthesia, weight gain, and cognitive changes. Additionally, CNS penetrants and TRK-retaining inhibitors of wild-type ROS1 kinase domains and ROS1 with acquired resistance mutations, occurring alone or in combination, are needed. These acquired resistance mutations include G2032R, D2033N, S1986F, S1986Y, L2026M, L1951R, E1935G, L1947R, G1971E, E1974K, L1982F, F2004C, F2004V, E2020K, C2060G, F2075V, V2089M, V2098I, G2101A, D2113N, D2113G, L2155S, L2032K, and L2086F. Similarly, CNS penetrants and TRK-retaining inhibitors of ALK with acquired resistance mutations are also needed. A variety of ALK resistance mutations, occurring alone or in combination, have been reported, including G1202R, L1196M, G1269A, C1156Y, I1171T, I1171N, I1171S, F1174L, F1174S, V1180L, S1206Y, E1210K, 1151Tins, T1151M, F1174C, G1202del, D1203N, S1206Y, S1206C, L1152R, L1196Q, L1198P, L1198F, R1275Q, L1152P, C1156T, and F1245V.

[0007] Furthermore, for the production of active pharmaceutical ingredients intended for human use, appropriate procedures are required to control impurity levels and ensure that the API product consistently meets its intended specifications. Therefore, a method is needed to prepare ROS1 and ALK inhibitors suitable for human use, especially on a commercial scale, i.e., particularly safe, scalable, effective, economically viable, and / or possessing other desired properties. Among other entities, crystalline forms and pharmaceutical compositions comprising such crystalline forms are disclosed herein to meet these needs and provide exemplary advantages. Summary of the Invention

[0008] This document provides a solid form of a compound comprising formula (I) (also known as compound 1) or a stereoisomer or mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof:

[0009]

[0010] In some embodiments, the solid form is a crystalline form. In other embodiments, the solid form is an amorphous form. In some embodiments, the solid form is a solid form of a compound of formula (I). In some embodiments, the solid form is a solid form of a free base of a compound of formula (I). In some embodiments, the solid form is a crystalline form of a free base of a compound of formula (I).

[0011] This document also provides methods for preparing the solid form of the compound. In some embodiments, this document provides methods for preparing the solid form of the free base of formula (I).

[0012] This article also provides a method for treating cancer, the method comprising administering a therapeutically effective amount of a compound of formula (I) provided herein in solid form to a subject in need.

[0013] This document also provides pharmaceutical compositions comprising a solid form of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises a solid form of a free base of a compound of formula (I). In some embodiments, the pharmaceutical composition comprises a solid form of a pharmaceutically acceptable salt of a compound of formula (I).

[0014] This article also provides preparative (II) compounds:

[0015]

[0016] A method for the use of its stereoisomers or mixtures thereof, or pharmaceutically acceptable salts thereof, the method comprising:

[0017] (Step 2.0) Make compound (III) into:

[0018]

[0019] The reaction of its stereoisomers or mixtures of stereoisomers or its pharmaceutically acceptable salts with a brominating agent.

[0020] This article also provides methods for preparing compounds of formula (II):

[0021]

[0022] A method for the use of its stereoisomers or mixtures thereof, or pharmaceutically acceptable salts thereof, the method comprising:

[0023] (Step 2a.1) Make compound of formula (XXIX):

[0024]

[0025] Or its stereoisomers or mixtures of stereoisomers or its pharmaceutically acceptable salts with compounds of formula (XXX):

[0026]

[0027] Or a pharmaceutically acceptable salt reaction.

[0028] In some implementations, the method further includes:

[0029] (Step 1.0) Cyclate the compound of formula (II) or a stereoisomer or mixture of stereoisomers or a pharmaceutically acceptable salt thereof to provide the compound of formula (I):

[0030]

[0031] Or its stereoisomers or mixtures of stereoisomers or its pharmaceutically acceptable salts.

[0032] This article also provides a method for treating cancer, which includes administering a therapeutically effective amount of the solid form provided herein.

[0033] This article also provides pharmaceutical compositions comprising compound 1:

[0034]

[0035] Or its stereoisomers or mixtures thereof, or pharmaceutically acceptable salts, diluents, disintegrants, gliding agents, binders and lubricants.

[0036] This article also provides a method for treating cancer, the method comprising administering a therapeutically effective amount of the pharmaceutical composition provided herein.

[0037] This article also provides salts of compounds of formula (II):

[0038]

[0039] This article also provides the solid form of salts containing compounds of formula (II):

[0040]

[0041] 3. Incorporate by reference

[0042] All publications, patents and patent applications mentioned in this specification are incorporated herein by reference in their entirety as if each individual publication, patent or patent application were specifically and individually indicated to be incorporated by reference. Attached Figure Description

[0043] Figure 1AThe representative X-ray powder diffraction (XRPD) pattern of compound 1 in its free base form 1 (2-methylTHF solvate); Figure 1B This is a representative XRPD spectrum of the free base form 1 (isopropyl acetate solvate) of compound 1.

[0044] Figure 2 The representative integrated thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) spectra of compound 1 in its free base form 1 (2-methylTHF solvate).

[0045] Figure 3 The representative integrated thermal TGA and DSC spectra of compound 1 in its free base form 1 (isopropyl acetate solvate) are shown.

[0046] Figure 4 This is a representative XRPD spectrum of compound 1 in its free base form 2.

[0047] Figure 5 This is a representative DSC thermogram of the free base form 2 of compound 1.

[0048] Figure 6 The DVS isotherm is representative of the free base form 2 of compound 1.

[0049] Figure 7 A representative depiction of the a-axis of the unit cell in a single-crystal X-ray diffraction study of the free base form 2 of compound 1.

[0050] Figure 8 This is a representative XRPD spectrum of the free base form 3 of compound 1.

[0051] Figure 9 The following is a representative integrated TGA and DSC thermogram of the free base form 3 of compound 1.

[0052] Figure 10 This is a representative XRPD spectrum of the free base form 4 of compound 1.

[0053] Figure 11 The following is a representative integrated TGA and DSC thermogram of the free base form 4 of compound 1.

[0054] Figure 12A The XRPD spectrum is a representative representation of the free base form 5 (a mixed solvate of tert-butanol and isopropanol) of compound 1. Figure 12B The XRPD spectrum is a representative representation of the free base form 5 (a mixed solvate of tert-butanol and acetone) of compound 1. Figure 12C The image shows a representative XRPD pattern of compound 1 in its free base form 5 (a mixed solvate of tert-butanol and THF).

[0055] Figure 13 The integrated TGA and DSC thermograms represent the free base form 5 (a mixed solvate of tert-butanol and isopropanol) of compound 1.

[0056] Figure 14 The following is a representative integrated TGA and DSC thermogram of the free base form 5 (a mixed solvate of tert-butanol and acetone) of compound 1.

[0057] Figure 15 The following is a representative integrated TGA and DSC thermogram of the free base form 5 (a mixed solvate of tert-butanol and THF) of compound 1.

[0058] Figure 16 This is a representative XRPD spectrum of the free base form 6 of compound 1.

[0059] Figure 17 This is a representative XRPD spectrum of compound 1 in its free base form 7.

[0060] Figure 18 The following is a representative integrated TGA and DSC thermogram of the free base form 7 of compound 1.

[0061] Figure 19 This is a representative XRPD spectrum of compound 1 in its free base form 8.

[0062] Figure 20 The following is a representative integrated TGA and DSC thermogram of the free base form 8 of compound 1.

[0063] Figure 21 The image shows a representative XRPD pattern of compound 1 in its free base form, 9.

[0064] Figure 22 The following is a representative integrated TGA and DSC thermogram of the free base form 9 of compound 1.

[0065] Figure 23 The image shows a representative XRPD pattern of compound 1 in its free base form, 10.

[0066] Figure 24 The following is a representative integrated TGA and DSC thermogram of the free base form 10 of compound 1.

[0067] Figure 25 The image shows a representative XRPD pattern of compound 1 in its free base form, 11.

[0068] Figure 26 The following is a representative integrated TGA and DSC thermogram of the free base form 11 of compound 1.

[0069] Figure 27This is a representative XRPD spectrum of compound 1 in its free base form 12.

[0070] Figure 28 The following is a representative integrated TGA and DSC thermogram of the free base form 12 of compound 1.

[0071] Figure 29 This is a representative XRPD pattern of compound 1 in its free base form 13.

[0072] Figure 30 The following is a representative integrated TGA and DSC thermogram of the free base form 13 of compound 1.

[0073] Figure 31 The image shows a representative XRPD pattern of compound 1 in its free base form, 14.

[0074] Figure 32 The following is a representative integrated TGA and DSC thermogram of the free base form 14 of compound 1.

[0075] Figure 33 The image shows a representative XRPD pattern of compound 1 in its free base form, 15.

[0076] Figure 34 The following is a representative integrated TGA and DSC thermogram of the free base form 15 of compound 1.

[0077] Figure 35 The image shows a representative XRPD pattern of methanesulfonate form A of compound 2.

[0078] Figure 36 This is a representative DSC thermogram of methanesulfonate form A of compound 2.

[0079] Figure 37 This is a representative TGA thermogram of methanesulfonate form A of compound 2.

[0080] Figure 38 The image shows a representative XRPD pattern of camphor sulfonate form A of compound 2.

[0081] Figure 39 The image shows a representative DSC thermogram of camphor sulfonate form A of compound 2.

[0082] Figure 40 The image shows a representative TGA thermogram of camphor sulfonate form A of compound 2.

[0083] Figure 41 The representative DVS isotherm is for camphor sulfonate form A of compound 2.

[0084] Figure 42The image shows a representative XRPD pattern of ethanesulfonate form A of compound 2.

[0085] Figure 43 This is a representative DSC thermogram of ethanesulfonate form A of compound 2.

[0086] Figure 44 This is a representative TGA thermogram of ethanesulfonate form A of compound 2.

[0087] Figure 45 The DVS isotherm is representative of the ethanesulfonate form A of compound 2.

[0088] Figure 46 This is a representative XRPD spectrum of the sulfate form A of compound 2.

[0089] Figure 47 This is a representative DSC thermogram of the sulfate form A of compound 2.

[0090] Figure 48 This is a representative TGA thermogram of the sulfate form A of compound 2.

[0091] Figure 49 The DVS isotherm is representative of the sulfate form A of compound 2.

[0092] Figure 50 The image shows a representative XRPD pattern of toluenesulfonate form A of compound 2.

[0093] Figure 51 This is a representative DSC thermogram of toluenesulfonate form A of compound 2.

[0094] Figure 52 The image shows a representative XRPD pattern of benzenesulfonate form A of compound 2.

[0095] Figure 53 This is a representative DSC thermogram of benzenesulfonate form A of compound 2.

[0096] Figure 54 The image shows a representative XRPD pattern of benzenesulfonate form B of compound 2.

[0097] Figure 55 The image shows a representative XRPD pattern of compound 2 in the form of 2-naphthalenesulfonate, A.

[0098] Figure 56 This is a representative DSC thermogram of compound 2 in the form of 2-naphthalenesulfonate A.

[0099] Figure 57 The dissolution profile of the tablets containing compound 1 is shown.

[0100] Figure 58 The image shows a representative XRPD pattern of salicylate form A of compound 1.

[0101] Figure 59 This is a representative XRPD spectrum of maleate form A of compound 1. Detailed Implementation

[0102] 5.1 Definition

[0103] Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by one skilled in the art within the scope of this disclosure. The following references provide general definitions for many of the terms used in this disclosure: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd edition, 1994); The Cambridge Dictionary of Science and Technology (Walker, ed., 1988); The Glossary of Genetics, 5th edition, R. Rieger et al. (eds.), Springer Verlag (1991); and Hale and Marham, The Harper Collins Dictionary of Biology (1991). As used herein, unless otherwise specified, the following terms have the meanings assigned to them below.

[0104] In some implementations, the chemical structure is disclosed using the corresponding chemical name. In cases of conflict, the chemical structure controls the meaning, not the name.

[0105] As used herein, the terms “comprising” and “including” are used interchangeably. The terms “comprising” and “including” should be interpreted as specifying the presence of the mentioned stated features or components, but do not preclude the presence or addition of one or more features, components, or groups thereof. Additionally, the terms “comprising” and “including” are intended to include instances covered by the term “consisting of”. Therefore, the term “consisting of” can be used in place of the terms “comprising” and “including” to provide more specific embodiments of the invention.

[0106] The term "composed of" means that the subject matter has at least 90%, 95%, 97%, 98%, or 99% of the stated features or components that constitute the subject matter. In another embodiment, the term "composed of" excludes any other features or components from the scope of any subsequent description, except those that are not essential to the technical effect to be achieved.

[0107] Unless specifically stated herein or obvious, the term "or" as used herein shall be understood as inclusive. Unless specifically stated herein or obvious, the terms "a / an" and "described" as used herein shall be understood as singular or plural. For example, when a compound provided herein is administered to a "patient," it includes administering said compound to an individual patient or a group of patients.

[0108] As used herein and unless otherwise specified, "stereoisomer" refers to various stereoisomeric forms of compounds whose structure contains one or more asymmetric centers or steric hindrance. In some embodiments, stereoisomers are their enantiomers, mixtures of enantiomers, transisomers, or tautomers. For example, the compounds described herein may be in the form of individual enantiomers, diastereomers, or geometric isomers (e.g., transisomers), or may be in the form of mixtures of stereoisomers, including racemic mixtures and mixtures enriched with one or more stereoisomers. In some embodiments, the compounds provided herein may be transisomers. In some embodiments, transisomers are stereoisomers resulting from hindered rotation around a single bond, wherein an energy difference attributable to steric strain or other contributing factors creates a rotation barrier that is high enough to allow separation of individual conformational isomers. Stereoisomers can be separated from mixtures by methods known to those skilled in the art, including chiral high-performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, ELStereochemistry of Carbon Compounds (McGraw–Hill, NY, 1962); and Wilen, SH Tables of Resolving Agents and Optical Resolutions, p. 268 (edited by Eliel, Univ. of Notre Dame Press, Notre Dame, 1972). This invention also covers compounds as single isomers substantially free of other isomers, and alternatively as mixtures of various isomers.

[0109] In some embodiments, the compounds provided herein may be racemic. In some embodiments, the compounds provided herein may be enriched with one enantiomer. For example, the compounds provided herein may have greater than about 30% ee, about 40% ee, about 50% ee, about 60% ee, about 70% ee, about 80% ee, about 90% ee, or even about 95% or greater ee. In some embodiments, the compounds provided herein may have more than one stereocenter. In some such embodiments, the compounds provided herein may be enriched with one or more diastereomers. For example, the compounds provided herein may have greater than about 30% de, about 40% de, about 50% de, about 60% de, about 70% de, about 80% de, about 90% de, or even about 95% or greater de.

[0110] In some embodiments, the therapeutic agent may be enriched to primarily provide one enantiomer of the compound. The enantiomer-enriched mixture may contain, for example, at least about 60 mol% of one enantiomer, or more specifically at least about 75, about 90, about 95, or even about 99 mol%. In some embodiments, the compound enriched with one enantiomer is substantially free of the other enantiomer, where substantially free means that the composition in question constitutes less than about 10%, or less than about 5%, or less than about 4%, or less than about 3%, or less than about 2%, or less than about 1% compared to, for example, the amount of the other enantiomer in the composition or compound mixture. For example, if the composition or compound mixture contains about 98 grams of the first enantiomer and about 2 grams of the second enantiomer, it may be said that it contains about 98 mol% of the first enantiomer and only about 2% of the second enantiomer.

[0111] In some embodiments, the therapeutic agent may be enriched to primarily provide one diastereomer of the compound. The mixture enriched with diastereomers may contain, for example, at least about 60 mol% of one diastereomer, or more specifically at least about 75, about 90, about 95, or even about 99 mol%.

[0112] In some embodiments, portions of the compound exist as a mixture of tautomers. A "tautomer" is a structural isomer of a portion or compound that is readily interchangeable with another structural isomer. For example, the pyrazole ring has two tautomers:

[0113]

[0114] The difference lies in the π bond and the position of the hydrogen atom. Unless otherwise specified, a drawing of one tautomer of a part or compound covers all possible tautomers.

[0115] The term "subject" for which administration is considered includes, but is not limited to, humans (i.e., males or females of any age group, such as pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged, or elderly)) and / or other primates (e.g., cynomolgus monkeys, rhesus monkeys); mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and / or dogs; and / or birds, including commercially relevant birds such as chickens, ducks, geese, quails, and / or turkeys. In some embodiments, the subject is a person. In some embodiments, the subject is an adult at least 40 years of age. In some embodiments, the subject is an adult at least 50 years of age. In some embodiments, the subject is an adult at least 60 years of age. In some embodiments, the subject is an adult at least 70 years of age. In some embodiments, the subject is an adult at least 18 years of age or at least 12 years of age. As used herein and unless otherwise specified, a person subject for whom administration of a therapeutic agent (e.g., a compound as described herein) for the treatment, prevention, or management of a disease, condition, or ailment or its symptoms is also referred to as a "patient."

[0116] As used herein, a therapeutic agent that "prevents" a condition or disease refers to a compound that, in a statistical sample, reduces the occurrence of the condition or disease in a treated sample relative to an untreated control sample, or delays the onset of the condition or disease or reduces the severity of one or more symptoms relative to an untreated control sample. These effects are also referred to as "prevention" effects. Therefore, as used herein and unless otherwise specified, the term "prevention" refers to a method for obtaining a beneficial or desired outcome, including but not limited to preventive benefits. Regarding preventive benefits, a therapeutic agent may be administered to a patient at risk of developing a specific disease, or to a patient reporting one or more physiological symptoms of a disease, even if the disease may not yet be diagnosed. In one embodiment, the therapeutic agent is administered prior to the clinical manifestation of an adverse condition (e.g., a disease or other adverse condition of the subject) to achieve a preventive benefit (e.g., protecting the subject from developing the adverse condition).

[0117] As used herein and unless otherwise specified, the term "treatment" means a therapeutic or palliative measure. Beneficial or desired clinical outcomes include, but are not limited to, complete or partial relief of symptoms associated with a disease or symptom or disorder; reduction of disease severity; stabilization (i.e., non-exacerbation) of a disease state; delay or slowing of disease progression; improvement or palliative effect of a disease state (e.g., one or more symptoms of the disease); and relief (whether partial or complete), whether detectable or undetectable. "Treatment" may also mean extended survival compared to expected survival without treatment. In one embodiment, "treatment" includes administering a therapeutic agent (i.e., one designed to reduce, improve, or stabilize an existing adverse condition or its side effects) following an adverse disease presentation.

[0118] As used herein and unless otherwise specified, “cancer” means any malignant and / or invasive growth or tumor caused by abnormal cell growth, including solid tumors named after the type of cells that form the solid tumor, and cancers of the blood, bone marrow, or lymphatic system. Examples of solid tumors include, but are not limited to, sarcomas and carcinomas. Examples of blood cancers include, but are not limited to, leukemia, lymphoma, and myeloma. Cancer includes, but is not limited to, primary cancer originating in a specific part of the body, metastatic cancer that has spread from the site of onset to other parts of the body, recurrence of an initial primary cancer after remission, and a second primary cancer that is a new primary cancer in a person with a prior cancer history, the type of which is different from the latter cancer.

[0119] As used herein and unless otherwise specified, “abnormal cell growth” means cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). Abnormal cell growth can be benign (non-cancerous) or malignant (cancerous). In some embodiments of the methods provided herein, abnormal cell growth is cancerous.

[0120] In some embodiments, abnormal cell growth is cancer mediated by anaplastic lymphoma kinase (ALK). In some such embodiments, the ALK is a genetically altered ALK. In other embodiments, abnormal cell growth is cancer mediated by ROS1 kinase. In some such embodiments, the ROS1 kinase is a genetically altered ROS1 kinase. In some embodiments, abnormal cell growth is cancer, particularly NSCLC. In some such embodiments, NSCLC is mediated by either ALK or ROS1. In a particular embodiment, the cancer is NSCLC mediated by either genetically altered ALK or genetically altered ROS1.

[0121] As used herein and unless otherwise indicated, the term “management” encompasses preventing the recurrence of a particular disease or condition in a patient who already has the disease or condition, prolonging the time a patient with the disease or condition remains in remission, reducing patient mortality, and / or maintaining or avoiding the severity of symptoms associated with the managed disease or condition.

[0122] As used herein, "effective amount" means an amount sufficient to achieve the desired biological effect. As used herein, "therapeutic effective amount" means an amount sufficient to achieve the desired therapeutic effect. For example, a therapeutic effective amount may refer to an amount sufficient to improve at least one symptom or sign of cancer.

[0123] A “response” to treatment may include a reduction or improvement in negative symptoms, a decrease in the progression of the disease or its symptoms, an increase in beneficial symptoms or clinical outcomes, a reduction in side effects, stabilization of the disease, or partial or complete treatment of the disease.

[0124] As used herein and unless otherwise indicated, the term “relapse” refers to a condition, disease, or ailment that has responded to prior treatment (e.g., achieved a complete response) and then progresses. Prior treatment may include one or more lines of treatment.

[0125] As used herein and unless otherwise indicated, the term "refractory" means a condition, disease, or ailment that does not respond to prior treatment, which may include one or more lines of treatment.

[0126] As used herein, “crystal” refers to a homogeneous solid formed by repeating three-dimensional patterns of atoms, ions, or molecules with fixed distances between their constituent parts. The unit cell is the simplest repeating unit in this pattern. While ideal crystals are isomorphic, perfect crystals are rare (if any). As used herein, “crystal” encompasses crystalline forms that include crystallization defects, such as those typically formed by manipulation (e.g., preparation, purification) of the crystalline forms described herein. Despite the presence of such defects, those skilled in the art can determine whether a compound sample is crystalline. Crystallization forms can be characterized by analytical methods such as X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), nuclear magnetic resonance spectroscopy (NMR), single-crystal X-ray diffraction, Raman spectroscopy, Fourier transform infrared spectroscopy (FTIR), and / or any other suitable analytical technique.

[0127] As used herein, a solvate is a crystalline form of molecules, atoms, and / or ions that further comprises one or more solvent molecules incorporated into a crystal lattice structure. Solvent molecules in a solvate may exist in a regular and / or disordered arrangement. A solvate may contain stoichiometric or non-stoichiometric amounts of solvent molecules. For example, a solvate with non-stoichiometric amounts of solvent molecules may arise due to partial loss of solvent from the solvate. A solvate may exist as a dimer or oligomer containing more than one molecule or compound ABC in its crystal lattice structure.

[0128] As used herein, "amorphous" refers to a non-crystalline solid form of molecules, atoms, and / or ions. Specifically, the term "amorphous form" describes a disordered solid form, i.e., a solid form lacking long-range crystalline order. Amorphous solids do not exhibit well-defined X-ray diffraction patterns. In some embodiments, the amorphous form of a substance may be substantially free of other amorphous forms and / or crystalline structures.

[0129] As used herein and unless otherwise specified, the term "solid form" and related terms refer to a physical form that is not predominantly liquid or gaseous. A solid form can be crystalline, amorphous, or a mixture thereof. As used herein and unless otherwise specified, the term "crystalline form" and related terms refer to a crystalline solid form. Crystalline forms include, but are not limited to, nonsolvents, nonhydrates, solvates, hydrates, and other molecular complexes, as well as their salts, solvates of salts, hydrates of salts, and other molecular complexes of salts. In some embodiments, the solid form or crystalline form of a substance may be substantially free of amorphous forms and / or other solid forms and / or crystalline forms. In some embodiments, the solid form and / or crystalline form of a substance may contain less than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of one or more amorphous forms and / or other solid forms and / or crystalline forms. In some embodiments, the solid form or crystalline form of the substance may be physically and / or chemically pure. In some embodiments, the solid form or crystalline form of the substance may be about 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90% physically and / or chemically pure. In some embodiments, the solid form or crystalline form may be substantially chemically pure and / or substantially physically pure.

[0130] When used without further limitations, "substantially pure" means that, based on the weight of the compound, the compound has a purity greater than about 90% by weight, for example greater than about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% by weight, and also includes a purity equal to about 100% by weight. The remaining material may contain other forms of the compound and / or reaction impurities and / or processing impurities arising from its preparation. Purity can be assessed using techniques known in the art, such as HPLC analysis.

[0131] The term "substantially pure" can also be defined. If the compound is "substantially pure" with respect to the presence of chemical impurities (e.g., reaction impurities and / or processing impurities arising from their preparation), it may be referred to as "substantially chemically pure." If the compound is "substantially pure" with respect to the presence of another enantiomer, it may be referred to as "substantially enantiomerically pure." In some embodiments, the compound (e.g., compound 1) is substantially enantiomerically pure, wherein less than about 10%, less than about 5%, less than about 3%, less than about 1%, less than about 0.5%, or less than about 0.1% by weight of another enantiomer (e.g., the S enantiomer). If the compound is "substantially pure" with respect to the presence of other physical forms of the compound having the indicated structure, it may be referred to as "substantially physically pure." When defined, "substantially pure" means that the indicated compound contains less than about 10%, less than about 5%, less than about 3%, less than about 1%, less than about 0.5%, or less than about 0.1% by weight of the indicated impurity. In some embodiments, the solid form of compound 1 is substantially pure (e.g., having a purity of at least about 90 wt%, at least about 95 wt%, at least about 96 wt%, at least about 97 wt%, at least about 98 wt%, or at least about 99 wt%). In some embodiments, the solid form of compound 1 has a purity of at least about 95 wt%. In some embodiments, the solid form of compound 1 is substantially enantiomerically pure (e.g., having an enantiomerically pure purity of at least about 98.0 wt%, at least about 99.0 wt%, at least about 99.5 wt%, or at least about 99.9 wt%). In some embodiments, the solid form of compound 1 has an enantiomerically pure purity of at least about 99.5 wt%. In some embodiments, the pharmaceutical composition comprising compound 1 has a purity of at least about 95 wt%. In some embodiments, the pharmaceutical composition comprising compound 1 has a purity of at least about 96 wt%. In some embodiments, the pharmaceutical composition comprising compound 1 has a purity of at least about 97 wt%. In some embodiments, the pharmaceutical composition comprising compound 1 has a purity of at least about 98% by weight. In some embodiments, the pharmaceutical composition comprising compound 1 has a purity of at least about 99% by weight. In some embodiments, the pharmaceutical composition comprising compound 1 has a purity of at least about 95% by weight over 12 months.

[0132] Solid forms can exhibit unique physical characterization data specific to a particular solid form, such as the crystal forms described herein. This characterization data can be obtained using various techniques known to those skilled in the art. Data provided by these techniques can be used to identify a particular solid form. For example, one or more figures herein show XRPD patterns, DSC thermograms, or TGA thermal profiles, respectively. An XRPD pattern, DSC thermogram, or TGA thermal profile that “matches” or is interchangeably “substantially identical” to said figure is a figure that will be regarded by those skilled in the art as representing the same single-crystal form of the compound sample as the one or more figures provided herein. Therefore, a matching or substantially identical XRPD pattern, DSC thermogram, or TGA thermal profile may be identical to one of said figures, or more likely, may be slightly different from one or more of said figures. For example, an XRPD pattern that is slightly different from one or more of said figures may not necessarily show every line of the diffraction pattern presented herein, and / or may show slight variations in the appearance or intensity of the lines or line shifts. These differences are typically caused by variations in the conditions involved in obtaining the data or by variations in the purity of the samples used to obtain the data. Those skilled in the art can determine whether a sample of a crystalline compound is identical or different from the form disclosed herein by comparing its XRPD, DSC, or TGA thermal profile with the corresponding XRPD, DSC, or TGA thermal profile disclosed herein.

[0133] As used herein and unless otherwise specified, when referring to the dosage, amount, or weight percentage of a component of a combination composition or dosage form, the terms “about” and “approximately” mean a dosage, amount, or weight percentage that is readily available to a person skilled in the art as equivalent to the pharmacological effect obtained from the stated dosage, amount, or weight percentage. In some embodiments, when used herein, the terms “about” and “approximately” refer to a dosage, amount, or weight percentage within 30%, 20%, 15%, 10%, or 5% of the stated dosage, amount, or weight percentage.

[0134] As used herein and unless otherwise specified, the terms “about” and “approximately” are used in conjunction with numerical values ​​or ranges of values ​​provided to characterize a particular solid form, such as: a particular temperature or temperature range, for example describing melting, dehydration, desolvation, or glass transition temperatures; mass changes, such as mass changes with temperature or humidity; solvent or water content expressed, for example, by mass or percentage; or peak positions, for example in analyses performed by IR or Raman spectroscopy or XRPD; the terms “about” and “approximately” indicate that the value or range of values ​​may deviate to a degree that would be reasonable to a person skilled in the art, while still describing the particular solid form. For example, in certain embodiments, when used herein, the terms “about” and “approximately” indicate that the numerical value or range of values ​​may vary within 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1.5%, 1%, 0.5%, or 0.25% of the stated value or range of values. For example, in some embodiments, the XRPD peak position value can vary up to ±0.2°2θ while still describing a specific XRPD peak. In one embodiment, the XRPD peak position value can vary up to ±0.1°2θ. In another embodiment, the XRPD peak position value can vary up to ±0.05°2θ.

[0135] The term "between" includes the endpoint numbers at the two boundaries of a range. For example, a range described by "between 3 and 5" includes the numbers "3" and "5".

[0136] As used herein and unless otherwise specified, the term "pharmaceutically acceptable salt" means salts that are suitable for contact with the tissues of a subject to reasonable medical judgment without excessive toxicity, irritation, anaphylactic reactions, etc., and in proportion to a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1–19. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, alkyl, dialkyl, trialkyl, or tetraalkylammonium salts. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, L-arginine, phenethylbenzylamine, benzathine penicillin, betaine, calcium hydroxide, choline, dianophenate, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N-methylglucosamine, heptamethasone, 1H-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyl)morpholine, piperazine, potassium, 1-(2-hydroxyethyl)pyrrolidine, sodium, triethanolamine, tromethamine, and zinc salts. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, Na, Ca, K, Mg, Zn, or other metal salts.

[0137] Pharmaceutically acceptable acid addition salts can also exist as various solvates, such as those with water, methanol, ethanol, dimethylformamide, etc. Mixtures of such solvates can also be prepared. These solvates can originate from crystallization solvents, be inherent in the solvents used for preparation or crystallization, or be foreign substances to such solvents.

[0138] Pharmaceutically acceptable anionic salts include, but are not limited to, acetates, aspartate, benzenesulfonate, benzoate, besylate, bicarbonate, tartrate, bromide, camphor sulfonate, carbonate, chloride, citrate, decanoate, edetate, ethanesulfonate, fumarate, gluconate, gluconate, glutamate, glycolate, hexanoate, hydroxynaphthylcarbamate, iodide, hydroxyethanesulfonate, lactate, lactobionate, malate, maleate, amygdalinate, methanesulfonate, methyl sulfate, mucilage, naphthalenesulfonate, nitrate, octanoate, oleate, dihydroxynaphthyl salt, pantothenate, phosphate, polygalacturonate, propionate, salicylate, stearate, acetate, succinate, sulfate, tartrate, theochloroate, and toluenesulfonate.

[0139] As used herein and unless otherwise specified, the term "enantiomer-pure" means that the composition contains at least about 50%, at least about 75%, at least about 90%, at least about 95%, or at least about 99% of an enantiomer of a compound having one or more chiral centers in excess. In some embodiments, the composition may be "substantially enantiomer-pure," which means that the formulation of the composition has at least about 85% by weight, such as at least about 90% by weight, and further such as at least 95% by weight of an enantiomer (relative to another enantiomer of the compound). In some embodiments, the compositions provided herein contain at least about 90% by weight of an enantiomer of the compound in excess. In other embodiments, the composition contains at least about 95%, at least about 98%, or at least about 99% by weight of an enantiomer of the compound in excess.

[0140] As used herein and unless otherwise indicated, the term "method" means a method provided herein that can be used to prepare compounds as described herein or in their solid form (e.g., crystalline, partially crystalline, or amorphous) as provided herein. Modifications to the methods provided herein are also provided herein (e.g., starting materials, reagents, protecting groups, solvents, temperatures, reaction times, purification). Generally, the technical teachings of one embodiment provided herein can be combined with the technical teachings disclosed in any other embodiment provided herein.

[0141] As used herein and unless otherwise indicated, the terms “addition,” “reaction,” “treatment,” etc., mean bringing one reactant, reagent, solvent, catalyst, reactive group, etc., into contact with another reactant, reagent, solvent, catalyst, reactive group, etc. Reactants, reagents, solvents, catalysts, reactive groups, etc., may be added individually, simultaneously, or separately, and may be added in any order. Reactants, reagents, solvents, catalysts, reactive groups, etc., may be added individually at once, either simultaneously or over a period of time; or they may be added discretely, also either simultaneously or over a period of time. They may be added with or without heating, and optionally under an inert atmosphere. “Reaction” can refer to in-situ formation or intramolecular reaction, wherein the reactive groups are in the same molecule.

[0142] As used herein, the term "combining" refers to combining one or more chemical entities with one or more other chemical entities. Combining includes the process of adding one or more compounds to a solid, liquid, or gaseous mixture, or a liquid solution or multiphase liquid mixture of one or more compounds (identical or other chemical entities). Combining behavior includes one or more processes of reacting one or more compounds with one or more compounds (identical or other chemical entities) (e.g., bond formation or cleavage; salt formation, solvate formation, chelation, or other nonbonded alteration association). Combining behavior may include altering one or more compounds, such as through isomerization (e.g., tautomerization, separation of one isomer with another, or racemization).

[0143] As used herein and unless otherwise indicated, the term “transforming” refers to subjecting a given compound to reaction conditions suitable for the formation of the desired compound.

[0144] As used herein, the term "recovery" includes, but is not limited to, the act of obtaining one or more compounds by collection during and / or after process steps as disclosed herein, and the act of obtaining one or more compounds by separating one or more compounds from one or more other chemical entities during and / or after process steps as disclosed herein. The term "collection" refers to any action known in the art for this purpose, including but not limited to filtration, decanting mother liquor from a solid to obtain one or more compounds, and evaporating a liquid medium in a solution or other mixture to provide a solid, oil, or other residue comprising one or more compounds. The solid may be crystalline, amorphous, partially crystalline, or amorphous, powder, granules, having different particle sizes, having a uniform particle size, and other characteristics known in the art. Oils may vary in color and viscosity and may include one or more solid forms as heterogeneous mixtures, and other characteristics known in the art. The term "separation" refers to any action known in the art for this purpose, including but not limited to the separation of one or more compounds from a solution or mixture using techniques such as seeded crystallization or seedless crystallization or other precipitation techniques (e.g., adding an antisolvent to a solution to induce compound precipitation; heating a solution and then cooling it to induce compound precipitation; scraping the surface of a solution with a tool to induce compound precipitation) and distillation techniques. Recovery of one or more compounds may include preparing their salts, solvates, hydrates, chelates, or other complexes, followed by collection or separation as described above.

[0145] As used herein, the term "catalyst precursor" refers to a chemical composition in which one or more components of an active catalyst (e.g., a metal center and a supporting ligand) are added to a reaction mixture to cause the formation of an active catalyst in situ. For example, a palladium catalyst coordinated to cataCXium A can be formed in situ by adding a catalyst precursor comprising a palladium source (e.g., Pd(OAc)₂) and a cataCXium A source (e.g., cataCXium A). Those skilled in the art will recognize that even when the metal source and supporting ligand are added to the reaction mixture in the form of a single chemical entity (e.g., Pd(dppf)Cl₂), further activation and / or in-situ reactions may be required to produce an active catalyst. Nevertheless, as used herein, the term "catalyst" includes, but is not limited to, a chemical composition in which more than one component of an active catalyst (e.g., a metal center and a supporting ligand) is added to the reaction mixture in the form of a single chemical entity (e.g., Pd(dppf)Cl₂), even if further activation and / or in-situ reactions are required to produce an active catalyst.

[0146] Although most of the embodiments and examples provided herein are for one enantiomer of a compound, it should be understood that relative enantiomers of a compound can be prepared by the methods provided when the stereochemistry of chiral reactants, reagents, solvents, catalysts, ligands, etc., is reversed.

[0147] As used herein and unless otherwise specified, the terms “solvent,” “organic solvent,” or “inert solvent” each mean a solvent that is inert under the described reaction conditions. Unless otherwise specified, 1 cc (or mL) of solvent constitutes 1 volume equivalent (or “vol.”) for every gram of the limiting reagent.

[0148] This disclosure can be more fully understood by referring to the following detailed description and illustrative embodiments, which are intended to exemplify non-limiting implementations.

[0149] 5.2 Solid form

[0150] Potential drug solids include crystalline solids and amorphous solids. Amorphous solids are characterized by a lack of long-range structural order, while crystalline solids are characterized by periodic structures. The desired category of drug solid depends on the specific application; amorphous solids are sometimes selected based on, for example, enhanced dissolution profiles, while crystalline solids may be desired for properties such as physical or chemical stability (see, for example, SRVippagunta et al., Adv. Drug. Deliv. Rev., (2001) 48:3-26; L. Yu, Adv. Drug. Deliv. Rev., (2001) 48:27-42). Variations in solid form can affect a wide range of physical and chemical properties, which can provide benefits or drawbacks in terms of processing, formulation, stability, bioavailability, and other important drug characteristics.

[0151] Whether crystalline or amorphous, the potential solid forms of drug compounds can include single-component and multi-component solids. Single-component solids consist essentially of the drug compound and contain no other compounds. The diversity of single-component crystalline materials may potentially arise from polymorphism, where multiple three-dimensional arrangements exist for a particular drug compound (see, for example, SRByrn et al., Solid State Chemistry of Drugs, (1999) SSCI, West Lafayette).

[0152] Additional diversity in the potential solid forms of pharmaceutical compounds can stem from the possibility of multicomponent solids. Crystalline solids containing two or more ionic substances are called salts (see, for example, Handbook of Pharmaceutical Salts: Properties, Selection and Use, edited by PHStahl and CGWermuth, (2002), Wiley, Weinheim). Additional types of multicomponent solids that could potentially provide further property enhancements to pharmaceutical compounds or their salts include, for example, hydrates, solvates, eutectics, and cages (see, for example, SRByrn et al., Solid State Chemistry of Drugs, (1999) SSCI, West Lafayette). Multicomponent crystal forms can potentially be sensitive to polymorphism, where a given multicomponent composition can exist in more than one three-dimensional crystalline arrangement. The discovery of solid forms is of great significance for the development of safe, effective, stable, and marketable pharmaceutical compounds.

[0153] The solid forms provided herein can be used as active pharmaceutical ingredients to prepare formulations for use in animals or humans. Therefore, the embodiments described herein cover the use of these solid forms as final pharmaceutical products. Some embodiments provide solid forms that can be used to prepare final dosage forms with improved properties, such as powder flow properties, compaction properties, tableting properties, stability properties, and excipient compatibility properties, which are necessary for the manufacture, processing, formulation, and / or storage of the final pharmaceutical product. Some embodiments described herein provide pharmaceutical compositions comprising a single-component crystalline form and / or a multi-component crystalline form, said multi-component crystalline form comprising a compound of formula (I) and a pharmaceutically acceptable excipient.

[0154] Solid form and related terms refer to physical forms that are not predominantly liquid or gaseous. Solid forms can be crystalline or mixtures of crystalline and amorphous forms. A “single-component” solid form containing a specific compound consists essentially of that compound. A “multi-component” solid form containing a specific compound includes that compound and a large number of one or more additional substances, such as ions and / or molecules, within the solid form. Solid forms described herein can be crystalline or intermediate forms (e.g., mixtures of crystalline and amorphous forms). Thus, crystal forms described herein can have different degrees of crystallinity or lattice order. Solid forms described herein are not limited to any particular degree of crystallinity or lattice order and can be 0–100% crystalline. Methods for determining crystallinity are known to those skilled in the art, such as those described below: Suryanarayanan, R., X-Ray Powder Diffractometry, Physical Characterization of Pharmaceutical Solids, HGBrittain (ed.), Marcel Dekker, Murray Hill, NJ, 1995, pp. 187–199, which are incorporated herein by reference in their entirety. In some embodiments, the solid form described herein is about 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100% crystalline.

[0155] Solid forms can exhibit unique physical characterization data characteristic of a particular solid form, such as the crystal forms described herein. This characterization data can be obtained using various techniques known to those skilled in the art, including, for example, X-ray powder diffraction, differential scanning calorimetry, thermogravimetric analysis, and nuclear magnetic resonance spectroscopy. Data provided by these techniques can be used to identify a particular solid form. Those skilled in the art can determine whether a solid form is one of the forms described herein, identified as characteristic of a particular solid form, by performing one of these characterization techniques and determining whether the resulting data is “substantially similar” to reference data provided herein. Those skilled in the art will understand that characterization data “substantially similar” to those of a reference solid form corresponds to the same solid form as the reference solid form. In analyzing whether data are “substantially similar,” those skilled in the art will understand that specific characterization data points can vary to a reasonable degree due to, for example, experimental errors and routine inter-sample analysis, while still describing a given solid form.

[0156] In some embodiments, this document provides a solid form comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:

[0157]

[0158] In one embodiment, the solid form comprising the compound of formula (I) may be a crystalline form, a partially crystalline form, or a mixture of crystalline and amorphous forms. In one embodiment, a solid form comprising the crystalline form of the compound of formula (I) is provided herein. In one embodiment, the solid form comprises a salt thereof, a solvate (e.g., a hydrate), or a solvate of a salt thereof, or a mixture thereof. In another embodiment, the solid form is an amorphous form. In one embodiment, the solid form is substantially pure. In one embodiment, the solid form is substantially chemically pure. In one embodiment, the solid form is substantially physically pure. In one embodiment, the solid form is substantially enantiomerically pure. In one embodiment, the solid form (e.g., formula 2) has an enantiomeric purity of at least about 98% (e.g., about 99% or about 99.5%). The compound of formula (I) is described in International Patent Application No. PCT / US2021 / 030940, the entire contents of which are incorporated herein by reference.

[0159] 5.2.1. Solid form of the free base of compound 1

[0160] This article provides a solid form of a compound comprising formula (I):

[0161]

[0162] In one embodiment, this document provides a solid form of a free base comprising compound 1. In one embodiment, this document provides a solid form of an anhydrous free base comprising compound 1. In one embodiment, this document provides a solid form of a solvate comprising compound 1. In one embodiment, this document provides a solid form of a hydrate comprising compound 1. In one embodiment, this document provides a solid form of a solvate comprising 2-MeTHF, isopropyl acetate, 1,4-dioxane, 2-propanol, acetone, THF, tert-butanol, MIBK, cyclohexanone, MEK, methylcyclohexane, or cyclohexane comprising compound 1.

[0163] As used herein, “compound 1”, “free base of compound 1”, “free base of compound (I)” and “free base of compound 1” are used interchangeably.

[0164] Compound 1, or its stereoisomers or mixtures thereof, or pharmaceutically acceptable salts thereof, are expected to exist in a variety of solid forms. Such solid forms include crystalline solids (e.g., crystalline forms of anhydrous compound 1, crystalline forms of the hydrate of compound 1, and crystalline forms of the solvate of compound 1), amorphous solids, or mixtures of crystalline and amorphous solids. In one embodiment, the solid form is substantially crystalline.

[0165] In some embodiments, the molar ratio of compound 1 in the solid form to a solvent (e.g., water) is in the range of about 10:1 to about 1:10. In some embodiments, the molar ratio of compound 1 in the solid form to a solvent (e.g., water) is in the range of about 5:1 to about 1:5. In some embodiments, the molar ratio of compound 1 in the solid form to a solvent (e.g., water) is in the range of about 3:1 to about 1:3. In some embodiments, the molar ratio of compound 1 in the solid form to a solvent (e.g., water) is in the range of about 2:1 to about 1:2. In one embodiment, the molar ratio is about 1:2 (i.e., a disolvent or dihydrate). In another embodiment, the molar ratio is about 1:1 (i.e., a monosolvent or monohydrate). In yet another embodiment, the molar ratio is about 2:1 (i.e., a hemisolvent or hemihydrate).

[0166] 5.2.1.1 Form 1 of Compound 1

[0167] In one embodiment, form 1 of compound 1 is provided herein.

[0168] Representative XRPD spectra of compound 1 in form 1 are provided. Figure 1A middle.

[0169] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 6.0, 8.9, 9.2, 10.3, 11.1, 12.2, 12.8, 15.8, 17.1, 17.3, 18.1, 18.5, 19.3, 19.5, 20.6, 21.4, 22.2, 22.5, 23.4, 24.5, 25.3, 25.7, 26.2, and 28.2 °2θ. In one embodiment, the solid form is characterized by at least three of the said peaks. In one embodiment, the solid form is characterized by at least 5 of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0170] In one embodiment, this document provides a solid form (e.g., crystalline form) of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.0, 8.9, 9.2, 11.1, 12.2, 12.8, 17.1, 18.1, 18.5, 20.6, and 22.5°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.0, 8.9, 9.2, 11.1, 12.2, 12.8, 17.1, 18.1, 18.5, 20.6, and 22.5°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.0, 8.9, 9.2, 11.1, 12.2, 12.8, 17.1, 18.1, 18.5, 20.6, and 22.5°2θ.

[0171] In one embodiment, this document provides a solid form (e.g., crystalline form) of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.0, 18.5, and 20.6°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 12.8 and 17.1°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 9.2 and 22.5°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.0, 8.9, 9.2, 11.1, 12.8, 17.1, 18.5, 20.6, and 22.5°2θ.

[0172] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 1A The XRPD map depicted in the image matches. In one implementation, it provides... Figure 1A Form 1 is a 2-MeTHF solvate.

[0173] Another representative XRPD spectrum of compound 1 in form 1 is provided. Figure 1B middle.

[0174] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 5.8, 6.0, 8.7, 8.8, 9.1, 10.8, 10.9, 12.0, 12.1, 12.7, 14.4, 15.7, 17.0, 18.0, 18.3, 19.3, 20.3, 20.4, 21.3, 22.2, 22.4, 25.0, 25.7, 26.0, 28.3 and 31.7 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least seven of the peaks. In one embodiment, the solid form is characterized by at least nine of the peaks. In one embodiment, the solid form is characterized by at least eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0175] In one embodiment, this document provides a solid form (e.g., crystalline form) of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.0, 10.8, 12.7, 14.4, 17.0, 18.0, 18.3, 19.3, and 20.4°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.0, 10.8, 12.7, 14.4, 17.0, 18.0, 18.3, 19.3, and 20.4°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.0, 10.8, 12.7, 14.4, 17.0, 18.0, 18.3, 19.3, and 20.4°2θ.

[0176] In one embodiment, this document provides a solid form (e.g., crystalline form) of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.0, 10.8, and 20.4°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 12.7 and 18.3°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 14.4 and 17.0°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.0, 10.8, 12.7, 14.4, 17.0, 18.0, 18.3, 19.3, and 20.4°2θ.

[0177] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 1B The XRPD map depicted in the image matches. In one implementation, it provides... Figure 1B Form 1 is an isopropyl acetate solvate.

[0178] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0179] Representative overlay plots of Form 1 TGA / DSC thermograms are provided. Figure 2In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting an (endothermic) thermal event as characterized by DSC, wherein the onset temperature is about 79°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 90°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 2 The DSC thermograms depicted in the diagram match. In one embodiment, the DSC thermograms are measured as described by DSC using a scan rate of approximately 10 °C / min. In one embodiment, a solid form comprising a free base of compound 1 is provided herein, which exhibits a weight loss of approximately 15.8% after heating from approximately 60 °C to approximately 110 °C. In one embodiment, the solid form is characterized by a TGA thermogram that matches... Figure 2 The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10°C / min. In one embodiment, it is provided... Figure 2 Form 1 is a 2-MeTHF solvate.

[0180] Another representative overlay of the TGA / DSC thermogram of Form 1 is provided. Figure 3 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting an (endothermic) thermal event as characterized by DSC, wherein the peak temperature is about 117°C (e.g., ±2°). In one embodiment, the thermal event has an onset temperature of about 110°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 3 The DSC thermograms depicted in the diagram match. In one embodiment, the DSC thermograms are measured as described by DSC using a scan rate of approximately 10 °C / min. In one embodiment, a solid form comprising a free base of compound 1 is provided herein, which exhibits a weight loss of approximately 13.0% after heating from approximately 25 °C to approximately 150 °C. In one embodiment, the solid form is characterized by a TGA thermogram that matches... Figure 3 The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10°C / min. In one embodiment, it is provided... Figure 3 Form 1 is an isopropyl acetate solvate.

[0181] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0182] In one embodiment, this document provides a solid form comprising a free base of compound 1, which is an isomeric solvate. In one embodiment, this document provides a solid form comprising a free base of compound 1, wherein the molar ratio of compound 1 to the solvent is in the range of about 1:0.5 to about 1:1. In one embodiment, the solid form is a 2-MeTHF solvate of the free base of compound 1. In another embodiment, the solid form is an isopropyl acetate solvate of the free base of compound 1.

[0183] In one embodiment, this document provides a form 1 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising a form 1 comprising a free base of compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0184] This application covers all combinations of the above-described embodiments.

[0185] 5.2.1.2 Form 2 of Compound 1

[0186] In one embodiment, form 2 of compound 1 is provided herein. A representative XRPD spectrum of form 2 of compound 1 is provided. Figure 4 middle.

[0187] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 7.6, 9.4, 11.2, 12.4, 13.2, 14.3, 15.4, 15.6, 16.2, 16.9, 17.9, 18.9, 21.1, 21.6, 21.8, 22.5, 22.7, 23.0, 24.5, 24.9, 27.0, and 28.8 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0188] In one embodiment, this document provides a solid form (e.g., a crystalline or substantially crystalline form) of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 11.2, 12.4, 13.2, 14.3, 18.9, 21.1, 21.6, 21.8, 22.5, 22.7, 23.0, and 27.0°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 11.2, 12.4, 13.2, 14.3, 18.9, 21.1, 21.6, 21.8, 22.5, 22.7, 23.0, and 27.0°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 11.2, 12.4, 13.2, 14.3, 18.9, 21.1, 21.6, 21.8, 22.5, 22.7, 23.0, and 27.0°2θ.

[0189] In one embodiment, this document provides a solid form (e.g., crystalline form) of a free base comprising compound 1, characterized in that its XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 12.4, 18.9, and 21.1°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 13.2 and 22.5°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 11.2 and 22.7°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 11.2, 12.4, 13.2, 14.3, 18.9, 21.1, 21.8, 22.5, 22.7, 23.0, and 27.0°2θ.

[0190] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 4 The XRPD map depicted in the image matches.

[0191] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0192] Representative DSC thermograms of Form 2 are provided. Figure 5 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting a thermal event (endothermic) as characterized by DSC, wherein the initial temperature is about 260°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 261°C (e.g., ±2°). In one embodiment, without being bound by any particular theory, the thermal event corresponds to melting. In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 5 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min.

[0193] Representative DVS isotherms of Form 2 are provided in Figure 6 In one embodiment, this document provides a solid form comprising a free base of compound 1, which exhibits a weight increase of about 0.3% (e.g., ±0.05%) when subjected to an increase in relative humidity from about 0 to about 90%. In one embodiment, the solid form is characterized by a DVS isotherm that... Figure 6The DVS isotherm is matched. In one embodiment, the DVS isotherm is measured as if at approximately 25°C.

[0194] In one embodiment, this document provides a solid form comprising a free base of compound 1 having an approximate unit cell size: α = 90°, β = 90°, and γ = 90°. In one embodiment, form 2 has an approximate cell size: α = 90°, β = 90°, and γ = 90°. In one embodiment, form 2 has an approximate cell size: α = 90°, β = 90°, and γ = 90°. In one embodiment, form 2 has a unit cell with space group P212121. In one embodiment, form 2 has approximately / cell volume. In one embodiment, the Z-value of form 2 is 4. In one embodiment, form 2 has approximately 1.336 g / cm³. 3 The density.

[0195] In one embodiment, this document provides a solid form comprising a free base of compound 1, which is anhydrous. In one embodiment, the solid form is a crystalline anhydrous free base of compound 1. In one embodiment, the solid form is substantially free of amorphous compound 1. In one embodiment, the solid form is substantially free of other crystalline forms of compound 1. In one embodiment, the solid form is substantially free of salts of compound 1. In one embodiment, the solid form is not solvated. In one embodiment, one or more residual solvents may be present in the solid form, but the residual solvents do not form solvates of compound 1. In one embodiment, the solid form is substantially pure. In one embodiment, the solid form is substantially chemically pure. In one embodiment, the solid form is chemically pure for about more than 95% by weight. In one embodiment, the solid form is chemically pure for about more than 96% by weight. In one embodiment, the solid form is chemically pure for about more than 97% by weight. In one embodiment, the solid form is chemically pure for about more than 98% by weight. In one embodiment, the solid form is chemically pure for about more than 99% by weight. In one embodiment, the solid form is substantially enantiomerically pure. In one embodiment, the solid form is about 98% enantiomerically pure. In one embodiment, the solid form is about 99% enantiomerically pure. In one embodiment, the solid form is about 99.5% enantiomerically pure. In one embodiment, the solid form is substantially physically pure.

[0196] In one embodiment, form 2 is substantially non-hygroscopic. In one embodiment, form 2 is non-hygroscopic. In one embodiment, form 2 is stable after being stored at 30°C ± 2°C / 65% ± 5% RH for at least 12 months. In one embodiment, form 2 is stable after being stored at 40°C ± 2°C / 75% ± 5% RH for at least 6 months. In one embodiment, form 2 stored at 30°C ± 2°C / 65% ± 5% RH for at least 12 months or at 40°C ± 2°C / 75% ± 5% RH for at least 6 months is at least 97% chemically pure by weight. In one embodiment, form 2 stored at 30°C ± 2°C / 65% ± 5% RH for at least 12 months or at 40°C ± 2°C / 75% ± 5% RH for at least 6 months is at least 99% enantiomer pure. In one embodiment, Form 2, stored at 30°C ± 2°C / 65% ± 5% RH for at least 12 months or at 40°C ± 2°C / 75% ± 5% RH for at least 6 months, is at least 99% by weight physically pure (e.g., substantially free of amorphous Compound 1 or other solid forms of Compound 1).

[0197] In one embodiment, this document provides a form 2 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising a form 2 comprising a free base of compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0198] This application covers all combinations of the above-described embodiments.

[0199] 5.2.1.3 Form 3 of Compound 1

[0200] In one embodiment, form 3 of compound 1 is provided herein. A representative XRPD spectrum of form 3 of compound 1 is provided. Figure 8 middle.

[0201] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 9.0, 9.4, 10.4, 12.8, 15.3, 16.4, 16.6, 18.2, and 20.6 °2θ. In one embodiment, the solid form is characterized by at least 3 of the peaks. In one embodiment, the solid form is characterized by at least 5 of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0202] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 9.0, 9.4, 10.4, 12.8, 15.3, 16.4, 16.6, 18.2, and 20.6°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 9.0, 9.4, 10.4, 12.8, 15.3, 16.4, 16.6, 18.2, and 20.6°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 9.0, 9.4, 10.4, 12.8, 15.3, 16.4, 16.6, 18.2, and 20.6°2θ.

[0203] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 9.4, 12.8, and 15.3°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 16.6 and 20.6°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 9.0 and 16.4°2θ. In one embodiment, the XRPD spectrum further contains a peak at approximately (e.g., ±0.2°) 10.4°2θ. In one embodiment, the XRPD spectrum further contains a peak at approximately (e.g., ±0.2°) 18.2°2θ.

[0204] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 8 The XRPD map depicted in the image matches.

[0205] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0206] Representative overlay plots of Form 3 TGA / DSC thermograms are provided. Figure 9In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting an (endothermic) thermal event as characterized by DSC, wherein the onset temperature is about 100°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 108°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 9 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 9 Form 3 is a 2-MeTHF solvate.

[0207] In one embodiment, this document provides a solid form comprising a free base of compound 1, which exhibits a weight loss of approximately 13.3% upon heating from approximately 50°C to approximately 200°C. In one embodiment, the solid form is characterized by a TGA thermogram that is consistent with... Figure 9 The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10 °C / min.

[0208] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0209] In one embodiment, this document provides a solid form comprising a free base of compound 1, wherein the molar ratio of compound 1 to solvent is in the range of about 1:1 to about 1:8. In one embodiment, the molar ratio of compound 1 to solvent is in the range of about 1:4 to about 1:5. In one embodiment, the molar ratio of compound 1 to water is in the range of about 1:1 to about 1:6. In one embodiment, the molar ratio of compound 1 to water is in the range of about 1:3 to about 1:5. In one embodiment, the molar ratio of compound 1 to organic solvent is in the range of about 1:0.5 to about 1:1.5. In one embodiment, the molar ratio of compound 1 to organic solvent is in the range of about 1:0.8 to about 1:1.1. In one embodiment, the solid form is a 2-MeTHF solvate of the free base of compound 1. In one embodiment, the molar ratio of compound 1 to 2-MeTHF is about 1:0.7. In one embodiment, the molar ratio of compound 1 to 2-MeTHF is about 1:0.8. In one embodiment, the molar ratio of compound 1 to 2-MeTHF is about 1:1.

[0210] In one embodiment, this document provides a form 3 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising a form 3 comprising a free base of compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0211] This application covers all combinations of the above-described embodiments.

[0212] 5.2.1.4 Form 4 of Compound 1

[0213] In one embodiment, form 4 of compound 1 is provided herein. A representative XRPD spectrum of form 4 of compound 1 is provided. Figure 10 middle.

[0214] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 6.0, 6.1, 9.0, 9.2, 11.0, 12.2, 12.7, 17.2, 18.2, 18.4, 19.4, 20.5, 21.5, and 22.5 °2θ. In one embodiment, the solid form is characterized by at least 3 of the peaks. In one embodiment, the solid form is characterized by at least 5 of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0215] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.1, 9.2, 11.0, 12.2, 12.7, 17.2, 18.2, 20.5, and 21.5°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.1, 9.2, 11.0, 12.2, 12.7, 17.2, 18.2, 20.5, and 21.5°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.1, 9.2, 11.0, 12.2, 12.7, 17.2, 18.2, 20.5, and 21.5°2θ.

[0216] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.1, 17.2, and 18.2°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 12.7 and 20.5°2θ. In another embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 12.2 and 21.5°2θ. In yet another embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.1, 9.2, 11.0, 12.2, 12.7, 17.2, 18.2, 20.5, and 21.5°2θ.

[0217] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 10 The XRPD map depicted in the image matches.

[0218] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0219] Representative overlay plots of TGA / DSC thermograms of Form 4 are provided. Figure 11 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting a thermal event (endothermic) as characterized by DSC, wherein the onset temperature is about 64°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 67°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 11 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 11 Form 4 is a 1,4-dioxane solvate.

[0220] In one embodiment, this document provides a solid form comprising a free base of compound 1, which exhibits a weight loss of approximately 17.1% upon heating from approximately 75°C to approximately 165°C. In one embodiment, the solid form is characterized by a TGA thermogram that is consistent with... Figure 11The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10 °C / min.

[0221] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0222] In one embodiment, this document provides a solid form comprising a free base of compound 1, wherein the molar ratio of compound 1 to solvent is in the range of about 1:0.5 to about 1:1.5. In one embodiment, the molar ratio of compound 1 to solvent is in the range of about 1:0.6 to about 1:2. In one embodiment, the solid form is a 1,4-dioxane solvate of the free base of compound 1. In one embodiment, the molar ratio of compound 1 to 1,4-dioxane is about 1:0.8. In one embodiment, the molar ratio of compound 1 to 1,4-dioxane is about 1:1.1.

[0223] In one embodiment, this document provides a form 4 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising a form 4 comprising a free base of compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0224] This application covers all combinations of the above-described embodiments.

[0225] 5.2.1.5 Form 5 of Compound 1

[0226] In one embodiment, this document provides form 5 of compound 1.

[0227] Representative XRPD spectra of form 5 of compound 1 are provided. Figure 12A middle.

[0228] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 6.8, 7.0, 10.0, 10.3, 11.0, 17.2, 17.7, 18.9, 19.4, 20.0, 21.1, 21.3, 21.8, 22.2, 22.8, 23.2, and 23.5 °2θ. In one embodiment, the solid form is characterized by at least 3 of the peaks. In one embodiment, the solid form is characterized by at least 5 of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In another embodiment, the solid form is characterized by all of the peaks.

[0229] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.8, 7.0, 10.0, 17.2, 18.9, 19.4, 21.1, 22.2, and 22.8°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.8, 7.0, 10.0, 17.2, 18.9, 19.4, 21.1, 22.2, and 22.8°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.8, 7.0, 10.0, 17.2, 18.9, 19.4, 21.1, 22.2, and 22.8°2θ.

[0230] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.8, 10.0, and 18.9°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 19.4 and 22.8°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 7.0 and 22.2°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.8, 7.0, 10.0, 17.2, 18.9, 19.4, 21.1, 22.2, and 22.8°2θ.

[0231] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 12A The XRPD map depicted in the image matches. In one implementation, it provides... Figure 12A Form 5 is a mixed solvate of 2-propanol and tert-butanol.

[0232] Another representative XRPD spectrum of compound 1 in form 5 is provided. Figure 12B middle.

[0233] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 6.9, 9.1, 9.9, 10.2, 11.9, 12.6, 17.2, 18.6, 19.1, 19.7, 20.8, 21.5, and 22.4 °2θ. In one embodiment, the solid form is characterized by at least 3 of the peaks. In one embodiment, the solid form is characterized by at least 5 of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0234] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.9, 9.9, 10.2, 12.6, 18.6, 19.1, 20.8, 21.5, and 22.4°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.9, 9.9, 10.2, 12.6, 18.6, 19.1, 20.8, 21.5, and 22.4°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.9, 9.9, 10.2, 12.6, 18.6, 19.1, 20.8, 21.5, and 22.4°2θ.

[0235] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.9, 9.9, and 19.1°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 10.2 and 18.6°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 20.8 and 22.4°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.9, 9.9, 10.2, 12.6, 18.6, 19.1, 20.8, 21.5, and 22.4°2θ.

[0236] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 12B The XRPD map depicted in the image matches. In one implementation, it provides... Figure 12B Form 5 is a mixed solvate of tert-butanol and acetone.

[0237] Another representative XRPD spectrum of compound 1 in form 5 is provided. Figure 12C middle.

[0238] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 3.2, 6.0, 6.9, 9.8, 12.7, 17.2, 19.2, 19.7, 20.9, 22.2, 25.6, and 28.8 °2θ. In one embodiment, the solid form is characterized by at least 3 of the peaks. In one embodiment, the solid form is characterized by at least 5 of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0239] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.0, 6.9, 9.8, 12.7, 17.2, 19.2, 19.7, 20.9, and 22.2°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.0, 6.9, 9.8, 12.7, 17.2, 19.2, 19.7, 20.9, and 22.2°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.0, 6.9, 9.8, 12.7, 17.2, 19.2, 19.7, 20.9, and 22.2°2θ.

[0240] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.9, 17.2, and 19.2°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.0 and 22.2°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 9.8 and 19.7°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.0, 6.9, 9.8, 12.7, 17.2, 19.2, 19.7, 20.9, and 22.2°2θ.

[0241] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 12C The XRPD map depicted in the image matches. In one implementation, it provides... Figure 12C Form 5 is a mixed solvate of tert-butanol and THF.

[0242] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0243] Representative overlay plots of TGA / DSC thermograms of Form 5 are provided. Figure 13 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting a thermal event (endothermic) as characterized by DSC, wherein the initial temperature is about 68°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 72°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 13 The DSC thermograms depicted in the diagram match the actual DSC thermograms. In one embodiment, the DSC thermograms are measured using a scan rate of approximately 10 °C / min via DSC. In one embodiment, a solid form comprising a free base of compound 1 is provided herein, which exhibits a weight loss of approximately 15.7% upon heating from approximately 25 °C to approximately 170 °C. In one embodiment, the solid form is characterized by a TGA thermogram that matches the actual DSC thermograms depicted in the diagram. Figure 13 The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10°C / min. In one embodiment, it is provided... Figure 13 Form 5 is a mixed solvate of 2-propanol and tert-butanol.

[0244] Representative overlay plots of TGA / DSC thermograms of Form 5 are provided. Figure 14 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting a thermal event (endothermic) as characterized by DSC, wherein the initial temperature is about 67°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 71°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 14The DSC thermograms depicted in the diagram match. In one embodiment, the DSC thermograms are measured as described by DSC using a scan rate of approximately 10 °C / min. In one embodiment, a solid form comprising a free base of compound 1 is provided herein, which exhibits approximately 12.9% weight loss upon heating from approximately 25 °C to approximately 170 °C. In one embodiment, the solid form is characterized by a TGA thermogram that matches... Figure 14 The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10°C / min. In one embodiment, it is provided... Figure 14 Form 5 is a mixed solvate of acetone and tert-butanol.

[0245] Representative overlay plots of TGA / DSC thermograms of Form 5 are provided. Figure 15 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting a thermal event (endothermic) as characterized by DSC, wherein the onset temperature is about 59°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 62°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 15 The DSC thermograms depicted in the diagram match the actual DSC thermograms. In one embodiment, the DSC thermograms are measured using a scan rate of approximately 10 °C / min via DSC. In one embodiment, a solid form comprising a free base of compound 1 is provided herein, which exhibits a weight loss of approximately 19.1% upon heating from approximately 25 °C to approximately 170 °C. In one embodiment, the solid form is characterized by a TGA thermogram that matches the actual DSC thermograms depicted in the diagram. Figure 15 The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10°C / min. In one embodiment, it is provided... Figure 15 Form 5 is a mixed solvate of THF and tert-butanol.

[0246] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0247] In one embodiment, this document provides a solid form comprising a free base of compound 1, which is an isomeric solvate. In one embodiment, this document provides a solid form comprising a free base of compound 1, which is a mixed solvate. In one embodiment, the solid form is a mixed solvate of 2-propanol and tert-butanol. In another embodiment, the solid form is a mixed solvate of acetone and tert-butanol. In another embodiment, the solid form is a mixed solvate of THF and tert-butanol. In one embodiment, this document provides a solid form comprising a free base of compound 1, wherein the molar ratio of compound 1 to the solvent is in the range of about 1:0.1 to about 1:1.1. In one embodiment, the molar ratio of compound 1 to the solvent (e.g., acetone) is about 1:0.1. In one embodiment, the molar ratio of compound 1 to the solvent (e.g., 2-propanol) is about 1:0.4. In one embodiment, the molar ratio of compound 1 to the solvent (e.g., tert-butanol) is about 1:0.6. In one embodiment, the molar ratio of compound 1 to the solvent (e.g., THF) is about 1:0.7. In one embodiment, the molar ratio of compound 1 to the solvent is about 1:0.7. In one embodiment, the molar ratio of compound 1 to a mixture of two solvents is about 1:0.5 to 1:1.9. In one embodiment, the molar ratio of compound 1 to a mixture of two solvents (e.g., 2-propanol and tert-butanol) is about 1:1.0. In one embodiment, the molar ratio of compound 1 to a mixture of two solvents (e.g., acetone and tert-butanol) is about 1:0.8. In one embodiment, the molar ratio of compound 1 to a mixture of two solvents (e.g., THF and tert-butanol) is about 1:1.3.

[0248] In one embodiment, this document provides a form 5 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising a form 5 comprising a free base of compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0249] This application covers all combinations of the above-described embodiments.

[0250] 5.2.1.6 Form 6 of Compound 1

[0251] In one embodiment, form 6 of compound 1 is provided herein. A representative XRPD spectrum of form 6 of compound 1 is provided. Figure 16 middle.

[0252] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 5.8, 6.0, 9.0, 10.0, 11.5, 12.0, 17.3, 18.0, 19.0, 20.1, 21.5, 22.4, and 24.1 °2θ. In one embodiment, the solid form is characterized by at least 3 of the peaks. In one embodiment, the solid form is characterized by at least 5 of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0253] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.8, 6.0, 10.0, 18.1, 20.1, 22.4, and 24.1°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.8, 6.0, 10.0, 18.1, 20.1, 22.4, and 24.1°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.8, 6.0, 10.0, 18.1, 20.1, 22.4, and 24.1°2θ.

[0254] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.8, 10.0, and 18.1°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.0 and 22.4°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 20.1 and 24.1°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 11.5 and 12.0°2θ.

[0255] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 16 The XRPD map depicted in the image matches.

[0256] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0257] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0258] In one embodiment, this document provides a form 6 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising a form 6 comprising a free base of compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0259] This application covers all combinations of the above-described embodiments.

[0260] 5.2.1.7 Form 7 of Compound 1

[0261] In one embodiment, form 7 of compound 1 is provided herein. A representative XRPD spectrum of form 7 of compound 1 is provided. Figure 17 middle.

[0262] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 5.9, 8.6, 9.1, 10.6, 12.0, 12.1, 16.7, 17.8, 19.6, 20.7, 21.0, 21.2, 21.4, and 23.4 °2θ. In one embodiment, the solid form is characterized by at least 3 of the peaks. In one embodiment, the solid form is characterized by at least 5 of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0263] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.9, 9.1, 10.6, 12.0, 16.7, 17.8, 19.6, 21.2, and 23.4°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.9, 9.1, 10.6, 12.0, 16.7, 17.8, 19.6, 21.2, and 23.4°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 5.9, 9.1, 10.6, 12.0, 16.7, 17.8, 19.6, 21.2, and 23.4°2θ.

[0264] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.9, 9.1, and 19.6°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 12.0 and 23.4°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 10.6 and 21.2°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.9, 9.1, 10.6, 12.0, 16.7, 17.8, 19.6, 21.2, and 23.4°2θ.

[0265] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 17 The XRPD map depicted in the image matches.

[0266] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0267] Representative overlay plots of TGA / DSC thermograms of Form 7 are provided. Figure 18 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting a thermal event (endothermic) as characterized by DSC, wherein the onset temperature is about 83°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 89°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 18 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 18 Form 7 is a MIBK solvate.

[0268] In one embodiment, this document provides a solid form comprising a free base of compound 1, which exhibits a weight loss of approximately 15.5% upon heating from approximately 85°C to approximately 135°C. In one embodiment, the solid form is characterized by a TGA thermogram that is consistent with... Figure 18The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10 °C / min.

[0269] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0270] In one embodiment, this document provides a solid form comprising a free base of compound 1, wherein the molar ratio of compound 1 to solvent is in the range of about 1:0.5 to about 1:1.5. In one embodiment, the molar ratio of compound 1 to solvent is in the range of about 1:0.6 to about 1:1.1. In one embodiment, the solid form is a MIBK solvate of the free base of compound 1. In one embodiment, the molar ratio of compound 1 to MIBK is about 1:0.7. In one embodiment, the molar ratio of compound 1 to MIBK is about 1:0.8.

[0271] In one embodiment, this document provides a form 7 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising a form 7 comprising a free base of compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0272] This application covers all combinations of the above-described embodiments.

[0273] 5.2.1.8 Form 8 of Compound 1

[0274] In one embodiment, form 8 of compound 1 is provided herein. A representative XRPD spectrum of form 8 of compound 1 is provided. Figure 19 middle.

[0275] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 6.0, 6.1, 8.8, 9.2, 9.8, 10.8, 11.9, 12.1, 17.0, 18.0, 18.9, 19.7, 20.1, 20.3, 20.9, 21.3, 21.5, 21.6, 23.6, 24.0, and 25.6 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0276] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.0, 9.2, 10.8, 11.9, 12.1, 17.0, 18.0, 19.7, and 21.5°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.0, 9.2, 10.8, 11.9, 12.1, 17.0, 18.0, 19.7, and 21.5°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.0, 9.2, 10.8, 11.9, 12.1, 17.0, 18.0, 19.7, and 21.5°2θ.

[0277] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.0, 17.0, and 19.7°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 9.2 and 21.5°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 10.8 and 18.0°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.0, 9.2, 10.8, 11.9, 12.1, 17.0, 18.0, 19.7, and 21.5°2θ.

[0278] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 19 The XRPD map depicted in the image matches.

[0279] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0280] Representative overlay plots of TGA / DSC thermograms in Form 8 are provided. Figure 20 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting a thermal event (endothermic) as characterized by DSC, wherein the onset temperature is about 74°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 77°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 20 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 20 Form 8 is a THF solvate.

[0281] In one embodiment, this document provides a solid form comprising a free base of compound 1, which exhibits a weight loss of approximately 15.5% upon heating from approximately 70°C to approximately 150°C. In one embodiment, the solid form is characterized by a TGA thermogram that is consistent with... Figure 20The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10 °C / min.

[0282] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0283] In one embodiment, this document provides a solid form comprising a free base of compound 1, wherein the molar ratio of compound 1 to solvent is in the range of about 1:0.5 to about 1:2. In one embodiment, the molar ratio of compound 1 to solvent is in the range of about 1:1 to about 1:1.7. In one embodiment, the solid form is a THF solvate of the free base of compound 1. In one embodiment, the molar ratio of compound 1 to THF is about 1:1.1. In one embodiment, the molar ratio of compound 1 to THF is about 1:1.6.

[0284] In one embodiment, this document provides a form 8 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising a form 8 comprising a free base of compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0285] This application covers all combinations of the above-described embodiments.

[0286] 5.2.1.9 Form 9 of Compound 1

[0287] In one embodiment, form 9 of compound 1 is provided herein. A representative XRPD spectrum of form 9 of compound 1 is provided. Figure 21 middle.

[0288] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 5.9, 8.7, 8.8, 9.2, 9.7, 10.5, 11.9, 12.0, 14.1, 17.2, 17.7, 18.0, 19.1, 19.4, 19.6, 21.1, 21.4, 23.3, 23.7, and 25.5 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least seven of the peaks. In one embodiment, the solid form is characterized by at least nine of the peaks. In one embodiment, the solid form is characterized by at least eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0289] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.9, 10.5, 11.9, 12.0, 17.2, 17.7, 19.4, 19.6, 21.4, and 23.3°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.9, 10.5, 11.9, 12.0, 17.2, 17.7, 19.4, 19.6, 21.4, and 23.3°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 5.9, 10.5, 11.9, 12.0, 17.2, 17.7, 19.4, 19.6, 21.4, and 23.3°2θ.

[0290] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.9, 17.2, and 19.4°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 17.7 and 19.6°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 11.9 and 23.3°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.9, 10.5, 11.9, 12.0, 17.2, 17.7, 19.4, 19.6, 21.4, and 23.3°2θ.

[0291] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 21 The XRPD map depicted in the image matches.

[0292] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0293] Representative overlay plots of TGA / DSC thermograms of Form 9 are provided. Figure 22 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting a thermal event (endothermic) as characterized by DSC, wherein the initial temperature is about 112°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 117°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 22 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 22 Form 9 is a cyclohexanone solvate.

[0294] In one embodiment, this document provides a solid form comprising a free base of compound 1, which exhibits a weight loss of approximately 17.9% upon heating from approximately 110°C to approximately 180°C. In one embodiment, the solid form is characterized by a TGA thermogram that is consistent with... Figure 22The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10 °C / min.

[0295] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0296] In one embodiment, this document provides a solid form comprising a free base of compound 1, wherein the molar ratio of compound 1 to solvent is in the range of about 1:0.5 to about 1:1.5. In one embodiment, the molar ratio of compound 1 to solvent is in the range of about 1:0.8 to about 1:1.2. In one embodiment, the solid form is a cyclohexanone solvate of the free base of compound 1. In one embodiment, the molar ratio of compound 1 to cyclohexanone is about 1:1.

[0297] In one embodiment, this document provides a form 9 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising a form 9 comprising a free base of compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0298] This application covers all combinations of the above-described embodiments.

[0299] 5.2.1.10 Form 10 of Compound 1

[0300] In one embodiment, form 10 of compound 1 is provided herein. A representative XRPD spectrum of form 10 of compound 1 is provided. Figure 23 middle.

[0301] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 5.7, 5.8, 5.9, 8.2, 8.4, 8.6, 10.6, 11.2, 12.9, 16.1, 17.7, 19.2, 19.3, 20.2, 21.0, 21.1, 21.3, 22.5, 22.7, and 22.9 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least seven of the peaks. In one embodiment, the solid form is characterized by at least nine of the peaks. In one embodiment, the solid form is characterized by at least eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0302] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.9, 8.4, 8.6, 10.6, 11.2, 12.9, 16.1, 19.3, and 21.1°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.9, 8.4, 8.6, 10.6, 11.2, 12.9, 16.1, 19.3, and 21.1°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 5.9, 8.4, 8.6, 10.6, 11.2, 12.9, 16.1, 19.3, and 21.1°2θ.

[0303] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.9, 8.4, and 8.6°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 10.6 and 16.1°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 11.2 and 19.3°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.9, 8.4, 8.6, 10.6, 11.2, 12.9, 16.1, 19.3, and 21.1°2θ.

[0304] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 23 The XRPD map depicted in the image matches.

[0305] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0306] Representative overlay plots of TGA / DSC thermograms of Form 10 are provided. Figure 24 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting a thermal event (endothermic) as characterized by DSC, wherein the initial temperature is about 85°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 91°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 24 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 24 Form 10 is a MIBK solvate.

[0307] In one embodiment, this document provides a solid form comprising a free base of compound 1, which exhibits a weight loss of approximately 17.6% upon heating from approximately 85°C to approximately 120°C. In one embodiment, the solid form is characterized by a TGA thermogram that is consistent with... Figure 24The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10 °C / min.

[0308] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0309] In one embodiment, this document provides a solid form comprising a free base of compound 1, wherein the molar ratio of compound 1 to solvent is in the range of about 1:0.5 to about 1:1.5. In one embodiment, the molar ratio of compound 1 to solvent is in the range of about 1:0.8 to about 1:1.2. In one embodiment, the solid form is a MIBK solvate of the free base of compound 1. In one embodiment, the molar ratio of compound 1 to MIBK is about 1:1.

[0310] In one embodiment, this document provides a form 10 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising a form 10 comprising a free base of compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0311] This application covers all combinations of the above-described embodiments.

[0312] 5.2.1.11 Form 11 of Compound 1

[0313] In one embodiment, form 11 of compound 1 is provided herein. A representative XRPD spectrum of form 11 of compound 1 is provided. Figure 25 middle.

[0314] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 5.9, 8.6, 9.1, 10.0, 10.7, 10.9, 11.7, 12.0, 12.2, 14.4, 14.8, 16.7, 17.8, 19.3, 20.1, 20.7, 21.3, and 24.7 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least seven of the peaks. In one embodiment, the solid form is characterized by at least nine of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In another embodiment, the solid form is characterized by all of the peaks.

[0315] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.9, 9.1, 10.7, 12.0, 12.2, 16.7, 17.8, 20.1, and 21.3°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.9, 9.1, 10.7, 12.0, 12.2, 16.7, 17.8, 20.1, and 21.3°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 5.9, 9.1, 10.7, 12.0, 12.2, 16.7, 17.8, 20.1, and 21.3°2θ.

[0316] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.9, 10.7, and 20.1°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 12.0 and 23.1°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 9.1 and 16.7°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.9, 9.1, 10.7, 12.0, 12.2, 16.7, 17.8, 20.1, and 21.3°2θ.

[0317] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 25 The XRPD map depicted in the image matches.

[0318] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0319] A representative overlay of the TGA / DSC thermogram of Form 11 is provided. Figure 26 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting a thermal event (endothermic) as characterized by DSC, wherein the initial temperature is about 92°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 97°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 26 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 26 Form 11 is a MEK solvate.

[0320] In one embodiment, this document provides a solid form comprising a free base of compound 1, which exhibits a weight loss of approximately 14.4% upon heating from approximately 90°C to approximately 150°C. In one embodiment, the solid form is characterized by a TGA thermogram that is consistent with... Figure 26The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10 °C / min.

[0321] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0322] In one embodiment, this document provides a solid form comprising a free base of compound 1, wherein the molar ratio of compound 1 to solvent is in the range of about 1:0.5 to about 1:1.5. In one embodiment, the molar ratio of compound 1 to solvent is in the range of about 1:0.7 to about 1:1.2. In one embodiment, the solid form is a MEK solvate of the free base of compound 1. In one embodiment, the molar ratio of compound 1 to MEK is about 1:0.8. In one embodiment, the molar ratio of compound 1 to MEK is about 1:1.

[0323] In one embodiment, this document provides a form 11 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising form 11 of free base compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0324] This application covers all combinations of the above-described embodiments.

[0325] 5.2.1.12 Form 12 of Compound 1

[0326] In one embodiment, form 12 of compound 1 is provided herein. A representative XRPD spectrum of form 12 of compound 1 is provided. Figure 27 middle.

[0327] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 5.8, 5.9, 8.7, 9.1, 10.5, 11.8, 11.9, 14.0, 16.9, 17.7, 18.8, 19.2, 19.9, 20.4, 20.8, 21.1, 21.7, 22.1, and 23.0 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least seven of the peaks. In one embodiment, the solid form is characterized by at least nine of the peaks. In one embodiment, the solid form is characterized by at least eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0328] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.8, 5.9, 8.7, 9.1, 17.7, 18.8, 19.2, 21.1, and 22.1°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.8, 5.9, 8.7, 9.1, 17.7, 18.8, 19.2, 21.1, and 22.1°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 5.8, 5.9, 8.7, 9.1, 17.7, 18.8, 19.2, 21.1, and 22.1°2θ.

[0329] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.8, 19.2, and 22.1°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.9 and 17.7°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 8.7 and 18.8°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.8, 5.9, 8.7, 9.1, 17.7, 18.8, 19.2, 21.1, and 22.1°2θ.

[0330] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 27 The XRPD map depicted in the image matches.

[0331] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0332] Representative overlay plots of TGA / DSC thermograms of Form 12 are provided. Figure 28 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting a thermal event (endothermic) as characterized by DSC, wherein the initial temperature is about 95°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 102°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 28 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 28 Form 12 is a methylcyclohexane solvate.

[0333] In one embodiment, this document provides a solid form comprising a free base of compound 1, which exhibits a weight loss of approximately 16.1% upon heating from approximately 95°C to approximately 150°C. In one embodiment, the solid form is characterized by a TGA thermogram that is consistent with... Figure 28The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10 °C / min.

[0334] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0335] In one embodiment, this document provides a solid form comprising a free base of compound 1, wherein the molar ratio of compound 1 to solvent is in the range of about 1:0.5 to about 1:1.5. In one embodiment, the molar ratio of compound 1 to solvent is in the range of about 1:0.7 to about 1:1.1. In one embodiment, the solid form is a methylcyclohexane solvate of the free base of compound 1. In one embodiment, the molar ratio of compound 1 to methylcyclohexane is about 1:0.8. In one embodiment, the molar ratio of compound 1 to methylcyclohexane is about 1:0.9.

[0336] In one embodiment, this document provides a form 12 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising form 12 of free base compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0337] This application covers all combinations of the above-described embodiments.

[0338] 5.2.1.13 Form 13 of Compound 1

[0339] In one embodiment, form 13 of compound 1 is provided herein. A representative XRPD spectrum of form 13 of compound 1 is provided. Figure 29 middle.

[0340] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 5.9, 8.9, 9.2, 9.5, 10.4, 11.6, 11.9, 12.1, 13.9, 15.6, 17.2, 17.8, 18.5, 19.2, 19.9, 20.3, 20.8, 21.4, 22.2, 22.9, 23.1 and 24.0 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0341] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.9, 8.9, 9.2, 10.4, 11.9, 17.2, 17.8, 19.2, 21.4, and 23.1°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 5.9, 8.9, 9.2, 10.4, 11.9, 17.2, 17.8, 19.2, 21.4, and 23.1°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 5.9, 8.9, 9.2, 10.4, 11.9, 17.2, 17.8, 19.2, 21.4, and 23.1°2θ.

[0342] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.9, 9.2, and 19.2°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 11.9 and 17.2°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 10.4, 21.4, and 23.1°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 5.9, 8.9, 9.2, 10.4, 11.9, 17.2, 17.8, 19.2, 21.4, and 23.1°2θ.

[0343] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 29 The XRPD map depicted in the image matches.

[0344] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0345] A representative overlay of the TGA / DSC thermogram of Form 13 is provided. Figure 30 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting a thermal event (endothermic) as characterized by DSC, wherein the initial temperature is about 123°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 129°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 30 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 30 Form 13 is a cyclohexane solvate.

[0346] In one embodiment, this document provides a solid form comprising a free base of compound 1, which exhibits a weight loss of approximately 14.5% upon heating from approximately 120°C to approximately 150°C. In one embodiment, the solid form is characterized by a TGA thermogram that is consistent with... Figure 30The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10 °C / min.

[0347] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0348] In one embodiment, this document provides a solid form comprising a free base of compound 1, wherein the molar ratio of compound 1 to solvent is in the range of about 1:0.5 to about 1:1.5. In one embodiment, the molar ratio of compound 1 to solvent is in the range of about 1:0.6 to about 1:1.1. In one embodiment, the solid form is a cyclohexane solvate of the free base of compound 1. In one embodiment, the molar ratio of compound 1 to cyclohexane is about 1:0.7. In one embodiment, the molar ratio of compound 1 to cyclohexane is about 1:0.9.

[0349] In one embodiment, this document provides a form 13 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising a free base of compound 1 in form 13 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0350] This application covers all combinations of the above-described embodiments.

[0351] 5.2.1.14 Form 14 of Compound 1

[0352] In one embodiment, form 14 of compound 1 is provided herein. A representative XRPD spectrum of form 14 of compound 1 is provided. Figure 31 middle.

[0353] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 6.7, 6.8, 9.7, 10.1, 12.5, 16.6, 16.9, 17.1, 18.2, 18.9, 19.4, 20.6, 21.2, 21.8, 22.2, 22.6, 23.5, 24.5, and 25.2 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least seven of the peaks. In one embodiment, the solid form is characterized by at least nine of the peaks. In one embodiment, the solid form is characterized by at least eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0354] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.7, 6.8, 9.7, 12.5, 16.9, 17.1, 18.9, 21.2, and 22.2°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.7, 6.8, 9.7, 12.5, 16.9, 17.1, 18.9, 21.2, and 22.2°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.7, 6.8, 9.7, 12.5, 16.9, 17.1, 18.9, 21.2, and 22.2°2θ.

[0355] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.7, 16.9, and 18.9°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.8 and 22.2°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 9.7 and 21.2°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.7, 6.8, 9.7, 12.5, 16.9, 17.1, 18.9, 21.2, and 22.2°2θ.

[0356] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 31 The XRPD map depicted in the image matches.

[0357] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0358] A representative overlay of the TGA / DSC thermograms of Form 14 is provided. Figure 32 In one embodiment, this document provides a solid form comprising a free base of compound 1, exhibiting a thermal event (endothermic) as characterized by DSC, wherein the initial temperature is about 75°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 80°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 32 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 32 Form 14 is a mixed solvate of cyclohexanone and tert-butanol.

[0359] In one embodiment, this document provides a solid form comprising a free base of compound 1, which exhibits a weight loss of approximately 27.9% upon heating from approximately 75°C to approximately 150°C. In one embodiment, the solid form is characterized by a TGA thermogram that is consistent with… Figure 32The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10 °C / min.

[0360] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0361] In one embodiment, this document provides a solid form comprising a free base of compound 1, which is a mixed solvate. In one embodiment, the solid form is a mixed solvate of cyclohexanone and tert-butanol. In one embodiment, this document provides a solid form comprising a free base of compound 1, wherein the molar ratio of compound 1 to the solvent is in the range of about 1:0.9 to about 1:2. In one embodiment, the molar ratio of compound 1 to the solvent is about 1:1.4.

[0362] In one embodiment, this document provides a form 14 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising form 14 comprising a free base of compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0363] This application covers all combinations of the above-described embodiments.

[0364] 5.2.1.15 Form 15 of Compound 1

[0365] In one embodiment, form 15 of compound 1 is provided herein. A representative XRPD spectrum of form 15 of compound 1 is provided. Figure 33 middle.

[0366] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 5.7, 6.1, 6.7, 7.1, 7.7, 9.1, 10.0, 10.6, 12.8, 16.7, 17.5, 18.8, 19.3, 20.0, 20.5, 22.0, 22.8, 23.4, and 24.8 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least seven of the peaks. In one embodiment, the solid form is characterized by at least nine of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In another embodiment, the solid form is characterized by all of the peaks.

[0367] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.7, 7.1, 10.0, 10.6, 18.8, 20.0, 20.5, 22.0, and 22.8°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.7, 7.1, 10.0, 10.6, 18.8, 20.0, 20.5, 22.0, and 22.8°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.7, 7.1, 10.0, 10.6, 18.8, 20.0, 20.5, 22.0, and 22.8°2θ.

[0368] In one embodiment, this document provides a solid form of a free base comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.7, 22.0, and 22.8°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 18.8 and 20.5°2θ. In one embodiment, the solid form is further characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 10.6 and 20.0°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.7, 7.1, 10.0, 10.6, 18.8, 20.0, 20.5, 22.0, and 22.8°2θ.

[0369] In one embodiment, this document provides a solid form comprising a free base of compound 1, characterized in that its XRPD pattern is consistent with... Figure 33 The XRPD map depicted in the image matches.

[0370] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0371] Representative overlay plots of TGA / DSC thermograms in Form 15 are provided. Figure 34 In one embodiment, this document provides a solid form comprising a free base of compound 1, which exhibits a thermal event (exothermic) as characterized by DSC, wherein the onset temperature is about 173°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 179°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 34 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 34 Form 15 is an acetone solvate.

[0372] In one embodiment, this document provides a solid form comprising a free base of compound 1, which exhibits a weight loss of approximately 8.5% upon heating from approximately 25°C to approximately 150°C. In one embodiment, the solid form is characterized by a TGA thermogram that is consistent with... Figure 34The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10 °C / min.

[0373] In some embodiments, this document provides a solid form comprising a free base of compound 1, which is a crystalline solvate of the free base of compound 1. In some embodiments, the solid form is substantially free of amorphous compound 1. In some embodiments, the solid form is substantially free of other solid forms of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0374] In one embodiment, this document provides a solid form comprising a free base of compound 1, wherein the molar ratio of compound 1 to solvent is in the range of about 1:0.5 to about 1:1.2. In one embodiment, the molar ratio of compound 1 to solvent is in the range of about 1:0.6 to about 1:1.1. In one embodiment, the solid form is an acetone solvate of the free base of compound 1. In one embodiment, the molar ratio of compound 1 to acetone is about 1:0.7. In one embodiment, the molar ratio of compound 1 to acetone is about 1:1.

[0375] In one embodiment, this document provides a form 15 comprising a free base of compound 1 and a solid form of an amorphous free base of compound 1. In one embodiment, this document provides a solid form comprising a form 15 comprising a free base of compound 1 and one or more other crystalline forms of the free base of compound 1 provided herein.

[0376] This application covers all combinations of the above-described embodiments.

[0377] 5.2.2. Method for preparing compound 1 in solid form

[0378] As used herein and unless otherwise specified, all solvent ratios refer to volume ratios.

[0379] In one embodiment, this document provides a method for preparing form 1 of a compound of formula (I), the method comprising:

[0380] (i) exposing a composition comprising at least one non-form 1 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the non-form 1 solid form to form 1; and

[0381] (ii) Recycle Form 1.

[0382] In one embodiment, the non-form 1 solid form is exposed to a solvent. In one embodiment, the non-form 1 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 1 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is 2-MeTHF, isopropyl acetate, heptane, or a mixture thereof. In one embodiment, the solvent is 2-MeTHF. In one embodiment, the solvent is isopropyl acetate. In one embodiment, the solvent is a mixture of 2-MeTHF and heptane. In one embodiment, the ratio of 2-MeTHF to heptane is about 1:2 to about 1:6. In one embodiment, the solvent is a mixture of isopropyl acetate and heptane. In one embodiment, the ratio of isopropyl acetate to heptane is about 1:2 to about 1:6. In one embodiment, an antisolvent is added to the solvent. In one embodiment, the antisolvent is a nonpolar organic solvent. In one embodiment, the nonpolar organic solvent is a hydrocarbon solvent. In one embodiment, the antisolvent is heptane. In one embodiment, the solvent is 2-MeTHF and the antisolvent is heptane. In one embodiment, the solvent is isopropyl acetate and the antisolvent is heptane. In one embodiment, the final solvent to antisolvent ratio is from about 1:2 to about 1:6. In one embodiment, the non-form 1 solid form is exposed to the solvent and / or antisolvent at room temperature. In one embodiment, the non-form 1 solid form is exposed to the solvent and / or antisolvent at a temperature above room temperature. In one embodiment, the non-form 1 solid form is exposed to the solvent and / or antisolvent at a temperature from about 25°C to about 60°C.

[0383] In one embodiment, the non-form 1 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 1 solid form is any one of form 2 to form 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 1 solid form into form 1 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0384] Form 1 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0385] In one embodiment, form 1 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is 2-MeTHF. In one embodiment, the solvent is isopropyl acetate.

[0386] In one embodiment, form 1 of compound (I) is prepared by crystallizing or recrystallizing the compound of formula (I) from a solvent comprising a mixture of two solvents. In one embodiment, the mixture of the two solvents is a mixture of 2-MeTHF and heptane. In one embodiment, the volume ratio of 2-MeTHF to heptane is about 1:10 to about 1:2. In one embodiment, the mixture of the two solvents is a mixture of isopropyl acetate and heptane. In one embodiment, the volume ratio of isopropyl acetate to heptane is about 1:10 to about 1:2. In one embodiment, the volume ratio of isopropyl acetate to heptane is about 1:1.

[0387] In one embodiment, form 1 of the compound is prepared by evaporating a solution of the compound of formula (I) in 2-MeTHF. In one embodiment, the evaporation is carried out at about 20°C. In one embodiment, the evaporation is a slow evaporation (e.g., lasting about 7 days).

[0388] In one embodiment, form 1 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0389] In one embodiment, this document provides a method for preparing form 2 of a compound of formula (I), the method comprising:

[0390] (i) exposing a composition comprising at least one non-form 2 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the non-form 2 solid form to form 2; and

[0391] (ii) Recycle Form 2.

[0392] In one embodiment, the non-form 2 solid form is exposed to a solvent. In one embodiment, the non-form 2 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 2 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is ethanol, acetonitrile, tert-butyl methyl ether, isobutyl acetate, cyclopentyl methyl ether, isopropyl acetate, ethyl acetate, 1-butanol, 2-butanol, cyclohexane, THF, cyclopentylmethyl (CPME), diisopropyl ether (DIIPE), methyl ether ketone (MEK), methyl isobutyl ketone (MIBK), 1-propanol, 2-propanol, tert-amyl alcohol, n-butyl acetate, methanol, toluene, dichloromethane, ethyl tert-butyl ether (tBME), cyclopentyl methyl ether, methylcyclohexane, acetone, 2-methylTHF, 2-ethoxyethanol, anisole, DMSO, 1,4-dioxane, heptane, or mixtures thereof. In one embodiment, the solvent is ethanol. In one embodiment, the solvent is a mixture of ethanol and heptane. In one embodiment, the volume ratio of ethanol to heptane is from about 1:2 to about 1:15. In one embodiment, the volume ratio of ethanol to heptane is from about 1:6 to about 1:10. In one embodiment, the solvent is ethyl acetate. In one embodiment, the solvent is a mixture of ethyl acetate and heptane. In one embodiment, the volume ratio of ethyl acetate to heptane is from about 1:2 to about 1:15. In one embodiment, the volume ratio of ethyl acetate to heptane is from about 1:6 to about 1:10. In one embodiment, an antisolvent is added to the solvent. In one embodiment, the antisolvent is a nonpolar organic solvent. In one embodiment, the nonpolar organic solvent is a hydrocarbon solvent. In one embodiment, the antisolvent is heptane. In one embodiment, the final volume ratio of solvent to antisolvent is from about 1:1 to about 1:15. In one embodiment, the final volume ratio of solvent to antisolvent is from about 1:6 to about 1:10. In one embodiment, the non-form 2 solid form is exposed to the solvent and / or antisolvent at room temperature. In one embodiment, the non-form 2 solid form is exposed to the solvent and / or antisolvent at a temperature above room temperature. In one embodiment, the non-form 2 solid form is exposed to a solvent and / or anti-solvent at a temperature of about 25°C to about 60°C. In another embodiment, the non-form 2 solid form is exposed to a solvent and / or anti-solvent at a temperature of about 35°C to about 55°C.

[0393] In one embodiment, the non-form 2 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 2 solid form is any one of form 1 or form 3 to form 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 2 solid form into form 2 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0394] Form 2 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0395] In one embodiment, form 2 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is ethanol. In one embodiment, the solvent is ethyl acetate.

[0396] In one embodiment, form 2 of compound (I) is prepared by crystallizing or recrystallizing the compound of formula (I) from a solvent comprising a mixture of two solvents. In one embodiment, the mixture of the two solvents is a mixture of ethanol and heptane. In one embodiment, the volume ratio of ethanol to heptane is from about 1:15 to about 1:2. In one embodiment, the mixture of the two solvents is a mixture of ethyl acetate and heptane. In one embodiment, the volume ratio of ethyl acetate to heptane is from about 1:15 to about 1:2. In one embodiment, the volume ratio of ethyl acetate to heptane is from about 1:8. In one embodiment, the weight ratio of EtOAc to heptane is from about 1:3 to about 1:10. In one embodiment, the weight ratio of EtOAc to heptane is from about 1:6.2.

[0397] In one embodiment, form 2 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0398] In one embodiment, this document provides a method for preparing form 2 of compound (I), the method comprising:

[0399] (i) Dissolve the compound of formula (I) in a solvent;

[0400] (ii) Add antisolvent; and

[0401] (iii) Recycle Form 2.

[0402] In one embodiment, the solvent is ethanol. In one embodiment, the antisolvent is heptane. In one embodiment, the solvent is ethanol and the antisolvent is heptane.

[0403] In another embodiment, the solvent is ethyl acetate. In one embodiment, the antisolvent is heptane. In another embodiment, the solvent is ethyl acetate and the antisolvent is heptane.

[0404] In one embodiment, this document provides a method for preparing form 2 of compound (I), the method comprising:

[0405] (i) the desolvation of at least one non-form 2 solid form of the compound of formula (I) for a period of time sufficient to convert at least about 50% of the total amount of the non-form 2 solid form into form 2; and

[0406] (ii) Recycle Form 2.

[0407] In one embodiment, the at least one amorphous solid form 2 is desolvated at a temperature above room temperature. In one embodiment, the temperature is about 30 to about 60°C. In one embodiment, the temperature is about 40-60°C. In one embodiment, the temperature is about 50-60°C. In one embodiment, the temperature is about 100 to about 200°C. In one embodiment, the at least one amorphous solid form 2 is desolvated under vacuum. In one embodiment, the at least one amorphous solid form 2 is an amorphous solid form of the compound of formula (I). In one embodiment, the at least one amorphous solid form 2 is any one of form 1 or form 3 to form 15 of the compound of formula (I). In one embodiment, the at least one amorphous solid form 2 is form 1 of the compound of formula (I). In one embodiment, the at least one amorphous solid form 2 is form 3 of the compound of formula (I). In one implementation, the time period sufficient to convert at least about 50% of the total amount of the non-form 2 solid form into form 2 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0408] In one embodiment, form 2 of compound (I) is prepared by a method comprising: (i) concentrating a solution of compound 1 comprising a mixture of EtOH and heptane (EtOH:heptane in a volume ratio of about 1:0.2 to about 1:0.7); (ii) adding about 3 to about 15 times the solution volume (e.g., 6 to 8 times) of heptane; and (iii) heating the solution from about 45°C to about 55°C. In one embodiment, the method further comprises, after step (iii), stirring the solution at about 10-15°C.

[0409] In one embodiment, form 2 of the compound of formula (I) is prepared by a method comprising: (i) concentrating a solution containing the compound of formula (I) in EtOAc; (ii) adding heptane to form a solution; and (iii) heating the solution from about 45°C to about 55°C. In one embodiment, the concentration is carried out at about below 50°C. In one embodiment, the method further comprises, after step (ii), adding a seed amount of form 2. In some embodiments, the seed amount is about 0.5 wt% to about 15 wt% of the compound of formula (I). In some embodiments, the seed amount is about 1 wt% to about 10 wt% of the compound of formula (I). In some embodiments, the seed amount is about 5 wt% of the compound of formula (I). In some embodiments, the seed amount is about 4 wt% of the compound of formula (I). In some embodiments, the seed amount is about 3 wt% of the compound of formula (I). In some embodiments, the seed amount is about 2 wt% of the compound of formula (I). In some embodiments, the seed amount is about 1 wt% of the compound of formula (I).

[0410] In one embodiment, this document provides a method for preparing form 3 of a compound of formula (I), the method comprising:

[0411] (i) exposing a composition comprising at least one form 3 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the form 3 solid form to form 3; and

[0412] (ii) Recycle form 3.

[0413] In one embodiment, the non-form 3 solid form is exposed to a solvent. In one embodiment, the non-form 3 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 3 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is 2-MeTHF. In one embodiment, the non-form 3 solid form is exposed to the solvent at room temperature. In one embodiment, the non-form 3 solid form is exposed to the solvent at a temperature above room temperature. In one embodiment, the non-form 3 solid form is exposed to the solvent at a temperature of about 25°C to about 60°C.

[0414] In one embodiment, the non-form 3 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 3 solid form is any one of form 1 to form 2 or form 4 to form 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 3 solid form into form 3 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0415] Form 3 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0416] In one embodiment, form 3 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is 2-MeTHF.

[0417] In one embodiment, form 3 of compound (I) is prepared by evaporating a solution of the compound in 2-MeTHF. In one embodiment, evaporation is carried out at about 20°C. In one embodiment, evaporation is carried out at about 50°C. In one embodiment, evaporation is slow evaporation (e.g., lasting about 3 days or about 7 days).

[0418] In one embodiment, form 3 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0419] In one embodiment, this document provides a method for preparing form 4 of compound (I), the method comprising:

[0420] (i) exposing a composition comprising at least one form 4 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the form 4 solid form to form 4; and

[0421] (ii) Recycle form 4.

[0422] In one embodiment, the non-form 4 solid form is exposed to a solvent. In one embodiment, the non-form 4 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 4 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is 1,4-dioxane, water, heptane, or a mixture thereof. In one embodiment, the solvent is 1,4-dioxane. In one embodiment, the solvent is a mixture of 1,4-dioxane and heptane. In one embodiment, the volume ratio of 1,4-dioxane to heptane is from about 1:2 to about 1:6. In one embodiment, the solvent is a mixture of 1,4-dioxane and water. In one embodiment, the volume ratio of 1,4-dioxane to water is from about 1:2 to about 10:1. In one embodiment, an antisolvent is added to the solvent. In one embodiment, the antisolvent is a nonpolar organic solvent. In one embodiment, the nonpolar organic solvent is a hydrocarbon solvent. In one embodiment, the antisolvent is heptane. In one embodiment, the antisolvent is water. In one embodiment, the solvent is 1,4-dioxane and the antisolvent is heptane. In one embodiment, the solvent is 1,4-dioxane and the antisolvent is water. In one embodiment, the final solvent to antisolvent ratio is about 1:2. In one embodiment, the final solvent to antisolvent ratio is about 1:1 to about 10:1. In one embodiment, the final solvent to antisolvent ratio is about 8:1. In one embodiment, the non-form 4 solid form is exposed to the solvent and / or antisolvent at room temperature. In one embodiment, the non-form 4 solid form is exposed to the solvent and / or antisolvent at a temperature above room temperature. In one embodiment, the non-form 4 solid form is exposed to the solvent and / or antisolvent at a temperature of about 25°C to about 60°C.

[0423] In one embodiment, the non-form 4 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 4 solid form is any one of form 1 to form 3 or form 5 to form 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 4 solid form into form 4 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0424] Form 4 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0425] In one embodiment, form 4 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is 1,4-dioxane.

[0426] In one embodiment, form 4 of compound (I) is prepared by crystallizing or recrystallizing the compound (I) from a solvent comprising a mixture of two solvents. In one embodiment, the mixture of two solvents is a mixture of 1,4-dioxane and heptane. In one embodiment, the volume ratio of 1,4-dioxane to heptane is from about 1:10 to about 1:1. In one embodiment, the mixture of two solvents is a mixture of 1,4-dioxane and water. In one embodiment, the volume ratio of 1,4-dioxane to water is from about 1:10 to about 10:1. In one embodiment, the volume ratio of 1,4-dioxane to water is about 1:1. In one embodiment, the volume ratio of 1,4-dioxane to water is about 8:1.

[0427] In one embodiment, form 4 of compound (I) is prepared by a method comprising slurrying and / or stirring the compound in a mixture of 1,4-dioxane and water. In one embodiment, the mixture has a volume ratio of 1,4-dioxane to water of about 1:2. In one embodiment, the mixture has a volume ratio of 1,4-dioxane to water of about 8:1. In one embodiment, slurrying and / or stirring is carried out at about 20°C. In one embodiment, slurrying and / or stirring is carried out for at least 12 hours.

[0428] In one embodiment, form 4 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0429] In one embodiment, this document provides a method for preparing form 5 of a compound of formula (I), the method comprising:

[0430] (i) exposing a composition comprising at least one form 5 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the form 5 solid form to form 5; and

[0431] (ii) Recycle form 5.

[0432] In one embodiment, the non-form 5 solid form is exposed to a solvent. In one embodiment, the non-form 5 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 5 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is 2-propanol, tert-butanol, THF, acetone, heptane, or a mixture thereof. In one embodiment, the solvent is 2-propanol. In one embodiment, the solvent is tert-butanol. In one embodiment, the solvent is THF. In one embodiment, the solvent is acetone. In one embodiment, the solvent is a mixture of 2-propanol and tert-butanol. In one embodiment, the solvent is a mixture of acetone and tert-butanol. In one embodiment, the solvent is a mixture of THF and tert-butanol. In one embodiment, the non-form 5 solid form is exposed to the solvent at room temperature. In one embodiment, the non-form 5 solid form is exposed to the solvent at a temperature above room temperature. In one embodiment, the non-form 5 solid form is exposed to the solvent at a temperature from about 25°C to about 60°C.

[0433] In one embodiment, the non-form 5 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 5 solid form is any one of forms 1 to 4 or forms 6 to 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 5 solid form into form 5 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0434] Form 5 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0435] In one embodiment, form 5 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is 2-propanol, tert-butanol, THF, acetone, heptane, or a mixture thereof. In one embodiment, the solvent is 2-propanol. In one embodiment, the solvent is tert-butanol. In one embodiment, the solvent is THF. In one embodiment, the solvent is acetone.

[0436] In one embodiment, form 5 of compound (I) is prepared by crystallizing or recrystallizing the compound (I) from a solvent comprising a mixture of two solvents. In one embodiment, the solvent is a mixture of 2-propanol and tert-butanol. In one embodiment, the solvent is a mixture of acetone and tert-butanol. In one embodiment, the solvent is a mixture of THF and tert-butanol.

[0437] In one embodiment, form 5 of compound (I) is prepared by grinding the compound in tert-butanol (e.g., with steel beads). In one embodiment, the compound is ground with the beads at 6000 RPM. In one embodiment, the grinding is performed in cycles, for example, 90-second cycles, with a 10-second pause between each cycle. In one embodiment, 40 cycles are performed.

[0438] In one embodiment, form 5 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0439] In one embodiment, this document provides a method for preparing form 6 of compound (I), the method comprising:

[0440] (i) exposing a composition comprising at least one form 6 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the form 6 solid form to form 6; and

[0441] (ii) Recycle Form 6.

[0442] In one embodiment, the non-form 6 solid form is exposed to a solvent. In one embodiment, the non-form 6 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 6 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is acetone. In one embodiment, the non-form 6 solid form is exposed to a solvent at room temperature. In one embodiment, the non-form 6 solid form is exposed to a solvent at a temperature above room temperature. In one embodiment, the non-form 6 solid form is exposed to a solvent at a temperature from about 25°C to about 60°C.

[0443] In one embodiment, the non-form 6 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 6 solid form is any one of forms 1 to 5 or forms 7 to 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 6 solid form into form 6 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0444] Form 6 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0445] In one embodiment, form 6 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is acetone.

[0446] In one embodiment, form 6 of compound (I) is prepared by grinding the compound in acetone (e.g., with steel beads). In one embodiment, the compound is ground with the beads at 6000 RPM. In one embodiment, the grinding is performed in cycles, for example, 90-second cycles, with a 10-second pause between each cycle. In one embodiment, 40 cycles are performed.

[0447] In one embodiment, form 6 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0448] In one embodiment, this document provides a method for preparing form 7 of compound (I), the method comprising:

[0449] (i) exposing a composition comprising at least one non-form 7 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the non-form 7 solid form to form 7; and

[0450] (ii) Recycle form 7.

[0451] In one embodiment, the non-form 7 solid form is exposed to a solvent. In one embodiment, the non-form 7 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 7 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is MIBK, heptane, or a mixture thereof. In one embodiment, the solvent is MIBK. In one embodiment, the solvent is a mixture of MIBK and heptane. In one embodiment, the ratio of MIBK to heptane is from about 1:1 to about 1:6. In one embodiment, the ratio of MIBK to heptane is about 1:2. In one embodiment, an antisolvent is added to the solvent. In one embodiment, the antisolvent is a nonpolar organic solvent. In one embodiment, the nonpolar organic solvent is a hydrocarbon solvent. In one embodiment, the antisolvent is heptane. In one embodiment, the solvent is MIBK and the antisolvent is heptane. In one embodiment, the final ratio of solvent to antisolvent is from about 1:1 to about 1:6. In one embodiment, the final ratio of solvent to antisolvent is about 1:2. In one embodiment, the non-form 7 solid form is exposed to the solvent and / or anti-solvent at room temperature. In one embodiment, the non-form 7 solid form is exposed to the solvent and / or anti-solvent at a temperature above room temperature. In one embodiment, the non-form 7 solid form is exposed to the solvent and / or anti-solvent at a temperature of about 25°C to about 60°C.

[0452] In one embodiment, the non-form 7 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 7 solid form is any one of forms 1 to 6 or forms 8 to 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 7 solid form into form 7 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0453] Form 7 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0454] In one embodiment, form 7 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is MIBK.

[0455] In one embodiment, compound (I) in form 7 is prepared by crystallizing or recrystallizing the compound from a solvent comprising a mixture of two solvents. In one embodiment, the mixture of the two solvents is a mixture of MIBK and heptane. In one embodiment, the volume ratio of MIBK to heptane is from about 1:10 to about 1:1. In one embodiment, the volume ratio of MIBK to heptane is about 1:2.

[0456] In one embodiment, form 7 of compound (I) is prepared by a method comprising slurrying and / or stirring the compound in a mixture of MIBK and heptane. In one embodiment, the mixture has a volume ratio of MIBK to heptane of about 1:2. In one embodiment, the slurrying and / or stirring is carried out at about 20°C. In one embodiment, the slurrying and / or stirring is carried out for at least 12 hours.

[0457] In one embodiment, form 7 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0458] In one embodiment, this document provides a method for preparing form 8 of compound (I), the method comprising:

[0459] (i) exposing a composition comprising at least one non-form 8 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the non-form 8 solid form to form 8; and

[0460] (ii) Recycle form 8.

[0461] In one embodiment, the non-form 8 solid form is exposed to a solvent. In one embodiment, the non-form 8 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 8 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is THF, heptane, or a mixture thereof. In one embodiment, the solvent is THF. In one embodiment, the solvent is a mixture of THF and heptane. In one embodiment, the volume ratio of THF to heptane is from about 1:1 to about 1:6. In one embodiment, the volume ratio of THF to heptane is about 1:1. In one embodiment, an antisolvent is added to the solvent. In one embodiment, the antisolvent is a nonpolar organic solvent. In one embodiment, the nonpolar organic solvent is a hydrocarbon solvent. In one embodiment, the antisolvent is heptane. In one embodiment, the solvent is THF and the antisolvent is heptane. In one embodiment, the final volume ratio of solvent to antisolvent is from about 1:1 to about 1:6. In one embodiment, the final volume ratio of solvent to antisolvent is about 1:1. In one embodiment, the non-form 8 solid form is exposed to a solvent and / or anti-solvent at room temperature. In one embodiment, the non-form 8 solid form is exposed to a solvent and / or anti-solvent at a temperature above room temperature. In one embodiment, the non-form 8 solid form is exposed to a solvent and / or anti-solvent at a temperature of about 25°C to about 60°C.

[0462] In one embodiment, the non-form 8 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 8 solid form is any one of forms 1 to 7 or forms 9 to 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 8 solid form into form 8 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0463] Form 8 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0464] In one embodiment, form 8 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is THF.

[0465] In one embodiment, compound (I) in form 8 is prepared by crystallizing or recrystallizing the compound from a solvent comprising a mixture of two solvents. In one embodiment, the mixture of the two solvents is a mixture of THF and heptane. In one embodiment, the volume ratio of THF to heptane is from about 1:10 to about 1:1. In one embodiment, the volume ratio of THF to heptane is about 1:1.

[0466] In one embodiment, form 8 of compound (I) is prepared by a method comprising slurrying and / or stirring the compound in a mixture of THF and heptane. In one embodiment, the mixture has a THF to heptane volume ratio of about 1:2. In one embodiment, the slurrying and / or stirring is carried out at about 20°C. In one embodiment, the slurrying and / or stirring is carried out for at least 24 hours.

[0467] In one embodiment, form 8 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0468] In one embodiment, this document provides a method for preparing form 9 of compound (I), the method comprising:

[0469] (i) exposing a composition comprising at least one non-form 9 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the non-form 9 solid form to form 9; and

[0470] (ii) Recycle form 9.

[0471] In one embodiment, the non-form 9 solid form is exposed to a solvent. In one embodiment, the non-form 9 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 9 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is cyclohexanone, heptane, or a mixture thereof. In one embodiment, the solvent is cyclohexanone. In one embodiment, the solvent is cyclohexanone. In one embodiment, the ratio of cyclohexanone to heptane is from about 1:1 to about 1:6. In one embodiment, an antisolvent is added to the solvent. In one embodiment, the antisolvent is a nonpolar organic solvent. In one embodiment, the nonpolar organic solvent is a hydrocarbon solvent. In one embodiment, the antisolvent is heptane. In one embodiment, the solvent is cyclohexanone and the antisolvent is heptane. In one embodiment, the final ratio of solvent to antisolvent is from about 1:1 to about 1:6. In one embodiment, the non-form 9 solid form is exposed to the solvent and / or antisolvent at room temperature. In one embodiment, the non-form 9 solid form is exposed to the solvent and / or antisolvent at a temperature above room temperature. In one embodiment, the non-form 9 solid form is exposed to a solvent and / or anti-solvent at a temperature of about 25°C to about 60°C.

[0472] In one embodiment, the non-form 9 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 9 solid form is any one of forms 1 to 8 or forms 10 to 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 9 solid form into form 9 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0473] Form 9 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0474] In one embodiment, form 9 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture of stereoisomers or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is cyclohexanone.

[0475] In one embodiment, form 9 of compound (I) is prepared by crystallizing or recrystallizing the compound from a solvent comprising a mixture of two solvents. In one embodiment, the mixture of the two solvents is a mixture of cyclohexanone and heptane. In one embodiment, the volume ratio of cyclohexanone to heptane is from about 1:10 to about 1:1.

[0476] In one embodiment, the compound in form 9 is prepared by evaporating a solution of the compound of formula (I) in cyclohexanone. In one embodiment, the evaporation is carried out at about 20°C. In one embodiment, the evaporation is a slow evaporation (e.g., lasting about 7 days).

[0477] In one embodiment, form 9 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0478] In one embodiment, this document provides a method for preparing form 10 of a compound of formula (I), the method comprising:

[0479] (i) exposing a composition comprising at least one non-form 10 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the non-form 10 solid form to form 10; and

[0480] (ii) Recycle Form 10.

[0481] In one embodiment, the non-form 10 solid form is exposed to a solvent. In one embodiment, the non-form 10 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 10 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is MIBK. In one embodiment, the non-form 10 solid form is exposed to a solvent at room temperature. In one embodiment, the non-form 10 solid form is exposed to a solvent at a temperature above room temperature. In one embodiment, the non-form 10 solid form is exposed to a solvent at a temperature of about 25°C to about 60°C.

[0482] In one embodiment, the non-form 10 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 10 solid form is any one of forms 1 to 9 or forms 11 to 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 10 solid form into form 10 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0483] Form 10 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0484] In one embodiment, form 10 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture of stereoisomers or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is MIBK. In one embodiment, the solvent mixture is MIBK and water. In one embodiment, the solvent mixture is MIBK and water in a volume ratio of about 1:3 to 3:1. In one embodiment, the solvent mixture is MIBK and water in a volume ratio of about 1:1.

[0485] In one embodiment, the compound in form 10 is prepared by evaporating a solution of the compound of formula (I) in MIBK. In one embodiment, the evaporation is carried out at about 20°C. In one embodiment, the evaporation is a slow evaporation (e.g., lasting about 7 days).

[0486] In one embodiment, form 10 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0487] In one embodiment, this document provides a method for preparing form 11 of a compound of formula (I), the method comprising:

[0488] (i) exposing a composition comprising at least one non-form 11 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the non-form 11 solid form to form 11; and

[0489] (ii) Recycle form 11.

[0490] In one embodiment, the non-form 11 solid form is exposed to a solvent. In one embodiment, the non-form 11 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 11 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is MEK, heptane, or a mixture thereof. In one embodiment, the solvent is MEK. In one embodiment, the solvent is a mixture of MEK and heptane. In one embodiment, the volume ratio of MEK to heptane is from about 1:1 to about 1:6. In one embodiment, the volume ratio of MEK to heptane is about 1:1. In one embodiment, the solvent is a mixture of MEK and water. In one embodiment, the solvent is a mixture of MEK and water with a volume ratio of about 10:1 to 1:1. In one embodiment, the solvent is a mixture of MEK and water with a volume ratio of about 5:1. In one embodiment, an antisolvent is added to the solvent. In one embodiment, the antisolvent is a nonpolar organic solvent. In one embodiment, the nonpolar organic solvent is a hydrocarbon solvent. In one embodiment, the antisolvent is heptane. In one embodiment, the solvent is MEK and the antisolvent is heptane. In one embodiment, the final volume ratio of solvent to antisolvent is from about 1:1 to about 1:6. In one embodiment, the non-form 11 solid form is exposed to the solvent and / or antisolvent at room temperature. In one embodiment, the non-form 11 solid form is exposed to the solvent and / or antisolvent at a temperature above room temperature. In one embodiment, the non-form 11 solid form is exposed to the solvent and / or antisolvent at a temperature from about 25°C to about 60°C.

[0491] In one embodiment, the non-form 11 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 11 solid form is any one of form 1 to form 10 or form 12 to form 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 11 solid form into form 11 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0492] Form 11 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0493] In one embodiment, form 11 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture of stereoisomers or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is MEK.

[0494] In one embodiment, form 11 of compound (I) is prepared by crystallizing or recrystallizing the compound (I) from a solvent comprising a mixture of two solvents. In one embodiment, the mixture of the two solvents is a mixture of MEK and heptane. In one embodiment, the volume ratio of MEK to heptane is from about 1:10 to about 1:1.

[0495] In one embodiment, form 11 of compound (I) is prepared by a method comprising slurrying and / or stirring the compound in a mixture of MEK and heptane. In one embodiment, the mixture has a volume ratio of MEK to heptane of about 1:1. In one embodiment, the slurrying and / or stirring is carried out at about 20°C. In one embodiment, the slurrying and / or stirring is carried out for at least 12 hours.

[0496] In one embodiment, form 11 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0497] In one embodiment, this document provides a method for preparing form 12 of a compound of formula (I), the method comprising:

[0498] (i) exposing a composition comprising at least one non-form 12 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the non-form 12 solid form to form 12; and

[0499] (ii) Recycle form 12.

[0500] In one embodiment, the non-form 12 solid form is exposed to a solvent. In one embodiment, the non-form 12 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 12 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is methylcyclohexane. In one embodiment, the non-form 12 solid form is exposed to a solvent at room temperature. In one embodiment, the non-form 12 solid form is exposed to a solvent at a temperature above room temperature. In one embodiment, the non-form 12 solid form is exposed to a solvent at a temperature from about 25°C to about 60°C.

[0501] In one embodiment, the non-form 12 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 12 solid form is any one of form 1 to form 11 or form 13 to form 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 12 solid form into form 12 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0502] Form 12 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0503] In one embodiment, form 12 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is methylcyclohexane.

[0504] In one embodiment, form 12 of compound (I) is prepared by a method comprising pulping and / or stirring the compound in methylcyclohexane. In one embodiment, the pulping and / or stirring is carried out at about 20°C. In one embodiment, the pulping and / or stirring is carried out for at least 24 hours.

[0505] In one embodiment, form 12 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0506] In one embodiment, this document provides a method for preparing form 13 of compound (I), the method comprising:

[0507] (i) exposing a composition comprising at least one non-form 13 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the non-form 13 solid form to form 13; and

[0508] (ii) Recycle form 13.

[0509] In one embodiment, the non-form 13 solid form is exposed to a solvent. In one embodiment, the non-form 13 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 13 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is cyclohexane. In one embodiment, the non-form 13 solid form is exposed to a solvent at room temperature. In one embodiment, the non-form 13 solid form is exposed to a solvent at a temperature above room temperature. In one embodiment, the non-form 13 solid form is exposed to a solvent at a temperature of about 25°C to about 60°C.

[0510] In one embodiment, the non-form 13 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 13 solid form is any one of form 1 to form 12 or form 14 to form 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 13 solid form into form 13 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0511] Form 13 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0512] In one embodiment, form 13 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is cyclohexane.

[0513] In one embodiment, form 13 of compound (I) is prepared by a method comprising pulping and / or stirring the compound in cyclohexane. In one embodiment, the pulping and / or stirring is carried out at about 20°C. In one embodiment, the pulping and / or stirring is carried out for at least 24 hours.

[0514] In one embodiment, form 13 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0515] In one embodiment, this document provides a method for preparing form 14 of a compound of formula (I), the method comprising:

[0516] (i) exposing a composition comprising at least one non-form 14 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the non-form 14 solid form to form 14; and

[0517] (ii) Recycle form 14.

[0518] In one embodiment, the non-form 14 solid form is exposed to a solvent. In one embodiment, the non-form 14 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 14 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is cyclohexanone, tert-butanol, or a mixture thereof. In one embodiment, the solvent is cyclohexanone. In one embodiment, the non-form 14 solid form is exposed to a solvent at room temperature. In one embodiment, the non-form 14 solid form is exposed to a solvent at a temperature above room temperature. In one embodiment, the non-form 14 solid form is exposed to a solvent at a temperature from about 25°C to about 60°C.

[0519] In one embodiment, the non-form 14 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 14 solid form is any one of form 1 to form 13 or form 15 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 14 solid form into form 14 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0520] Form 14 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0521] In one embodiment, form 14 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture thereof or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is cyclohexanone, tert-butanol, or a mixture thereof.

[0522] In one embodiment, compound of formula (I) form 14 is prepared by grinding the compound in cyclohexanone (e.g., with steel beads). In one embodiment, the compound is ground with the beads at 6000 RPM. In one embodiment, the grinding is performed in cycles, for example, 90-second cycles, with a 10-second pause between each cycle. In one embodiment, 40 cycles are performed.

[0523] In one embodiment, form 14 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0524] In one embodiment, this document provides a method for preparing form 15 of a compound of formula (I), the method comprising:

[0525] (i) exposing a composition comprising at least one non-form 15 solid form of a compound of formula (I) to one or more solvents for a period of time sufficient to convert at least about 50% of the total amount of the non-form 15 solid form to form 15; and

[0526] (ii) Recycle Form 15.

[0527] In one embodiment, the non-form 15 solid form is exposed to a solvent. In one embodiment, the non-form 15 solid form is exposed to a mixture of two solvents. In one embodiment, the non-form 15 solid form is exposed to one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is acetone. In one embodiment, the non-form 15 solid form is exposed to a solvent at room temperature. In one embodiment, the non-form 15 solid form is exposed to a solvent at a temperature above room temperature. In one embodiment, the non-form 15 solid form is exposed to a solvent at a temperature from about 25°C to about 60°C.

[0528] In one embodiment, the non-form 15 solid form is an amorphous solid form of the compound of formula (I). In one embodiment, the non-form 15 solid form is any one of form 1 to form 14 of the compound of formula (I). In one embodiment, the time period sufficient to convert at least about 50% of the total amount of the non-form 15 solid form into form 15 is about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 20 hours, about 24 hours, about 30 hours, about 40 hours, about 48 hours, about 72 hours, about 97 hours, about 121 hours, or more than 121 hours.

[0529] Form 15 of compound (I) can be prepared by exposing a composition containing compound (I) to one or more solvents as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, rapid cooling, temperature cycling, slurrying, bead milling, or solvent drop milling.

[0530] In one embodiment, form 15 of compound (I) is prepared by crystallizing or recrystallizing a compound of formula (I) or a stereoisomer or mixture thereof or a pharmaceutically acceptable salt thereof from one or more solvents. In one embodiment, the solvent is an organic solvent. In one embodiment, the solvent is acetone.

[0531] In one embodiment, form 15 of compound (I) is prepared by a method comprising pulping and / or stirring the compound in acetone. In one embodiment, the pulping and / or stirring is carried out at about 20°C. In one embodiment, the pulping and / or stirring is carried out for at least 36 hours.

[0532] In one embodiment, form 15 of compound (I) is prepared by crystallization or recrystallization as described in the experiments provided herein, including but not limited to evaporation, antisolvent addition, slow cooling, or rapid cooling.

[0533] 5.2.3. Salts of compounds of formula (I)

[0534] In some embodiments, this document provides a solid form comprising a salt of a compound of formula (I):

[0535]

[0536] In one embodiment, this document provides hydrochloric acid salt, methanesulfonate, benzenesulfonic acid salt, maleate, phosphate, citrate, L-tartaric acid salt, fumarate, toluenesulfonic acid, or salicylate of compound 1.

[0537] The molar ratio of compound 1 to the equilibrium ion of its salt can be about 1:1, about 1:2, about 1:3, or about 1:4. In one embodiment, the molar ratio of compound 1 to the equilibrium ion is about 1:1. In another embodiment, the molar ratio of compound 1 to the equilibrium ion is about 1:2. In yet another embodiment, the molar ratio of compound 1 to the equilibrium ion is about 1:3. In yet another embodiment, the molar ratio of compound 1 to the equilibrium ion is about 1:4.

[0538] In one embodiment, the balancing ion is chloride, methanesulfonate, benzenesulfonate, maleate, phosphate, citrate, L-tartrate, fumarate, toluenesulfonate, or salicylate. In one embodiment, the salt of compound 1 is the hydrochloride salt of compound 1. In one embodiment, the salt of compound 1 is the methanesulfonate salt of compound 1. In one embodiment, the salt of compound 1 is the benzenesulfonate salt of compound 1. In one embodiment, the salt of compound 1 is the maleate salt of compound 1. In one embodiment, the salt of compound 1 is the phosphate salt of compound 1. In one embodiment, the salt of compound 1 is the citrate salt of compound 1. In one embodiment, the salt of compound 1 is L-tartrate. In one embodiment, the salt of compound 1 is fumarate. In one embodiment, the salt of compound 1 is toluenesulfonic acid (toluenesulfonate). In one embodiment, the salt of compound 1 is salicylate.

[0539] In one embodiment, this document provides a solid form comprising a salt of compound 1. In one embodiment, the salt of compound 1 provided herein is amorphous.

[0540] 5.2.4. Solid form of salts of compounds of formula (I)

[0541] This article provides the solid form of salts containing compounds of formula (I):

[0542]

[0543] In one embodiment, this document provides a solid form comprising a salt of compound 1. In one embodiment, the solid form comprises a salicylate or maleate of compound 1. In one embodiment, this document provides a solid form comprising an anhydrous salt of compound 1.

[0544] The salt of compound 1 is expected to exist in a variety of solid forms. Such solid forms include crystalline solids (e.g., the crystalline form of the anhydrous salt of compound 1), amorphous solids, or mixtures of crystalline and amorphous solids. In one embodiment, the solid form is substantially crystalline.

[0545] 5.2.4.1 Form A of the salicylate of compound 1

[0546] In one embodiment, this document provides salicylate form A of compound 1. In one embodiment, form A is a monosalicylate of compound 1.

[0547] A representative XRPD spectrum of the salicylate form A of compound 1 is provided. Figure 58 middle.

[0548] In one embodiment, this document provides a solid form comprising a salicylate of compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 6.5, 8.5, 9.0, 9.7, 11.7, 12.9, 13.7, 14.7, 14.9, 17.7, 18.2, 18.8, 19.6, 20.0, 21.6, 22.0, 23.0, 24.6, 25.0, and 25.9 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least seven of the peaks. In one embodiment, the solid form is characterized by at least nine of the peaks. In one embodiment, the solid form is characterized by at least eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0549] In one embodiment, this document provides a solid form (e.g., crystalline form) of a salicylate comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.5, 8.5, 9.7, 11.7, 14.7, 17.7, and 18.8°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.5, 8.5, 9.7, 11.7, 14.7, 17.7, and 18.8°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.5, 8.5, 9.7, 11.7, 14.7, 17.7, and 18.8°2θ.

[0550] In one embodiment, this document provides a solid form (e.g., crystalline form) of a salicylate comprising compound 1, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 9.7, 11.7, and 14.7°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 6.5 and 18.8°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 8.5 and 17.7°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.5, 8.5, 9.7, 11.7, 14.7, 17.7, 18.2, 18.8, and 19.6°2θ.

[0551] In one embodiment, this document provides a solid form comprising a salicylate of compound 1, characterized in that its XRPD pattern is consistent with... Figure 58 The XRPD map depicted in the image matches. In one implementation, it provides... Figure 58 Form A is anhydrous.

[0552] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0553] In some embodiments, this document provides a solid form comprising a salicylate of compound 1, which is a crystalline anhydrous salicylate of compound 1. In some embodiments, the solid form is substantially free of amorphous salicylate of compound 1. In some embodiments, the solid form is substantially free of other solid forms of salicylate of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of free base forms of compound 1. In some embodiments, the solid form is substantially free of other salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially enantiomerically pure. In some embodiments, the solid form is substantially physically pure.

[0554] In some embodiments, this document also provides a method for preparing the salicylate of compound 1, the method comprising exposing a composition containing the free base of compound 1 to salicylic acid. In one embodiment, the free base of compound 1 is exposed to salicylic acid in an organic solvent (such as isopropyl acetate). In some embodiments, the organic solvent is isopropyl acetate. In some embodiments, the organic solvent is ethyl acetate.

[0555] This application covers all combinations of the above-described embodiments.

[0556] 5.2.4.2 Maleate form A of compound 1

[0557] In one embodiment, this document provides maleate form A of compound 1. In one embodiment, form A is a monomaleate of compound 1.

[0558] A representative XRPD spectrum of maleate form A of compound 1 is provided. Figure 59 middle.

[0559] In one embodiment, this document provides a solid form comprising a maleate of compound 1, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 6.0, 10.5, 10.9, 11.3, 12.1, 13.8, 16.0, 17.4, 18.2, 19.7, 21.0, 21.3, 22.1, 22.3, 22.9, 23.9, 24.8, 25.3, 26.9, 27.5, 28.3, and 28.8 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0560] In one embodiment, this document provides a solid form (e.g., crystalline form) of a maleate comprising compound 1, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.0, 10.5, 10.9, 11.3, 12.1, 13.8, 16.0, 17.4, 18.2, 19.7, 21.0, 21.3, 22.1, 22.3, 22.9, 23.9, 24.8, 25.3, 26.9, 27.5, 28.3, and 28.8°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.0, 10.5, 10.9, 11.3, 12.1, 13.8, 16.0, 17.4, 18.2, 19.7, 21.0, 21.3, 22.1, 22.3, 22.9, 23.9, 24.8, 25.3, 26.9, 27.5, 28.3, and 28.8°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.0, 10.5, 10.9, 11.3, 12.1, 13.8, 16.0, 17.4, 18.2, 19.7, 21.0, 21.3, 22.1, 22.3, 22.9, 23.9, 24.8, 25.3, 26.9, 27.5, 28.3, and 28.8°2θ.

[0561] In one embodiment, this document provides a maleate salt comprising compound 1 in a solid form (e.g., crystalline form), characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.0, 13.8, and 21.3°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 16.0 and 17.4°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 18.2 and 22.9°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.0, 10.5, 10.9, 12.1, 13.8, 16.0, 17.4, 18.2, 21.3, and 22.9°2θ.

[0562] In one embodiment, this document provides a solid form comprising a maleate salt of compound 1, characterized by an XRPD pattern and Figure 59 The XRPD map depicted in the image matches. In one implementation, it provides... Figure 59 Form A is anhydrous.

[0563] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0564] In some embodiments, this document provides a solid form comprising the maleate salt of compound 1, which is a crystalline anhydrous maleate salt of compound 1. In some embodiments, the solid form is substantially free of the amorphous maleate salt of compound 1. In some embodiments, the solid form is substantially free of other solid forms of the maleate salt of compound 1 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of the free base form of compound 1. In some embodiments, the solid form is substantially free of other salts of compound 1. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially enantiomerically pure. In some embodiments, the solid form is substantially physically pure.

[0565] In some embodiments, this document also provides a method for preparing the maleate salt of compound 1, the method comprising exposing a composition containing the free base of compound 1 to maleic acid. In one embodiment, the free base of compound 1 is exposed to maleic acid in an organic solvent (such as isopropyl acetate). In some embodiments, the organic solvent is isopropyl acetate. In some embodiments, the organic solvent is ethyl acetate.

[0566] This application covers all combinations of the above-described embodiments.

[0567] 5.2.5. Salts of compounds of formula (II)

[0568] In some embodiments, salts of compounds of formula (II) are provided herein:

[0569]

[0570] In one embodiment, compounds of formula (II) are provided herein as benzenesulfonic acid, ethanedisulfonic acid, citric acid, fumaric acid, hydrochloric acid, L-malic acid, maleic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, sulfuric acid, succinic acid, L-tartaric acid, phosphoric acid, toluenesulfonic acid, oxalic acid, camphorsulfonic acid, ethanesulfonic acid, 2-naphthalenesulfonic acid, 2-hydroxyethanesulfonic acid, trifluoroacetic acid, or hydrobromide. In one embodiment, compounds of formula (II) are provided herein as methanesulfonic acid (methanesulfonate), toluenesulfonic acid (toluenesulfonate), camphorsulfonic acid (camphorsulfonate), ethanesulfonic acid (ethanesulfonate), benzenesulfonic acid (benzenesulfonate), 2-naphthalenesulfonic acid (2-naphthalenesulfonate), or sulfate (sulfate) salts.

[0571] The molar ratio of the compound of formula (II) (also referred to herein as "compound 2") to the salt of compound 2 can be about 1:1, about 1:2, about 1:3, or about 2:1. In one embodiment, the molar ratio of compound 2 to the equilibrium ion is about 1:1. In another embodiment, the molar ratio of compound 2 to the equilibrium ion is about 1:2.

[0572] In one embodiment, the balancing ion is benzenesulfonate, methanesulfonate, toluenesulfonate, camphorsulfonate, ethanesulfonate, sulfate, or 2-naphthalenesulfonate. In one embodiment, the salt of compound 2 is a benzenesulfonate of compound 2. In one embodiment, the salt of compound 2 is a monobenzenesulfonate of compound 2. In one embodiment, the salt of compound 2 is a methanesulfonate (methanesulfonate). In one embodiment, the salt of compound 2 is a monomethanesulfonate of compound 2. In one embodiment, the salt of compound 2 is a toluenesulfonate of compound 2. In one embodiment, the salt of compound 2 is a monotoluenesulfonate of compound 2. In one embodiment, the salt of compound 2 is a camphorsulfonate of compound 2. In one embodiment, the salt of compound 2 is a monocamphorsulfonate of compound 2. In one embodiment, the salt of compound 2 is an ethanesulfonate (ethanesulfonate). In one embodiment, the salt of compound 2 is a monoethanesulfonate of compound 2. In one embodiment, the salt of compound 2 is a sulfate of compound 2. In one embodiment, the salt of compound 2 is a hemisulfate of compound 2 (e.g., about 0.5 molar equivalent sulfate). In one embodiment, the salt of compound 2 is a 2-naphthalenesulfonate of compound 2. In one embodiment, the salt of compound 2 is a mono-2-naphthalenesulfonate of compound 2.

[0573] In one embodiment, this document provides a solid form comprising a salt of compound 2. In one embodiment, the salt of compound 2 provided herein is amorphous. In one embodiment, the salt of compound 2 provided herein is a crystalline solid form.

[0574] 5.2.6. Solid form of salts of compounds of formula (II)

[0575] This article provides the solid form of salts containing compounds of formula (II):

[0576]

[0577] In one embodiment, this document provides a solid form comprising a salt of compound 2. In one embodiment, the solid form comprises benzenesulfonic acid, ethanedisulfonic acid, citric acid, fumaric acid, hydrochloric acid, L-malic acid, maleic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, sulfuric acid, succinic acid, L-tartaric acid, phosphoric acid, toluenesulfonic acid, oxalic acid, camphorsulfonic acid, ethanesulfonic acid, 2-naphthalenesulfonic acid, 2-hydroxyethanesulfonic acid, trifluoroacetic acid, or hydrobromide salt of compound 2. In one embodiment, the solid form comprises methanesulfonic acid (methanesulfonate), toluenesulfonic acid (toluenesulfonate), camphorsulfonic acid (camphorsulfonate), ethanesulfonic acid (ethanesulfonate), benzenesulfonic acid (benzenesulfonate), 2-naphthalenesulfonic acid (2-naphthalenesulfonate), or sulfate salt of compound 2. In one embodiment, this document provides a solid form comprising an anhydrous salt of compound 2.

[0578] The salt of compound 2 is expected to exist in a variety of solid forms. Such solid forms include crystalline solids (e.g., the crystalline form of the anhydrous salt of compound 2), amorphous solids, or mixtures of crystalline and amorphous solids. In one embodiment, the solid form is substantially crystalline.

[0579] 5.2.6.1 The form A of the methanesulfonate of compound 2

[0580] In one embodiment, this document provides form A of the methanesulfonate of compound 2. In one embodiment, form A is a monomethanesulfonate of compound 2.

[0581] A representative XRPD spectrum of the methanesulfonate form A of compound 2 is provided. Figure 35 middle.

[0582] In one embodiment, this document provides a solid form of a methanesulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 7.7, 10.6, 11.7, 15.1, 15.9, 16.4, 17.1, 17.5, 17.9, 19.5, 19.7, 21.5, 22.7, 23.1, 23.4, 23.6, 23.9, 24.2, 25.5, 25.9, 27.0, 28.4, 28.5, 30.5 and 32.9 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least seven of the peaks. In one embodiment, the solid form is characterized by at least nine of the peaks. In one embodiment, the solid form is characterized by at least eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0583] In one embodiment, this document provides a solid form (e.g., crystalline form) of a methanesulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 7.7, 10.6, 11.7, 15.1, 15.9, 17.1, 17.5, 19.5, 19.7, 21.5, 22.7, 23.4, 23.6, and 25.9°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 7.7, 10.6, 11.7, 15.1, 15.9, 17.1, 17.5, 19.5, 19.7, 21.5, 22.7, 23.4, 23.6, and 25.9°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 7.7, 10.6, 11.7, 15.1, 15.9, 17.1, 17.5, 19.5, 19.7, 21.5, 22.7, 23.4, 23.6, and 25.9°2θ.

[0584] In one embodiment, this document provides a solid form (e.g., crystalline form) of a methanesulfonate comprising compound 2, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 15.9, 17.5, and 19.5°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 10.6 and 11.7°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 21.5 and 22.7°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 7.7, 10.6, 11.7, 15.9, 17.5, 19.5, 21.5, and 22.7°2θ.

[0585] In one embodiment, this document provides a solid form comprising a methanesulfonate of compound 2, characterized by an XRPD pattern and Figure 35 The XRPD map depicted in the image matches. In one implementation, it provides... Figure 35 Form A is anhydrous.

[0586] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0587] Representative DSC and TGA thermograms of the methanesulfonate form A of compound 2 are provided in [the following locations]. Figure 36 and Figure 37 In one embodiment, this document provides a solid form of a methanesulfonate comprising compound 2, which exhibits an endothermic event as characterized by DSC, wherein the onset temperature is about 194 °C (e.g., ±2 °C). In one embodiment, the thermal event has a peak temperature of about 196 °C (e.g., ±2 °C). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 36 The DSC thermograms depicted in the diagram match the actual DSC thermograms. In one embodiment, the DSC thermograms are measured using a scan rate of approximately 10 °C / min via DSC. In one embodiment, a solid form comprising a methanesulfonate of compound 2 is provided herein, which exhibits approximately 0% weight loss upon heating from approximately 30 °C to approximately 210 °C. In one embodiment, the solid form is characterized by a TGA thermogram that matches the actual TSC thermograms depicted in the diagram. Figure 37 The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10°C / min. In one embodiment, it is provided... Figure 36 and Figure 37 Form A is the anhydrous methanesulfonate of compound 2.

[0588] In some embodiments, this document provides a solid form comprising a methanesulfonate of compound 2, which is a crystalline anhydrous methanesulfonate of compound 2. In some embodiments, the solid form is substantially free of amorphous methanesulfonate of compound 2. In some embodiments, the solid form is substantially free of other solid forms of methanesulfonate of compound 2 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of free base form of compound 2. In some embodiments, the solid form is substantially free of other salts of compound 2. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially enantiomerically pure. In some embodiments, the solid form is substantially physically pure.

[0589] In some embodiments, this document also provides a method for preparing a methanesulfonate of compound 2, the method comprising exposing a composition containing a free base of compound 2 to methanesulfonic acid. In one embodiment, the free base of compound 2 is exposed to methanesulfonic acid in an organic solvent (such as acetonitrile, ethyl acetate, THF, isopropyl acetate, or a mixture of ethyl acetate and heptane). In some embodiments, the organic solvent is acetonitrile. In some embodiments, the organic solvent is ethyl acetate. In some embodiments, the organic solvent is isopropyl acetate. In some embodiments, the organic solvent is a mixture of ethyl acetate and heptane. In some embodiments, the organic solvent is a mixture of isopropyl acetate and heptane.

[0590] This application covers all combinations of the above-described embodiments.

[0591] 5.2.6.2 Camphor sulfonate form of compound 2 A

[0592] In one embodiment, this document provides camphor sulfonate form A of compound 2. In one embodiment, form A is a monocamphor sulfonate of compound 2.

[0593] A representative XRPD spectrum of camphor sulfonate form A of compound 2 is provided. Figure 38 middle.

[0594] In one embodiment, this document provides a solid form of camphor sulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 6.7, 8.7, 10.1, 11.0, 13.3, 14.1, 15.7, 16.0, 17.4, 17.6, 18.0, 18.7, 18.8, 20.0, 20.2, 20.8, 21.9, 22.1, 22.5, 23.7, 24.1, 24.8, 25.7, 26.8 and 32.2 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least seven of the peaks. In one embodiment, the solid form is characterized by at least nine of the peaks. In one embodiment, the solid form is characterized by at least eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0595] In one embodiment, this document provides a solid form (e.g., crystalline form) of camphor sulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.7, 8.7, 10.1, 11.0, 13.3, 16.0, 17.4, 18.0, 18.8, 20.2, 20.8, 22.5, 24.8, and 25.7°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of approximately (e.g., ±0.2°) 6.7, 8.7, 10.1, 11.0, 13.3, 16.0, 17.4, 18.0, 18.8, 20.2, 20.8, 22.5, 24.8, and 25.7°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.7, 8.7, 10.1, 11.0, 13.3, 16.0, 17.4, 18.0, 18.8, 20.2, 20.8, 22.5, 24.8, and 25.7°2θ.

[0596] In one embodiment, this document provides a camphor sulfonate comprising compound 2 in a solid form (e.g., crystalline form), characterized in that its XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.7, 13.3, and 20.2°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 10.1 and 16.0°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 8.7 and 18.0°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.7, 8.7, 10.1, 11.0, 13.3, 14.1, 16.0, 18.0, and 20.2°2θ.

[0597] In one embodiment, this document provides a solid form of camphor sulfonate comprising compound 2, characterized by an XRPD pattern and Figure 38 The XRPD map depicted in the image matches. In one implementation, it provides... Figure 38 Form A is anhydrous.

[0598] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0599] Representative DSC and TGA thermograms of camphor sulfonate form A of compound 2 are provided respectively. Figure 39 and Figure 40 In one embodiment, this document provides a solid form of camphor sulfonate comprising compound 2, which exhibits an (endothermic) thermal event as characterized by DSC, wherein the onset temperature is about 201°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 204°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 39 The DSC thermogram is matched with the image depicted in the diagram. In one embodiment, the DSC thermogram is measured as by DSC using a scan rate of approximately 10 °C / min. In one embodiment, a solid form of camphor sulfonate comprising compound 2 is provided herein, which exhibits approximately 0.2% weight loss upon heating from approximately 185 °C to approximately 215 °C. In one embodiment, the solid form is characterized by a TGA thermogram that matches the image depicted in the diagram. Figure 40The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10°C / min. In one embodiment, it is provided... Figure 39 and Figure 40 Form A is the anhydrous camphor sulfonate of compound 2.

[0600] In some embodiments, this document provides a solid form comprising camphor sulfonate of compound 2, which is a crystalline anhydrous camphor sulfonate of compound 2. In some embodiments, the solid form is substantially free of amorphous camphor sulfonate of compound 2. In some embodiments, the solid form is substantially free of other solid forms (e.g., crystalline forms) of camphor sulfonate of compound 2. In some embodiments, the solid form is substantially free of free base form of compound 2. In some embodiments, the solid form is substantially free of other salts of compound 2. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially enantiomerically pure. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0601] In some embodiments, this document also provides a method for preparing camphor sulfonate of compound 2, the method comprising exposing a composition containing the free base of compound 2 to camphor sulfonic acid. In one embodiment, the free base of compound 2 is exposed to camphor sulfonic acid in an organic solvent (such as a mixture of methyl acetate and heptane, a mixture of ethyl acetate and heptane, or a mixture of isopropyl acetate and heptane). In some embodiments, the organic solvent is about 1:1 methyl acetate and heptane. In some embodiments, the organic solvent is about 1:1 ethyl acetate and heptane. In some embodiments, the organic solvent is about 1:1 isopropyl acetate and heptane.

[0602] This application covers all combinations of the above-described embodiments.

[0603] 5.2.6.3 The form A of ethanesulfonate of compound 2

[0604] In one embodiment, this document provides form A of the ethanesulfonate of compound 2. In one embodiment, form A is the monoethanesulfonate of compound 2.

[0605] A representative XRPD spectrum of the ethanesulfonate form A of compound 2 is provided. Figure 42 middle.

[0606] In one embodiment, this document provides a solid form of an ethanesulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, one or all of the XRPD peaks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 are located at approximately the following positions (e.g., °2θ ± 0.2): 7.8, 10.5, 11.6, 12.6, 1 3.2, 14.4, 15.1, 15.7, 16.3, 17.0, 17.3, 17.7, 19.2, 19.6, 21.4, 22.6, 23.0, 23.2, 23.5, 24.0, 25.2, 25.5, 25.9, 26.6, 26.8, 27.8, 28.2, 28.4, 30.2, 30.9, 31.9, and 32.5°2θ. In one embodiment, the solid form is characterized by at least 3 of the peaks. In one embodiment, the solid form is characterized by at least 5 of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0607] In one embodiment, this document provides a solid form (e.g., crystalline form) of an ethanesulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of: approximately (e.g., ±0.2°) 8.7, 10.5, 11.6, 12.6, 13.2, 14.4, 15.1, 15.7, 17.0, 17.3, 19.2, 19.6, 21.4, 22.6, 23.0, 23.2, 23.5, and 25.5°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of: approximately (e.g., ±0.2°) 8.7, 10.5, 11.6, 12.6, 13.2, 14.4, 15.1, 15.7, 17.0, 17.3, 19.2, 19.6, 21.4, 22.6, 23.0, 23.2, 23.5, and 25.5°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 8.7, 10.5, 11.6, 12.6, 13.2, 14.4, 15.1, 15.7, 17.0, 17.3, 19.2, 19.6, 21.4, 22.6, 23.0, 23.2, 23.5, and 25.5°2θ.

[0608] In one embodiment, this document provides a solid form (e.g., crystalline form) of an ethanesulfonate comprising compound 2, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 11.6, 15.7, and 19.2°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 10.5 and 17.3°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 14.4 and 15.1°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 7.8, 10.5, 11.6, 12.6, 13.2, 14.4, 15.1, 15.7, 17.3, and 19.2°2θ.

[0609] In one embodiment, this document provides a solid form comprising an ethanesulfonate of compound 2, characterized by an XRPD pattern and Figure 42 The XRPD map depicted in the image matches. In one implementation, it provides... Figure 42 Form A is anhydrous.

[0610] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0611] Representative DSC and TGA thermograms of the ethanesulfonate form A of compound 2 are provided respectively. Figure 43 and Figure 44 In one embodiment, this document provides a solid form of an ethanesulfonate comprising compound 2, which exhibits an (endothermic) thermal event as characterized by DSC, wherein the onset temperature is about 189°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 193°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 43 The DSC thermograms depicted in the diagram match the actual DSC thermograms. In one embodiment, the DSC thermograms are measured as described by DSC using a scan rate of approximately 10 °C / min. In one embodiment, a solid form comprising an ethanesulfonate of compound 2 is provided herein, which exhibits approximately 0.5% weight loss upon heating from approximately 170 °C to approximately 235 °C. In one embodiment, the solid form is characterized by a TGA thermogram that matches the actual TSC thermograms depicted in the diagram. Figure 44 The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10°C / min. In one embodiment, it is provided... Figure 43 and Figure 44 Form A is the anhydrous ethanesulfonate of compound 2.

[0612] In some embodiments, this document provides a solid form comprising the ethanesulfonate of compound 2, which is a crystalline anhydrous ethanesulfonate of compound 2. In some embodiments, the solid form is substantially free of the amorphous ethanesulfonate of compound 2. In some embodiments, the solid form is substantially free of other solid forms of the ethanesulfonate of compound 2 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of the free base form of compound 2. In some embodiments, the solid form is substantially free of other salts of compound 2. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0613] In some embodiments, this document also provides a method for preparing an ethanesulfonate of compound 2, the method comprising exposing a composition containing a free base of compound 2 to ethanesulfonic acid. In one embodiment, the free base of compound 2 is exposed to ethanesulfonic acid in an organic solvent (such as a 1:1 mixture of ethyl acetate and heptane).

[0614] This application covers all combinations of the above-described embodiments.

[0615] 5.2.6.4 The sulfate form of compound 2, A

[0616] In one embodiment, form A of the sulfate of compound 2 is provided herein. In one embodiment, form A is a hemisulfate of compound 2 (e.g., about 0.5 molar equivalent sulfate).

[0617] A representative XRPD spectrum of the sulfate form A of compound 2 is provided. Figure 46 middle.

[0618] In one embodiment, this document provides a solid form of a sulfate comprising compound 2, characterized in that, when measured using Cu Kα radiation, one or all of the XRPD peaks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 are located at approximately the following positions (e.g., °2θ ± 0.2): 10.8, 11.4, 12.3, 13.1, 14.9, 15.1, 15.5, 16.8, 17.2, 17.8, 18.3, 18.8, 19.9, 21.0, 21.5, 22.1, 22.5, 22.8, 23.4, 23.7, 24.0, 24.5, 24.8, 25.7, 26.0, 26.2, 27.0, 27.3, 28.0, 29.2, 30.0, and 34.6°2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least seven of the peaks. In one embodiment, the solid form is characterized by at least nine of the peaks. In one embodiment, the solid form is characterized by at least eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0619] In one embodiment, this document provides a solid form (e.g., crystalline form) of a sulfate comprising compound 2, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of: approximately (e.g., ±0.2°) 10.8, 11.4, 12.3, 13.1, 15.1, 15.5, 17.2, 18.3, 19.9, 21.5, 22.1, 22.8, 24.0, and 24.8°2θ. In another embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of: approximately (e.g., ±0.2°) 10.8, 11.4, 12.3, 13.1, 15.1, 15.5, 17.2, 18.3, 19.9, 21.5, 22.1, 22.8, 24.0, and 24.8°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 10.8, 11.4, 12.3, 13.1, 15.1, 15.5, 17.2, 18.3, 19.9, 21.5, 22.1, 22.8, 24.0, and 24.8°2θ.

[0620] In one embodiment, this document provides a solid form (e.g., crystalline form) of a sulfate comprising compound 2, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 13.1, 17.2, and 18.3°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 10.8 and 11.4°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 15.1 and 19.9°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 10.8, 11.4, 12.3, 13.1, 15.1, 15.5, 16.8, 17.2, 18.3, and 19.9°2θ.

[0621] In one embodiment, this document provides a solid form comprising a sulfate of compound 2, characterized by an XRPD pattern and... Figure 46 The XRPD map depicted in the image matches. In one implementation, it provides... Figure 46 Form A is anhydrous.

[0622] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0623] Representative DSC and TGA thermograms of the sulfate form A of compound 2 are provided respectively. Figure 47 and Figure 48 In one embodiment, this document provides a solid form comprising a sulfate of compound 2 that exhibits an endothermic event as characterized by DSC, wherein the onset temperature is about 183°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 188°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 47 The DSC thermograms depicted in the diagram match the actual DSC thermograms. In one embodiment, the DSC thermograms are measured as described by DSC using a scan rate of approximately 10 °C / min. In one embodiment, a solid form comprising a sulfate of compound 2 is provided herein, which exhibits approximately 0.6% weight loss upon heating from approximately 30 °C to approximately 200 °C. In one embodiment, the solid form is characterized by a TGA thermogram that matches the actual TSC thermograms depicted in the diagram. Figure 48 The TGA thermogram is matched to the one depicted. In one embodiment, the TGA thermogram is measured using a heating rate of approximately 10°C / min. In one embodiment, it is provided... Figure 47 and Figure 48 Form A is the anhydrous sulfate of compound 2.

[0624] In some embodiments, this document provides a solid form comprising a sulfate of compound 2, which is a crystalline anhydrous sulfate of compound 2. In some embodiments, the solid form is substantially free of the amorphous sulfate of compound 2. In some embodiments, the solid form is substantially free of other solid forms of the sulfate of compound 2 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of the free base form of compound 2. In some embodiments, the solid form is substantially free of other salts of compound 2. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0625] In some embodiments, this document also provides a method for preparing a sulfate of compound 2, the method comprising exposing a composition containing a free base of compound 2 to sulfuric acid. In one embodiment, the free base of compound 2 is exposed to sulfuric acid in an organic solvent (such as a 1:1 mixture of ethanol and heptane).

[0626] This application covers all combinations of the above-described embodiments.

[0627] 5.2.6.5 Toluenesulfonate form A of compound 2

[0628] In one embodiment, this document provides form A of the toluenesulfonate salt of compound 2. In one embodiment, form A is a monotoluenesulfonate salt of compound 2.

[0629] A representative XRPD spectrum of toluenesulfonate form A of compound 2 is provided. Figure 50 middle.

[0630] In one embodiment, this document provides a solid form of a toluenesulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 7.0, 12.2, 13.5, 14.2, 15.1, 17.0, 17.6, 18.8, 19.2, 19.4, 19.8, 20.6, 21.2, 21.3, 21.7, 23.4, 24.8, 25.1, 25.3, and 25.5 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least seven of the peaks. In one embodiment, the solid form is characterized by at least nine of the peaks. In one embodiment, the solid form is characterized by at least eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0631] In one embodiment, this document provides a solid form (e.g., crystalline form) of a toluenesulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of: approximately (e.g., ±0.2°) 12.2, 13.5, 14.2, 15.1, 17.0, 17.6, 18.8, 19.2, 19.4, 19.8, 20.6, 21.2, 21.3, 21.7, 23.4, 24.8, 25.1, 25.3, and 25.5°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of: approximately (e.g., ±0.2°) 12.2, 13.5, 14.2, 15.1, 17.0, 17.6, 18.8, 19.2, 19.4, 19.8, 20.6, 21.2, 21.3, 21.7, 23.4, 24.8, 25.1, 25.3, and 25.5°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 12.2, 13.5, 14.2, 15.1, 17.0, 17.6, 18.8, 19.2, 19.4, 19.8, 20.6, 21.2, 21.3, 21.7, 23.4, 24.8, 25.1, 25.3, and 25.5°2θ.

[0632] In one embodiment, this document provides a solid form (e.g., crystalline form) of a toluenesulfonate comprising compound 2, characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 12.2, 14.2, and 17.6°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 19.2 and 20.6°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 19.8 and 21.2°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 7.0, 12.2, 13.5, 14.2, 15.1, 17.6, 19.2, 19.8, 20.6, and 21.2°2θ.

[0633] In one embodiment, this document provides a solid form comprising a toluenesulfonate of compound 2, characterized by an XRPD pattern and Figure 50 The XRPD map depicted in the image matches. In one implementation, it provides... Figure 50 Form A is anhydrous.

[0634] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0635] A representative DSC thermogram of toluenesulfonate form A of compound 2 is provided. Figure 51 In one embodiment, this document provides a solid form of a toluenesulfonate comprising compound 2, which exhibits an (endothermic) thermal event as characterized by DSC, wherein the onset temperature is about 143°C (e.g., ±2°). In one embodiment, the thermal event has a peak temperature of about 148°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 51 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 51 Form A is the anhydrous toluenesulfonate of compound 2.

[0636] In some embodiments, this document provides a solid form comprising a toluenesulfonate of compound 2, which is a crystalline anhydrous toluenesulfonate of compound 2. In some embodiments, the solid form is substantially free of amorphous toluenesulfonate of compound 2. In some embodiments, the solid form is substantially free of other solid forms of toluenesulfonate of compound 2 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of free base forms of compound 2. In some embodiments, the solid form is substantially free of other salts of compound 2. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0637] In some embodiments, this document also provides a method for preparing a toluenesulfonate of compound 2, the method comprising exposing a composition containing a free base of compound 2 to toluenesulfonic acid. In one embodiment, the free base of compound 2 is exposed to toluenesulfonic acid in an organic solvent (such as a 1:1 mixture of ethyl acetate and heptane).

[0638] This application covers all combinations of the above-described embodiments.

[0639] 5.2.6.6 The benzenesulfonate form of compound 2, A

[0640] In one embodiment, this document provides form A of the benzenesulfonate of compound 2. In one embodiment, form A is a monobenzenesulfonate of compound 2.

[0641] A representative XRPD spectrum of the benzenesulfonate form A of compound 2 is provided. Figure 52 middle.

[0642] In one embodiment, this document provides a solid form of a benzenesulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, one or all of the XRPD peaks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 are located at approximately the following positions (e.g., °2θ ± 0.2): 6.8, 6.9, 9.2, 10.0, 10... 0.9, 11.7, 12.7, 13.5, 13.8, 14.3, 14.5, 15.1, 16.8, 17.7, 18.1, 18.4, 19.0, 19.4, 19.7, 19.9, 20.1, 20.3, 20.8, 21.2, 21.5, 21.9, 22.3, 22.9, 23.6, 23.8, 24.3, and 25.4°2θ. In one embodiment, the solid form is characterized by at least 3 of the peaks. In one embodiment, the solid form is characterized by at least 5 of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0643] In one embodiment, this document provides a solid form (e.g., crystalline form) of a benzenesulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.9, 9.2, 10.0, 10.9, 11.7, 12.7, 13.5, 13.8, 14.3, 14.5, 15.1, 16.8, 17.7, 18.1, 18.4, 19.0, 19.4, 19.7, 19.9, 20.1, 20.3, and 20.8°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.9, 9.2, 10.0, 10.9, 11.7, 12.7, 13.5, 13.8, 14.3, 14.5, 15.1, 16.8, 17.7, 18.1, 18.4, 19.0, 19.4, 19.7, 19.9, 20.1, 20.3, and 20.8°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.9, 9.2, 10.0, 10.9, 11.7, 12.7, 13.5, 13.8, 14.3, 14.5, 15.1, 16.8, 17.7, 18.1, 18.4, 19.0, 19.4, 19.7, 19.9, 20.1, 20.3, and 20.8°2θ.

[0644] In one embodiment, this document provides a benzenesulfonate comprising compound 2 in a solid form (e.g., crystalline form), characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.9, 10.9, and 16.8°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 13.8 and 15.1°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 11.7 and 12.7°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.9, 9.2, 10.0, 10.9, 11.7, 12.7, 13.5, 13.8, 15.1, 16.8, 19.4, and 20.8°2θ.

[0645] In one embodiment, this document provides a solid form comprising a benzenesulfonate of compound 2, characterized by an XRPD pattern and... Figure 52 The XRPD map depicted in the image matches. In one implementation, it provides... Figure 52 Form A is anhydrous.

[0646] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0647] A representative DSC thermogram of benzenesulfonate form A of compound 2 is provided. Figure 53 In one embodiment, this document provides a solid form of a benzenesulfonate comprising compound 2, exhibiting a first (endothermic) thermal event as characterized by DSC, wherein the onset temperature is about 33°C (e.g., ±2°). In one embodiment, the first thermal event has a peak temperature of about 42°C (e.g., ±2°). In one embodiment, this document provides a solid form of a benzenesulfonate comprising compound 2, exhibiting a second (endothermic) thermal event as characterized by DSC, wherein the onset temperature is about 100°C (e.g., ±2°). In one embodiment, the second thermal event has a peak temperature of about 103°C (e.g., ±2°). In one embodiment, this document provides a solid form of a benzenesulfonate comprising compound 2, exhibiting a third (endothermic) thermal event as characterized by DSC, wherein the onset temperature is about 142°C (e.g., ±2°). In one embodiment, the third thermal event has a peak temperature of about 152°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 53 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 53 Form A is the anhydrous benzenesulfonate of compound 2.

[0648] In some embodiments, this document provides a solid form comprising a benzenesulfonate of compound 2, which is a crystalline anhydrous benzenesulfonate of compound 2. In some embodiments, the solid form is substantially free of amorphous benzenesulfonate of compound 2. In some embodiments, the solid form is substantially free of other solid forms of benzenesulfonate of compound 2 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of free base forms of compound 2. In some embodiments, the solid form is substantially free of other salts of compound 2. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0649] In some embodiments, this document also provides a method for preparing benzenesulfonate form A of compound 2, the method comprising exposing a composition containing the free base of compound 2 to benzenesulfonic acid. In one embodiment, the free base of compound 2 is exposed to benzenesulfonic acid in an organic solvent (such as a 1:1 mixture of methyl acetate and heptane). In one embodiment, the method further comprises drying the benzenesulfonate of compound 2 under vacuum.

[0650] This application covers all combinations of the above-described embodiments.

[0651] 5.2.6.7 Compound 2 in the form of benzenesulfonate B

[0652] In one embodiment, this document provides form B of the benzenesulfonate of compound 2. In one embodiment, form B is a monobenzenesulfonate of compound 2.

[0653] A representative XRPD spectrum of the benzenesulfonate form B of compound 2 is provided. Figure 54 middle.

[0654] In one embodiment, this document provides a solid form of a benzenesulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 7.3, 9.8, 11.0, 11.7, 12.4, 13.4, 15.9, 16.9, 17.2, 19.2, 19.8, 20.8, 21.1, 21.6, 21.7, 22.1, 22.4, 23.0, 23.8, 24.6, 24.9, and 26.9 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least 7 of the peaks. In one embodiment, the solid form is characterized by at least 9 of the peaks. In one embodiment, the solid form is characterized by at least 11 of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0655] In one embodiment, this document provides a solid form (e.g., crystalline form) of a benzenesulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of: approximately (e.g., ±0.2°) 11.0, 11.7, 12.4, 13.4, 15.9, 16.9, 17.2, 19.2, 19.8, 20.8, 21.1, 21.6, 21.7, 22.1, 22.4, 23.0, 23.8, 24.6, 24.9, and 26.9°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of: approximately (e.g., ±0.2°) 11.0, 11.7, 12.4, 13.4, 15.9, 16.9, 17.2, 19.2, 19.8, 20.8, 21.1, 21.6, 21.7, 22.1, 22.4, 23.0, 23.8, 24.6, 24.9, and 26.9°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 11.0, 11.7, 12.4, 13.4, 15.9, 16.9, 17.2, 19.2, 19.8, 20.8, 21.1, 21.6, 21.7, 22.1, 22.4, 23.0, 23.8, 24.6, 24.9, and 26.9°2θ.

[0656] In one embodiment, this document provides a benzenesulfonate comprising compound 2 in a solid form (e.g., crystalline form), characterized in that the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 11.0, 12.4, and 13.4°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 17.2 and 20.7°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 15.9 and 19.2°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 7.3, 9.8, 11.0, 11.7, 12.4, 13.4, 15.9, 17.2, 19.2, and 20.7°2θ.

[0657] In one embodiment, this document provides a solid form comprising a benzenesulfonate of compound 2, characterized by an XRPD pattern and... Figure 54 The XRPD map depicted in the image matches.

[0658] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0659] In some embodiments, this document provides a solid form comprising a benzenesulfonate of compound 2, which is a crystalline benzenesulfonate of compound 2. In some embodiments, the solid form is substantially free of amorphous benzenesulfonate of compound 2. In some embodiments, the solid form is substantially free of other solid forms of benzenesulfonate of compound 2 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of free base forms of compound 2. In some embodiments, the solid form is substantially free of other salts of compound 2. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0660] In some embodiments, this document also provides a method for preparing benzenesulfonate form B of compound 2, the method comprising exposing benzenesulfonate form A of compound 2 to a humidified environment, such as 95% RH.

[0661] This application covers all combinations of the above-described embodiments.

[0662] 5.2.6.8 Form A of 2-naphthalenesulfonate of compound 2

[0663] In one embodiment, this document provides form A of the 2-naphthalenesulfonate of compound 2. In one embodiment, form A is a mono-2-naphthalenesulfonate of compound 2.

[0664] A representative XRPD spectrum of compound 2 in the form of 2-naphthalenesulfonate A is provided. Figure 55 middle.

[0665] In one embodiment, this document provides a solid form of a 2-naphthalenesulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or all of the XRPD peaks are located at approximately the following positions (e.g., °2θ ± 0.2): 6.8, 7.9, 9.6, 10.6, 11.6, 13.7, 18.1, 18.6, 19.1, 19.8, 20.2, 20.9, 21.3, 21.9, 23.1, 23.7, 24.2, 25.7, and 26.3 °2θ. In one embodiment, the solid form is characterized by at least three of the peaks. In one embodiment, the solid form is characterized by at least five of the peaks. In one embodiment, the solid form is characterized by at least seven of the peaks. In one embodiment, the solid form is characterized by at least nine of the peaks. In one embodiment, the solid form is characterized by at least eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0666] In one embodiment, this document provides a solid form (e.g., crystalline form) of a 2-naphthalenesulfonate comprising compound 2, characterized in that, when measured using Cu Kα radiation, the XRPD spectrum contains at least three peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.8, 7.9, 9.6, 10.6, 11.6, 13.7, 18.1, 18.6, 19.1, 19.8, 20.2, 20.9, 21.3, 21.9, 23.1, 23.7, 24.2, 25.7, and 26.3°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least four peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.8, 7.9, 9.6, 10.6, 11.6, 13.7, 18.1, 18.6, 19.1, 19.8, 20.2, 20.9, 21.3, 21.9, 23.1, 23.7, 24.2, 25.7, and 26.3°2θ. In one embodiment, the solid form is characterized in that the XRPD spectrum contains at least five peaks selected from the group consisting of: approximately (e.g., ±0.2°) 6.8, 7.9, 9.6, 10.6, 11.6, 13.7, 18.1, 18.6, 19.1, 19.8, 20.2, 20.9, 21.3, 21.9, 23.1, 23.7, 24.2, 25.7, and 26.3°2θ.

[0667] In one embodiment, this document provides a solid form (e.g., crystalline form) of a 2-naphthalenesulfonate comprising compound 2, characterized in that its XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.8, 7.9, and 9.6°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 11.6 and 13.7°2θ. In one embodiment, the XRPD spectrum further contains peaks at approximately (e.g., ±0.2°) 10.6 and 19.8°2θ. In one embodiment, the XRPD spectrum contains peaks at approximately (e.g., ±0.2°) 6.8, 7.9, 9.6, 10.6, 11.6, 13.7, 18.1, 19.8, and 20.2°2θ.

[0668] In one embodiment, this document provides a solid form of a 2-naphthalenesulfonate comprising compound 2, characterized by an XRPD pattern and Figure 55 The XRPD map depicted in the image matches. In one implementation, it provides... Figure 55 Form A is anhydrous.

[0669] In one embodiment, the XRPD spectrum described herein is obtained using Cu Kα radiation. In another embodiment, the XRPD spectrum is measured by XRPD using Cu Kα radiation, wherein the Cu Kα radiation comprises… Kα1 radiation of wavelength and having Kα2 radiation at wavelength.

[0670] A representative DSC thermogram of compound 2 in the form of 2-naphthalenesulfonate A is provided. Figure 56 In one embodiment, this document provides a solid form of a 2-naphthalenesulfonate comprising compound 2, exhibiting a first (endothermic) thermal event as characterized by DSC, wherein the onset temperature is about 36°C (e.g., ±2°). In one embodiment, the first thermal event has a peak temperature of about 50°C (e.g., ±2°). In another embodiment, this document provides a solid form of a 2-naphthalenesulfonate comprising compound 2, exhibiting a second (endothermic) thermal event as characterized by DSC, wherein the onset temperature is about 97°C (e.g., ±2°). In one embodiment, the second thermal event has a peak temperature of about 109°C (e.g., ±2°). In one embodiment, the solid form is characterized by a DSC thermogram that is consistent with... Figure 56 The DSC thermogram is matched to the one depicted. In one embodiment, the DSC thermogram is measured as if by DSC using a scan rate of approximately 10 °C / min. In one embodiment, it is provided... Figure 56 Form A is the anhydrous 2-naphthalenesulfonate of compound 2.

[0671] In some embodiments, this document provides a solid form comprising 2-naphthalenesulfonate of compound 2, which is a crystalline anhydrous 2-naphthalenesulfonate of compound 2. In some embodiments, the solid form is substantially free of amorphous 2-naphthalenesulfonate of compound 2. In some embodiments, the solid form is substantially free of other solid forms of 2-naphthalenesulfonate of compound 2 (e.g., crystalline forms). In some embodiments, the solid form is substantially free of free base form of compound 2. In some embodiments, the solid form is substantially free of other salts of compound 2. In some embodiments, a substantially pure solid form is provided. In some embodiments, the solid form is substantially chemically pure. In some embodiments, the solid form is substantially physically pure.

[0672] In some embodiments, this document also provides a method for preparing a 2-naphthalenesulfonate of compound 2, the method comprising exposing a composition containing a free base of compound 2 to 2-naphthalenesulfonic acid. In one embodiment, the free base of compound 2 is exposed to 2-naphthalenesulfonic acid in an organic solvent (such as 2-MeTHF).

[0673] This application covers all combinations of the above-described embodiments.

[0674] 5.3 Preparation method of compound 1

[0675] In some embodiments, this document provides a preparative compound of formula (II):

[0676]

[0677] A method for the use of its stereoisomers or mixtures thereof, or pharmaceutically acceptable salts thereof, the method comprising:

[0678] (Step 2.0) Make compound (III) into:

[0679]

[0680] The reaction of its stereoisomers or mixtures of stereoisomers or its pharmaceutically acceptable salts with a brominating agent.

[0681] In another embodiment, this document provides a preparative compound of formula (II):

[0682]

[0683] A method for the use of its stereoisomers or mixtures thereof, or pharmaceutically acceptable salts thereof, the method comprising:

[0684] (Step 2a.1) Make compound of formula (XXIX):

[0685]

[0686] Or its stereoisomers or mixtures of stereoisomers or its pharmaceutically acceptable salts with compounds of formula (XXX):

[0687]

[0688] Or a pharmaceutically acceptable salt reaction.

[0689] In some implementations, the method further includes:

[0690] (Step 1.0) Cyclate the compound of formula (II) or a stereoisomer or mixture of stereoisomers or a pharmaceutically acceptable salt thereof to provide the compound of formula (I):

[0691]

[0692] Or its stereoisomers or mixtures of stereoisomers or its pharmaceutically acceptable salts.

[0693] In some embodiments, the salt of compound (II) is cyclized in step 1.0. In some embodiments, the solid form of the salt of compound (II) is cyclized in step 1.0. In one embodiment, the camphor sulfonate of compound (II) is cyclized in step 1.0. In one embodiment, the solid form of camphor sulfonate of compound (II) (e.g., form A) is cyclized in step 1.0. In another embodiment, step 1.0 includes:

[0694] (Step 1.1) Under alkaline conditions, the camphor sulfonate of compound (II) is converted into the free base of the compound; and

[0695] (Step 1.2) Cyclate the free base of the compound.

[0696] In some embodiments, step 1.0 occurs in the presence of a base. In some embodiments, the base is an organic base. In some embodiments, the organic base is a carboxylate base. In some embodiments, the carboxylate base is lithium acetate, sodium acetate, potassium acetate, lithium pivalate, sodium pivalate, potassium pivalate, cesium acetate, or cesium pivalate. In one embodiment, the base is potassium pivalate.

[0697] In some embodiments, the molar ratio of compound (II) to base in step 1.0 is about 1:2 to about 1:6. In one embodiment, the molar ratio of compound (II) to base in step 1.0 is about 1:3.

[0698] In some embodiments, step 1.0 occurs in the presence of a catalyst precursor. In some embodiments, the catalyst precursor comprises a palladium source. In some embodiments, the palladium source is Pd-G3, Pd2(dba)3, PdCl2(MeCN)2, Pd(OAc)2, Pd(PPh3)4, PdCl2(PPh3)2, PdCl2(Pcy3)2, PdCl2(dtbpf), PdCl2(dppf), PdCl2(Amphos), {Pd(μ-Br)[P(tBu)3]}2, PdCl2[P(Cy)3]2, Pd[P(tBu)3]2, PdCl2(dtbpf), Pd[P(Cy)3]2, or PdCl2[P(tBu)(Cy)2]2. In one embodiment, the palladium source is Pd(OAc)2. In one embodiment, the catalyst precursor comprises Pd(OAc)2. In some embodiments, the catalyst precursor comprises a ligand. In some embodiments, the ligand is a phosphine ligand or a bisphosphine ligand. In some embodiments, the ligand is a phosphine or bisphosphine ligand commonly used in the art. In one embodiment, the ligand is a cataCXium ligand. In one embodiment, the cataCXium ligand is cataCXium A, cataCXium Abn, cataCXium AHI, cataCXium PintB, cataCXium PICy, cataCXium PtB, cataCXium PomeB, or cataCXium C. In one embodiment, the cataCXium ligand is cataCXium A. In one embodiment, the catalyst precursor comprises cataCXium A. In some embodiments, the catalyst precursor comprises a palladium source and a ligand. In some embodiments, the catalyst precursor and the ligand are pre-formed palladium ligand complexes, such as cataCXium A Pd G2, cataCXium A Pd G3, or bis(butyldi-1-adamantylphosphine)palladium diacetate. In one embodiment, the catalyst precursor comprises Pd(OAc)2 and cataCXium A.

[0699] In some embodiments, the molar ratio of the compound of formula (II) in step 1.0 to the palladium source (e.g., Pd(OAc)2) is about 1:0.02 (i.e., 2 mol%) to about 1:0.3 (i.e., 30 mol%). In some embodiments, the molar ratio of the compound of formula (II) in step 1.0 to the palladium source is about 1:0.02, about 1:0.03, about 1:0.04, about 1:0.05, about 1:0.06, about 1:0.07, about 1:0.08, about 1:0.09, about 1:0.10, about 1:0.11, about 1:0.12, about 1:0.13, about 1:0.14, about 1:0.15, about 1:0.16, about 1:0.17, about 1:0.18, about 1:0.19, or about 1:0.20. In one embodiment, the molar ratio of compound (II) to palladium source in step 1.0 is about 1:0.05 (i.e., 5 mol%). In another embodiment, the molar ratio of compound (II) to palladium source in step 1.0 is about 1:0.12 (i.e., 12 mol%). In yet another embodiment, the palladium loading in step 1.0 is less than about 20 mol%, less than about 15 mol%, less than about 10 mol%, or less than about 5 mol%.

[0700] In some embodiments, the molar ratio of the compound of formula (II) in step 1.0 to the ligand (e.g., cataCXium ligand) is about 1:0.05 (i.e., 5 mol%) to about 1:0.32 (i.e., 32 mol%). In some embodiments, the molar ratio of the compound of formula (II) in step 1.0 to the ligand is about 1:0.05, about 1:0.08, about 1:0.10, about 1:0.16, about 1:0.17, about 1:0.18, about 1:0.19, about 1:0.20, about 1:0.21, about 1:0.22, about 1:0.23, about 1:0.24, about 1:0.25, about 1:0.26, about 1:0.27, about 1:0.28, about 1:0.29, about 1:0.30, about 1:0.31, or about 1:0.32. In one embodiment, the molar ratio of the compound of formula (II) to the ligand in step 1.0 is about 1:0.10 (i.e., 10 mol%). In one embodiment, the molar ratio of the compound of formula (II) to the ligand in step 1.0 is about 1:0.24 (i.e., 24 mol%). In one embodiment, a ligand loading of less than about 30 mol% is used in step 1.0.

[0701] In one embodiment, the molar ratio of the ligand (e.g., cataCXium ligand) to the palladium source (e.g., Pd(OAc)₂) in step 1.0 is about 5:1 to about 1:5. In one embodiment, the molar ratio of the ligand to the palladium source is about 2:1 to about 1:2. In one embodiment, the molar ratio of the ligand to the palladium source is about 2:1 to about 1:1. In one embodiment, the ligand is a monodentate ligand and the molar ratio of the ligand to the palladium source is about 2:1. In one embodiment, the ligand is a monodentate ligand and the molar ratio of the ligand to the palladium source is about 1:1. In one embodiment, the ligand is a bidentate ligand and the molar ratio of the ligand to the palladium source is about 1:1. In one embodiment, the ligand is a bidentate ligand and the molar ratio of the ligand to the palladium source is about 1:2.

[0702] Step 1.0 can occur in a suitable solvent for the reaction. In some embodiments, the solvent is an organic solvent or a mixture of organic solvents. In one embodiment, the solvent is a high-boiling-point solvent, including but not limited to C. 4-12 Aliphatic alcohols (branched or unbranched), anisole, 2-MeTHF, DMF, NMP, DMA, or tAmOH. In one embodiment, the solvent is an alcohol. In one embodiment, the solvent is tert-amyl alcohol (tAmOH). In one embodiment, the solvent is n-BuOH, s-BuOH, or t-BuOH.

[0703] In some embodiments, the volume of the solvent in step 1.0 is about 10 vol to about 30 vol. In one embodiment, the volume of the solvent in step 1.0 is about 20 vol.

[0704] As used herein, vol refers to the volume (L or mL) of solvent relative to the weight of the limiting reagent (kg or g, respectively). In some embodiments, step 1.0 occurs in an inert atmosphere (i.e., under conditions where the presence of atmospheric oxygen is eliminated or substantially reduced). In one embodiment, the solvent is sprayed with an inert gas (e.g., dinitrogen or argon) in step 1.0.

[0705] In some embodiments, step 1.0 occurs at a reaction temperature of about 90°C to about 120°C. In one embodiment, the reaction temperature is the boiling point of the solvent. In one embodiment, the reaction temperature is about 100°C to about 110°C. In one embodiment, the reaction temperature is about 102°C.

[0706] In some embodiments, step 1.0 occurs within a reaction time of approximately 16 hours to approximately 30 hours. In one embodiment, the reaction time is approximately 16 hours to approximately 20 hours.

[0707] In one embodiment, step 1.0 occurs in the presence of a potassium pivalate base and a catalyst precursor comprising Pd(OAc)₂ and cataCXium A. In one embodiment, the molar ratios of the compound of formula (II) to potassium pivalate, Pd(OAc)₂, and cataCXium A are about 1:3, about 1:0.12, and about 1:0.24, respectively. In one embodiment, the molar ratios of the compound of formula (II) to potassium pivalate, Pd(OAc)₂, and cataCXium A are about 1:0.05 and about 1:0.1, respectively. In one embodiment, step 1.0 occurs at a reaction temperature of about 100-110°C in a tert-amyl alcohol solvent and a solvent volume of 20 vol. In one embodiment, the solvent is injected with nitrogen gas in step 1.0. In some embodiments, a salt of the compound of formula (II) is used in step 1.0. In one embodiment, a camphor sulfonate of the compound of formula (II) is used in step 1.0. In another embodiment, step 1.0 comprises:

[0708] (Step 1.1) Under alkaline conditions, the camphor sulfonate of compound (II) is converted into the free base of the compound; and

[0709] (Step 1.2) Cyclate the free base of the compound.

[0710] In some embodiments, as determined by HPLC and / or NMR, step 1.0 is carried out over about 18 hours to achieve a conversion of greater than about 90%, greater than about 95%, greater than about 96%, greater than about 97%, greater than about 98%, or greater than about 99%. In some embodiments, step 1.0 provides less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% of impurities other than the compound of formula (I). The impurities provided in step 1.0 may include, but are not limited to, compounds of formula (II), compounds of formula (III), compounds of formula (V) described below, tert-butylcarbonylates of formula (SP-1), and / or dechlorinated substances of formula (SP-2).

[0711]

[0712] In one embodiment, the total amount of impurities provided in step 1.0 is less than about 10% by weight, less than about 8% by weight, less than about 5% by weight, less than about 4% by weight, less than about 3% by weight, less than about 2% by weight, less than about 1% by weight, less than about 0.5% by weight, less than about 0.1% by weight, less than about 0.05% by weight, less than about 0.03% by weight, or less than about 0.02% by weight.

[0713] In some embodiments, step 1.0 further includes purification of the compound of formula (I). In some embodiments, the compound of formula (I) produced in step 1.0 is purified by chromatography, palladium retrieval, and / or (re)crystallization.

[0714] In one embodiment, palladium remediation includes treatment with a palladium scavenger. In one embodiment, the palladium scavenger is a thiopropyl silica scavenger. In one embodiment, the reaction mixture is stirred with the thiopropyl silica scavenger and then the filter cake is filtered and washed with t-AmOH. In one embodiment, the reaction mixture is stirred with the thiopropyl silica scavenger and then the filter cake is filtered and washed with MTBE. In one embodiment, the palladium scavenger is an aqueous solution of L-cysteine. In one embodiment, the combined filtrate from the thiopropyl silica scavenger treatment is concentrated and further treated with L-cysteine. In one embodiment, palladium remediation occurs at a temperature above room temperature, for example, from about 40°C to about 80°C, for example, about 60°C. In one embodiment, palladium remediation includes treatment with a palladium scavenger for a period of time of about 1 hour, greater than 1 hour, greater than ...

Claims

1. A solid form comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:

2. The solid form of claim 1 which is crystalline.

3. A solid form as claimed in claim 1 or 2 comprising the free base of the compound of formula (I).

4. The solid form of claim 3, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 11.2, 12.4, 13.2, 14.3, 18.9, 21.1, 21.6, 21.8, 22.5, 22.7, 23.0, and 27.0 ° 2Θ (± 0.2°) when measured using Cu Ka radiation.

5. The solid form of claim 4, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 11.2, 12.4, 13.2, 14.3, 18.9, 21.1, 21.6, 21.8, 22.5, 22.7, 23.0, and 27.0 ° 2Θ (± 0.2°).

6. The solid form of claim 5, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 11.2, 12.4, 13.2, 14.3, 18.9, 21.1, 21.6, 21.8, 22.5, 22.7, 23.0, and 27.0 ° 2Θ (± 0.2°).

7. The solid form of claim 4, characterized in that The XRPD pattern contained peaks at approximately 12.4, 18.9 and 21.1° 2Θ (± 0.2°).

8. The solid form of claim 7, wherein the XRPD pattern further comprises peaks at approximately 13.2 and 22.5° 2θ (± 0.2°).

9. The solid form of claim 8, wherein the XRPD pattern further comprises peaks at approximately 11.2 and 22.7° 2θ (± 0.2°).

10. The solid form of claim 4, characterized in that The XRPD pattern matched the XRPD pattern depicted in FIG4 .

11. The solid form of any one of claims 4 to 10, which exhibits an endothermic event as characterized by DSC, wherein the onset temperature is about 260°C (±2°) and / or the peak temperature is about 261°C (±2°).

12. The solid form of any one of claims 4 to 11, which exhibits a weight increase of about 0.3% when subjected to an increase in relative humidity from about 0 to about 90% relative humidity.

13. A solid form as claimed in any one of claims 4 to 12 having a unit cell size of approximately: α=90°, β=90°, and γ=90°.

14. The solid form of any one of claims 4 to 13 which is anhydrous.

15. The solid form of claim 3, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 6.0, 8.9, 9.2, 11.1, 12.2, 12.8, 17.1, 18.1, 18.5, 20.6, and 22.5 degrees 2Θ (± 0.2°) when measured using Cu Ka radiation.

16. The solid form of claim 15, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 6.0, 8.9, 9.2, 11.1, 12.2, 12.8, 17.1, 18.1, 18.5, 20.6, and 22.5° 2Θ (± 0.2°).

17. The solid form of claim 16, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 6.0, 8.9, 9.2, 11.1, 12.2, 12.8, 17.1, 18.1, 18.5, 20.6, and 22.5° 2Θ (± 0.2°).

18. The solid form of claim 15, characterized in that The XRPD pattern contained peaks at approximately 6.0, 18.5 and 20.6° 2Θ (± 0.2°).

19. The solid form of claim 18, wherein the XRPD pattern further comprises peaks at approximately 12.8 and 17.1° 2θ (± 0.2°).

20. The solid form of claim 19, wherein the XRPD pattern further comprises peaks at approximately 9.2 and 22.5° 2Θ (± 0.2°).

21. The solid form of claim 15, characterized in that The XRPD pattern matched that depicted in Figure 1A.

22. The solid form of claim 3, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 9.0, 9.4, 10.4, 12.8, 15.3, 16.4, 16.6, 18.2, and 20.6 degrees 2-theta (± 0.2°) when measured using Cu Ka radiation.

23. The solid form of claim 22, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 9.0, 9.4, 10.4, 12.8, 15.3, 16.4, 16.6, 18.2, and 20.6 ° 2Θ (± 0.2°).

24. The solid form of claim 23, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 9.0, 9.4, 10.4, 12.8, 15.3, 16.4, 16.6, 18.2, and 20.6 ° 2Θ (± 0.2°).

25. The solid form of claim 22, characterized in that The XRPD pattern contained peaks at approximately 9.4, 12.8 and 15.3° 2Θ (± 0.2°).

26. The solid form of claim 25, wherein the XRPD pattern further comprises peaks at approximately 16.6 and 20.6° 2θ (± 0.2°).

27. The solid form of claim 26, wherein the XRPD pattern further comprises peaks at approximately 9.0 and 16.4° 2θ (± 0.2°).

28. The solid form of claim 27, wherein the XRPD pattern further comprises a peak at approximately 10.4° 2θ (± 0.2°).

29. The solid form of claim 22, characterized in that The XRPD pattern matched the XRPD pattern depicted in FIG8 .

30. The solid form of claim 3, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 6.1, 9.2, 11.0, 12.2, 12.7, 17.2, 18.2, 20.5 and 21.5 ° 2Θ (± 0.2°) when measured using Cu Ka radiation.

31. The solid form of claim 30, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 6.1, 9.2, 11.0, 12.2, 12.7, 17.2, 18.2, 20.5, and 21.5 ° 2Θ (± 0.2°).

32. The solid form of claim 31, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 6.1, 9.2, 11.0, 12.2, 12.7, 17.2, 18.2, 20.5 and 21.5 ° 2Θ (± 0.2°).

33. The solid form of claim 30, characterized in that The XRPD pattern contained peaks at approximately 6.1, 17.2 and 18.2° 2Θ (± 0.2°).

34. The solid form of claim 33, wherein the XRPD pattern further comprises peaks at approximately 12.7 and 20.5° 2θ (± 0.2°).

35. The solid form of claim 34, wherein the XRPD pattern further comprises peaks at approximately 12.2 and 21.5° 2θ (± 0.2°).

36. The solid form of claim 30, characterized in that The XRPD pattern matched the XRPD pattern depicted in FIG10 .

37. The solid form of claim 3, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 6.8, 7.0, 10.0, 17.2, 18.9, 19.4, 21.1, 22.2, and 22.8 degrees 2Θ (± 0.2°) when measured using Cu Ka radiation.

38. The solid form of claim 37, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 6.8, 7.0, 10.0, 17.2, 18.9, 19.4, 21.1, 22.2, and 22.8° 2Θ (± 0.2°).

39. The solid form of claim 38, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 6.8, 7.0, 10.0, 17.2, 18.9, 19.4, 21.1, 22.2, and 22.8° 2Θ (± 0.2°).

40. The solid form of claim 37, characterized in that The XRPD pattern contained peaks at approximately 6.8, 10.0 and 18.9° 2Θ (± 0.2°).

41. The solid form of claim 40, wherein the XRPD pattern further comprises peaks at approximately 19.4 and 22.8° 2θ (± 0.2°).

42. The solid form of claim 41, wherein the XRPD pattern further comprises peaks at approximately 7.0 and 22.2° 2θ (± 0.2°).

43. The solid form of claim 37, characterized in that The XRPD pattern matched that depicted in Figure 12A.

44. The solid form of claim 3, characterized in that When measured using Cu Ka radiation, the XRPD pattern comprises at least three peaks selected from the group consisting of approximately (eg, ± 0.2°) 5.8, 6.0, 10.0, 18.1, 20.1, 22.4, and 24.1° 2Θ (± 0.2°).

45. The solid form of claim 44, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 5.8, 6.0, 10.0, 18.1, 20.1, 22.4, and 24.1 ° 2Θ (± 0.2°).

46. ​​The solid form of claim 45, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 5.8, 6.0, 10.0, 18.1, 20.1, 22.4, and 24.1 ° 2Θ (± 0.2°).

47. The solid form of claim 44, characterized in that The XRPD pattern contained peaks at approximately 5.8, 10.0 and 18.1° 2Θ (± 0.2°).

48. The solid form of claim 47, wherein the XRPD pattern further comprises peaks at approximately 6.0 and 22.4° 2θ (± 0.2°).

49. The solid form of claim 48, wherein the XRPD pattern further comprises peaks at approximately 20.1 and 24.1 ° 2θ (± 0.2°).

50. The solid form of claim 48, wherein the XRPD pattern further comprises peaks at approximately 11.5 and 12.0° 2Θ (± 0.2°).

51. The solid form of claim 44, characterized in that The XRPD pattern matched the XRPD pattern depicted in FIG16 .

52. The solid form of claim 3, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 5.9, 9.1, 10.6, 12.0, 16.7, 17.8, 19.6, 21.2, and 23.4° 2Θ (±0.2°) when measured using Cu Ka radiation.

53. The solid form of claim 52, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 5.9, 9.1, 10.6, 12.0, 16.7, 17.8, 19.6, 21.2, and 23.4° 2Θ (± 0.2°).

54. The solid form of claim 53, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 5.9, 9.1, 10.6, 12.0, 16.7, 17.8, 19.6, 21.2, and 23.4° 2Θ (± 0.2°).

55. The solid form of claim 52, characterized in that The XRPD pattern contained peaks at approximately 5.9, 9.1 and 19.6° 2Θ (± 0.2°).

56. The solid form of claim 55, wherein the XRPD pattern further comprises peaks at approximately 12.0 and 23.4° 2θ (± 0.2°).

57. The solid form of claim 56, wherein the XRPD pattern further comprises peaks at approximately 10.6 and 21.2° 2θ (± 0.2°).

58. The solid form of claim 52, characterized in that The XRPD pattern matched the XRPD pattern depicted in FIG17 .

59. The solid form of claim 3, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 6.0, 9.2, 10.8, 11.9, 12.1, 17.0, 18.0, 19.7, and 21.5° 2Θ (±0.2°) when measured using Cu Ka radiation.

60. The solid form of claim 59, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 6.0, 9.2, 10.8, 11.9, 12.1, 17.0, 18.0, 19.7, and 21.5° 2Θ (± 0.2°).

61. The solid form of claim 60, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 6.0, 9.2, 10.8, 11.9, 12.1, 17.0, 18.0, 19.7, and 21.5° 2Θ (± 0.2°).

62. The solid form of claim 59, characterized in that The XRPD pattern contained peaks at approximately 6.0, 17.0 and 19.7° 2Θ (± 0.2°).

63. The solid form of claim 62, wherein the XRPD pattern further comprises peaks at approximately 9.2 and 21.5° 2θ (± 0.2°).

64. The solid form of claim 63, wherein the XRPD pattern further comprises peaks at approximately 10.8 and 18.0° 2θ (± 0.2°).

65. The solid form of claim 59, characterized in that The XRPD pattern matched the XRPD pattern depicted in FIG. 19 .

66. The solid form of claim 3, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 5.9, 10.5, 11.9, 12.0, 17.2, 17.7, 19.4, 19.6, 21.4, and 23.3 degrees 2Θ (± 0.2°) when measured using Cu Ka radiation.

67. The solid form of claim 66, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 5.9, 10.5, 11.9, 12.0, 17.2, 17.7, 19.4, 19.6, 21.4, and 23.3° 2Θ (± 0.2°).

68. The solid form of claim 67, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 5.9, 10.5, 11.9, 12.0, 17.2, 17.7, 19.4, 19.6, 21.4, and 23.3° 2Θ (± 0.2°).

69. The solid form of claim 66, characterized in that The XRPD pattern contained peaks at approximately 5.9, 17.2 and 19.4° 2Θ (± 0.2°).

70. The solid form of claim 69, wherein the XRPD pattern further comprises peaks at approximately 17.7 and 19.6° 2θ (± 0.2°).

71. The solid form of claim 70, wherein the XRPD pattern further comprises peaks at approximately 11.9 and 23.3° 2θ (± 0.2°).

72. The solid form of claim 66, characterized in that The XRPD pattern matched the XRPD pattern depicted in Figure 21.

73. The solid form of claim 3, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 5.9, 8.4, 8.6, 10.6, 11.2, 12.9, 16.1, 19.3, and 21.1 ° 2Θ (± 0.2°) when measured using Cu Ka radiation.

74. The solid form of claim 73, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 5.9, 8.4, 8.6, 10.6, 11.2, 12.9, 16.1, 19.3, and 21.1 ° 2Θ (± 0.2°).

75. The solid form of claim 74, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 5.9, 8.4, 8.6, 10.6, 11.2, 12.9, 16.1, 19.3, and 21.1 ° 2Θ (± 0.2°).

76. The solid form of claim 73, characterized in that The XRPD pattern contained peaks at approximately 5.9, 8.4 and 8.6° 2Θ (± 0.2°).

77. The solid form of claim 76, wherein the XRPD pattern further comprises peaks at approximately 10.6 and 16.1 ° 2θ (± 0.2°).

78. The solid form of claim 77, wherein the XRPD pattern further comprises peaks at approximately 11.2 and 19.3° 2θ (± 0.2°).

79. The solid form of claim 73, characterized in that The XRPD pattern matched the XRPD pattern depicted in FIG. 23 .

80. The solid form of claim 3, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 5.9, 9.1, 10.7, 12.0, 12.2, 16.7, 17.8, 20.1, and 21.3 degrees 2-theta (± 0.2°) when measured using Cu Ka radiation.

81. The solid form of claim 80, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 5.9, 9.1, 10.7, 12.0, 12.2, 16.7, 17.8, 20.1, and 21.3° 2Θ (± 0.2°).

82. The solid form of claim 81, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 5.9, 9.1, 10.7, 12.0, 12.2, 16.7, 17.8, 20.1, and 21.3° 2Θ (± 0.2°).

83. The solid form of claim 80, characterized in that The XRPD pattern contained peaks at approximately 5.9, 10.7 and 20.1° 2Θ (± 0.2°).

84. The solid form of claim 83, wherein the XRPD pattern further comprises peaks at approximately 12.0 and 23.1 ° 2θ (± 0.2°).

85. The solid form of claim 84, wherein the XRPD pattern further comprises peaks at approximately 9.1 and 16.7° 2θ (± 0.2°).

86. The solid form of claim 80, characterized in that The XRPD pattern matched the XRPD pattern depicted in FIG. 25 .

87. The solid form of claim 3, characterized in that When measured using Cu Ka radiation, the XRPD pattern comprises at least three peaks selected from the group consisting of approximately 5.8, 5.9, 8.7, 9.1, 17.7, 18.8, 19.2, 21.1, and 22.1 ° 2Θ (± 0.2°).

88. The solid form of claim 87, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 5.8, 5.9, 8.7, 9.1, 17.7, 18.8, 19.2, 21.1, and 22.1 ° 2Θ (± 0.2°).

89. The solid form of claim 88, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 5.8, 5.9, 8.7, 9.1, 17.7, 18.8, 19.2, 21.1, and 22.1 ° 2Θ (± 0.2°).

90. The solid form of claim 87, characterized in that The XRPD pattern contained peaks at approximately 5.8, 19.2 and 22.1° 2Θ (± 0.2°).

91. The solid form of claim 90, wherein the XRPD pattern further comprises peaks at approximately 5.9 and 17.7° 2θ (± 0.2°).

92. The solid form of claim 91, wherein the XRPD pattern further comprises peaks at approximately 8.7 and 18.8° 2θ (± 0.2°).

93. The solid form of claim 87, characterized in that The XRPD pattern matched the XRPD pattern depicted in FIG. 27 .

94. The solid form of claim 3, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 5.9, 8.9, 9.2, 10.4, 11.9, 17.2, 17.8, 19.2, and 21.4 ° 2Θ (± 0.2°) when measured using Cu Ka radiation.

95. The solid form of claim 94, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 5.9, 8.9, 9.2, 10.4, 11.9, 17.2, 17.8, 19.2, and 21.4 ° 2Θ (± 0.2°).

96. The solid form of claim 95, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 5.9, 8.9, 9.2, 10.4, 11.9, 17.2, 17.8, 19.2, and 21.4 ° 2Θ (± 0.2°).

97. The solid form of claim 94, characterized in that The XRPD pattern contained peaks at approximately 5.9, 9.2 and 19.2° 2Θ (± 0.2°).

98. The solid form of claim 97, wherein the XRPD pattern further comprises peaks at approximately 11.9 and 17.2° 2θ (± 0.2°).

99. The solid form of claim 98, wherein the XRPD pattern further comprises peaks at approximately 10.4 and 21.4° 2θ (± 0.2°).

100. The solid form of claim 94, characterized in that The XRPD pattern matched the XRPD pattern depicted in Figure 29.

101. The solid form of claim 3, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 6.7, 6.8, 9.7, 12.5, 16.9, 17.1, 18.9, 21.2, and 22.2° 2Θ (±0.2°) when measured using Cu Ka radiation.

102. The solid form of claim 101, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 6.7, 6.8, 9.7, 12.5, 16.9, 17.1, 18.9, 21.2, and 22.2° 2Θ (± 0.2°).

103. The solid form of claim 102, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 6.7, 6.8, 9.7, 12.5, 16.9, 17.1, 18.9, 21.2, and 22.2° 2Θ (± 0.2°).

104. The solid form of claim 101, characterized in that The XRPD pattern contained peaks at approximately 6.7, 16.9 and 18.9° 2Θ (± 0.2°).

105. The solid form of claim 104, wherein the XRPD pattern further comprises peaks at approximately 6.8 and 22.2° 2θ (± 0.2°).

106. The solid form of claim 105, wherein the XRPD pattern further comprises peaks at approximately 9.7 and 21.2° 2θ (± 0.2°).

107. The solid form of claim 101, characterized in that The XRPD pattern matched the XRPD pattern depicted in Figure 31.

108. The solid form of claim 3, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 6.7, 7.1, 10.0, 10.6, 18.8, 20.0, 20.5, 22.0 and 22.8 degrees 2Θ (± 0.2°) when measured using Cu Ka radiation.

109. The solid form of claim 108, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 6.7, 7.1, 10.0, 10.6, 18.8, 20.0, 20.5, 22.0, and 22.8 ° 2Θ (± 0.2°).

110. The solid form of claim 109, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 6.7, 7.1, 10.0, 10.6, 18.8, 20.0, 20.5, 22.0, and 22.8° 2Θ (± 0.2°).

111. The solid form of claim 108, characterized in that The XRPD pattern contained peaks at approximately 6.7, 22.0 and 22.8° 2Θ (± 0.2°).

112. The solid form of claim 111, wherein the XRPD pattern further comprises peaks at approximately 18.8 and 20.5° 2θ (± 0.2°).

113. The solid form of claim 112, wherein the XRPD pattern further comprises peaks at approximately 10.6 and 20.0° 2θ (± 0.2°).

114. The solid form of claim 108, characterized in that The XRPD pattern matched the XRPD pattern depicted in Figure 33.

115. The solid form of claim 1, comprising the hydrochloric acid, methanesulfonic acid, benzenesulfonic acid, maleic acid, phosphoric acid, or citrate salt of a compound of formula (I).

116. The solid form of any one of claims 1 to 115, which is substantially pure.

117. The solid form of any one of claims 1 to 115, having greater than about 95% by weight chemical purity.

118. The solid form of any one of claims 1 to 115, having greater than about 98% chemical purity by weight.

119. The solid form of any one of claims 1 to 115, having greater than about 99% chemical purity by weight.

120. The solid form of any one of claims 1 to 115, having greater than about 98% enantiomeric purity.

121. The solid form of any one of claims 1 to 115, having greater than about 99% enantiomeric purity.

122. The solid form of any one of claims 1 to 115, having greater than about 99.5% enantiomeric purity.

123. A hydrochloride, methanesulfonate (mesylate), benzenesulfonate, maleate, phosphate, citrate, L-tartrate, fumarate, toluenesulfonate (toluenesulfonate) or salicylate salt of a compound of formula (I):

124. A hydrochloride, methanesulfonate (mesylate), maleate, phosphate, citrate, L-tartrate, fumarate, toluenesulfonic acid (tosylate) or salicylate salt of a compound of formula (I):

125. A solid form comprising a hydrochloride, methanesulfonate (mesylate), benzenesulfonate, maleate, phosphate, citrate, L-tartrate, fumarate, toluenesulfonic acid (tosylate), or salicylate salt of a compound of formula (I):

126. A solid form comprising a hydrochloride, methanesulfonate (mesylate), maleate, phosphate, citrate, L-tartrate, fumarate, toluenesulfonic acid (tosylate), or salicylate salt of a compound of formula (I):

127. The solid form of claim 125 or claim 126, which is crystalline.

128. The solid form of any one of claims 125 to 127, comprising a salicylate salt of a compound of formula (I).

129. The solid form of claim 128, characterized in that The XRPD pattern contained peaks at approximately 9.7, 11.7 and 14.7° 2Θ (± 0.2°).

130. The solid form of claim 129, wherein the XRPD pattern further comprises peaks at approximately 6.5 and 18.8° 2θ (± 0.2°).

131. The solid form of claim 130, wherein the XRPD pattern further comprises peaks at approximately 8.5 and 17.7° 2θ (± 0.2°).

132. The solid form of any one of claims 125 to 127, comprising a maleate salt of a compound of formula (I).

133. The solid form of claim 132, characterized in that The XRPD pattern contained peaks at approximately 6.0, 13.8 and 21.3° 2Θ (± 0.2°).

134. The solid form of claim 133, wherein the XRPD pattern further comprises peaks at approximately 16.0 and 17.4° 2θ (± 0.2°).

135. The solid form of claim 134, wherein the XRPD pattern further comprises peaks at approximately 18.2 and 22.9° 2θ (± 0.2°).

136. A pharmaceutical composition comprising a solid form as claimed in any one of claims 1 to 122 or 125 to 135 or a salt as claimed in claim 123 or claim 124 and a pharmaceutically acceptable excipient.

137. A method of treating cancer comprising administering a therapeutically effective amount of a solid form as described in any one of claims 1 to 122 or 125 to 135, or a salt as described in claim 123 or claim 124, or a pharmaceutical composition as described in claim 136 to a subject in need thereof.

138. A method for preparing Form 2 of a compound of formula (I): The method comprises (i) dissolving the compound of formula (I) in a solvent; (ii) adding an anti-solvent; and (ii) recovering said Form 2.

139. The method of claim 138, wherein the solvent is ethyl acetate.

140. The method of claim 138, wherein the solvent is ethanol.

141. The process of any one of claims 138 to 140, wherein the anti-solvent is heptane.

142. A salt of a compound of formula (II):

143. A benzenesulfonic acid, ethanedisulfonic acid, citric acid, fumaric acid, hydrochloric acid, L-malic acid, maleic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, sulfuric acid, succinic acid, L-tartaric acid, phosphoric acid, toluenesulfonic acid, oxalic acid, camphorsulfonic acid, ethanesulfonic acid, 2-naphthalenesulfonic acid, 2-hydroxyethanesulfonic acid, trifluoroacetic acid or hydrobromide salt of a compound of formula (II):

144. A methanesulfonic acid (mesylate), toluenesulfonic acid (toluenesulfonate), camphorsulfonic acid (camphorsulfonate), ethanesulfonic acid (ethanesulfonate), benzenesulfonic acid (benzenesulfonate), 2-naphthalenesulfonic acid (2-naphthalenesulfonate) or sulfuric acid (sulfate) salt of a compound of formula (II):

145. A solid form comprising a salt of a compound of formula (II):

146. A solid form comprising a benzenesulfonic acid, ethanedisulfonic acid, citric acid, fumaric acid, hydrochloric acid, L-malic acid, maleic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, sulfuric acid, succinic acid, L-tartaric acid, phosphoric acid, toluenesulfonic acid, oxalic acid, camphorsulfonic acid, ethanesulfonic acid, 2-naphthalenesulfonic acid, 2-hydroxyethanesulfonic acid, trifluoroacetic acid or hydrobromide salt of a compound of formula (II):

147. A solid form comprising a methanesulfonic acid (mesylate), toluenesulfonic acid (toluenesulfonate), camphorsulfonic acid (camphorsulfonate), ethanesulfonic acid (ethanesulfonate), benzenesulfonic acid (benzenesulfonate), 2-naphthalenesulfonic acid (2-naphthalenesulfonate), or sulfuric acid (sulfate) salt of a compound of formula (II):

148. The solid form of any one of claims 145 to 147, which is crystalline.

149. The solid form of any one of claims 145 to 148, comprising a camphorsulfonic acid (camsylate) salt of a compound of formula (II).

150. The solid form of claim 149, characterized in that The XRPD pattern comprises at least three peaks selected from the group consisting of approximately 6.7, 8.7, 10.1, 11.0, 13.3, 16.0, 17.4, 18.0, 18.8, 20.2, 20.8, 22.5, 24.8 and 25.7 ° 2Θ (± 0.2°) when measured using Cu Ka radiation.

151. The solid form of claim 150, characterized in that The XRPD pattern comprises at least four peaks selected from the group consisting of approximately 6.7, 8.7, 10.1, 11.0, 13.3, 16.0, 17.4, 18.0, 18.8, 20.2, 20.8, 22.5, 24.8, and 25.7 ° 2Θ (± 0.2°).

152. The solid form of claim 151, characterized in that The XRPD pattern comprises at least five peaks selected from the group consisting of approximately 6.7, 8.7, 10.1, 11.0, 13.3, 16.0, 17.4, 18.0, 18.8, 20.2, 20.8, 22.5, 24.8, and 25.7 ° 2Θ (± 0.2°).

153. The solid form of claim 150, characterized in that The XRPD pattern contained peaks at approximately 6.7, 13.3 and 20.2° 2Θ (± 0.2°).

154. The solid form of claim 153, wherein the XRPD pattern further comprises peaks at approximately 10.1 and 16.0° 2θ (± 0.2°).

155. The solid form of claim 154, wherein the XRPD pattern further comprises peaks at approximately 8.7 and 18.0° 2θ (± 0.2°).

156. The solid form of claim 150, characterized in that The XRPD pattern matched the XRPD pattern depicted in Figure 38.

157. The solid form of any one of claims 150 to 156, which exhibits an endothermic event as characterized by DSC, wherein the onset temperature is about 201°C (±2°) and / or the peak temperature is about 204°C (±2°).

158. A solid form as described in any one of claims 145 to 148, comprising the methanesulfonic acid (mesylate) salt of a compound of formula (II).

159. The solid form of claim 158, characterized in that The XRPD pattern contained peaks at approximately 15.9, 17.5 and 19.5° 2Θ (± 0.2°).

160. The solid form of claim 159, wherein the XRPD pattern further comprises peaks at approximately 10.6 and 11.7° 2θ (± 0.2°).

161. The solid form of claim 160, wherein the XRPD pattern further comprises peaks at approximately 21.5 and 22.7° 2θ (± 0.2°).

162. The solid form of any one of claims 145 to 148, comprising the ethanesulfonic acid (ethanesulfonate) salt of a compound of formula (II).

163. The solid form of claim 162, characterized in that The XRPD pattern contained peaks at approximately 11.6, 15.7 and 19.2° 2Θ (± 0.2°).

164. The solid form of claim 163, wherein the XRPD pattern further comprises peaks at approximately 10.5 and 17.3° 2θ (± 0.2°).

165. The solid form of claim 164, wherein the XRPD pattern further comprises peaks at approximately 14.4 and 15.1 ° 2θ (± 0.2°).

166. A solid form as described in any one of claims 145 to 148, comprising a sulfuric acid (sulfate) salt of a compound of formula (II).

167. The solid form of claim 166, characterized in that The XRPD pattern contained peaks at approximately 13.1, 17.2 and 18.3° 2Θ (± 0.2°).

168. The solid form of claim 167, wherein the XRPD pattern further comprises peaks at approximately 10.8 and 11.4° 2θ (± 0.2°).

169. The solid form of claim 168, wherein the XRPD pattern further comprises peaks at approximately 15.1 and 19.9 ° 2θ (± 0.2°).

170. The solid form of any one of claims 145 to 148, comprising a toluenesulfonic acid (tosylate) salt of a compound of formula (II).

171. The solid form of claim 170, characterized in that The XRPD pattern contained peaks at approximately 12.2, 14.2 and 17.6° 2Θ (± 0.2°).

172. The solid form of any one of claims 145 to 148, comprising the benzenesulfonic acid (benzenesulfonate) salt of a compound of formula (II).

173. The solid form of claim 172, characterized in that The XRPD pattern contained peaks at approximately 6.9, 10.9 and 16.8° 2Θ (± 0.2°).

174. The solid form of claim 172, characterized in that The XRPD pattern contained peaks at approximately 11.0, 12.4 and 13.4° 2Θ (± 0.2°).

175. The solid form of any one of claims 145 to 148, comprising the 2-naphthalenesulfonic acid (2-naphthalenesulfonate) salt of a compound of formula (II).

176. The solid form of claim 175, characterized in that The XRPD pattern contained peaks at approximately 6.8, 7.9 and 9.6° 2Θ (± 0.2°).

177. A method for preparing a compound of formula (II): or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof, the method comprising: (Step 2.0) Compound (III): or a stereoisomer or a mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof is reacted with a brominating agent.

178. A method for preparing a compound of formula (II): or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof, the method comprising: (Step 2a.1) Compound (XXIX): or its stereoisomer or stereoisomer mixture or its pharmaceutically acceptable salt and a compound of formula (XXX): or a pharmaceutically acceptable salt thereof.

179. The method of claim 177 or claim 178, further comprising: (Step 1.0) Cyclizing the compound of formula (II) or its stereoisomer or stereoisomer mixture or a pharmaceutically acceptable salt thereof to provide a compound of formula (I): or a stereoisomer or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof.

180. The process of claim 179, wherein the free base form of the compound of formula (II) is cyclized in step 1.

0.

181. The process of claim 179, wherein the salt of the compound of formula (II) is cyclized in step 1.

0.

182. The process of claim 179, wherein the camphorsulfonate salt of the compound of formula (II) is cyclized in step 1.

0.

183. The method of claim 182, wherein step 1.0 comprises: (Step 1.1) converting the camphorsulfonate of the compound of formula (II) into the free base of the compound under alkaline conditions; and (Step 1.2) Cyclizing the free base of the compound.

184. The process of any one of claims 179 to 183, wherein step 1.0 occurs in the presence of a base.

185. The process of claim 184, wherein the base is potassium pivalate.

186. The process of any one of claims 179 to 185, wherein step 1.0 occurs in the presence of a catalyst precursor.

187. The method of claim 186, wherein the catalyst precursor comprises Pd(OAc)2.

188. The method of claim 186 or 187, wherein the catalyst precursor comprises a cataCXium A ligand.

189. The process of any one of claims 179 to 188, wherein step 1.0 occurs in tert-amyl alcohol (tAmOH) solvent.

190. The process of any one of claims 177 or 179 to 189, wherein in step 2.0, the brominating agent is N-bromosuccinimide (NBS).

191. The process of any one of claims 177 or 179 to 190, wherein step 2.0 occurs in tetrahydrofuran (THF), ethyl acetate (EtOAc) or isopropyl acetate solvent.

192. The method of any one of claims 177 or 179 to 191, wherein step 2.0 further comprises converting the free base form of the compound of formula (II) into a salt of the compound of formula (II).

193. The process of claim 192, wherein step 2.0 comprises reacting the free base form of the compound of formula (II) with camphorsulfonic acid to provide a camphorsulfonic acid salt of the compound of formula (II).

194. The method of any one of claims 177 or 179 to 193, wherein the compound of formula (III) or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof is prepared by a process comprising: (Step 3.0) Reducing the compound of formula (IV): or a stereoisomer or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof.

195. The process of claim 194, wherein step 3.0 occurs in the presence of a catalyst.

196. The process of claim 195, wherein the catalyst is Pt / C or Pt-V / C.

197. The process of any one of claims 194 to 196, wherein step 3.0 occurs in the presence of a hydrogen source.

198. The method of claim 197, wherein the hydrogen source is triethylammonium formate (HCOOH.Et3N).

199. The method of claim 197, wherein the hydrogen source is H2.

200. The process of any one of claims 194 to 199, wherein step 3.0 occurs in ethanol (EtOH) or EtOAc solvent.

201. The method of any one of claims 194 to 200, wherein the compound of formula (IV) or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof is prepared by a method comprising: (Step 4.0) Compound (V): or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof is reacted with a compound of formula (VI):

202. The method of claim 201, wherein step 4.0 occurs in the presence of a base.

203. The method of claim 202, wherein the base is potassium tert-butoxide (K t Bu).

204. The process of any one of claims 201 to 203, wherein step 4.0 occurs in toluene solvent.

205. The process of any one of claims 201 to 204, wherein step 4.0 further comprises crystallizing the compound of formula (IV) from a mixed solvent of isopropanol and methylcyclohexane (MCH).

206. The method of any one of claims 201 to 205, wherein the compound of formula (V) or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof is prepared by a process comprising: (Step 5.0) Compound (VII): or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof and a compound of formula (VIII): or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof.

207. The process of claim 206, wherein step 5.0 occurs in the presence of a catalyst.

208. The method of claim 207, wherein the catalyst is Pd(Amphos)Cl2.

209. The process of any one of claims 206 to 208, wherein step 5.0 occurs in the presence of a base.

210. The process of claim 209, wherein the base is potassium carbonate (K2CO3) or potassium phosphate (K3PO4).

211. The process of any one of claims 206 to 210, wherein step 5.0 occurs in a solvent mixture comprising dimethylformamide (DMF) and water, a solvent mixture comprising toluene and water, or a solvent mixture comprising MTBE and water.

212. The process of any one of claims 178 to 189, wherein step 2a.1 occurs in the presence of a diazene and a phosphine.

213. The method of claim 212, wherein in step 2a.1, the diazene is an azodicarbonamide compound or an azodicarbonate ester.

214. The method of claim 213, wherein the diazene is TMAD.

215. The process of any one of claims 212 to 214, wherein in step 2a.1, the phosphine is a trialkylphosphine.

216. The method of claim 215, wherein the phosphine is nBu3P.

217. The process of any one of claims 178 to 189 or 212 to 216, wherein step 2a.1 occurs in the presence of a base.

218. The process of claim 217, wherein the base is DBU.

219. The process of any one of claims 178 to 189 or 212 to 218, wherein step 2a.1 occurs in THF or 2-MeTHF solvent.

220. The process of any one of claims 178 to 189 or 212 to 219, wherein step 2a.1 further comprises converting the free base form of the compound of formula (II) into a salt of the compound of formula (II).

221. The process of claim 220, wherein step 2a.1 comprises reacting the free base form of the compound of formula (II) with camphorsulfonic acid to provide a camphorsulfonic acid salt of the compound of formula (II).

222. The method of any one of claims 178 to 189 or 212 to 221, wherein the compound of formula (XXIX) or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof is prepared by a process comprising: (Step 5.1) Compound (VII): or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof and a compound of formula (XXXI): or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof.

223. The process of claim 222, wherein step 5.1 occurs in the presence of a catalyst.

224. The process of claim 223, wherein the catalyst is Pd(Amphos)Cl2.

225. The process of any one of claims 222 to 224, wherein step 5.1 occurs in the presence of a base.

226. The process of claim 225, wherein the base is potassium carbonate (K2CO3) or potassium phosphate (K3PO4).

227. The process of any one of claims 222 to 226, wherein step 5.0 occurs in a solvent mixture comprising dimethylformamide (DMF) and water, a solvent mixture comprising toluene and water, or a solvent mixture comprising MTBE and water.

228. The method of any one of claims 179 to 227, wherein the compound of formula (I) or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof is prepared by a process comprising: (Step 1.0) cyclizing the compound of formula (II) or its stereoisomer or mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, to provide the compound of formula (I) or its stereoisomer or mixture of stereoisomers, or a pharmaceutically acceptable salt thereof; The compound of formula (II) is prepared by the following method: (Step 2.0) reacting the compound of formula (III) or its stereoisomer or stereoisomer mixture or a pharmaceutically acceptable salt thereof with a brominating agent; The compound of formula (III) is prepared by the following method: (Step 3.0) reducing the compound of formula (IV) or its stereoisomer or stereoisomer mixture or a pharmaceutically acceptable salt thereof; Wherein the compound of formula (IV) is prepared by a method comprising the following: (Step 4.0) reacting a compound of formula (V) or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof with a compound of formula (VI); and wherein the compound of formula (V) is prepared by a method comprising: (Step 5.0) The compound of formula (VII) or its stereoisomer or mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, is reacted with the compound of formula (VIII) or its stereoisomer or mixture of stereoisomers, or a pharmaceutically acceptable salt thereof.

229. The method of any one of claims 179 to 227, wherein the compound of formula (I) or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof is prepared by a process comprising: (Step 1.0) cyclizing a compound of formula (II) or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof to provide a compound of formula (I) or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof; wherein the compound of formula (II) is prepared by a process comprising: (Step 2a.1) reacting a compound of formula (XXIX) or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof with a compound of formula (XXX) or a pharmaceutically acceptable salt thereof in the presence of a diazene and a phosphine; wherein the compound of formula (XXIX) is prepared by a process comprising: (Step 5.1) The compound of formula (VII) or its stereoisomer or mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, is reacted with the compound of formula (XXXI) or its stereoisomer or mixture of stereoisomers, or a pharmaceutically acceptable salt thereof.

230. A method for preparing a compound of formula (I): or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof, the method comprising: (Step 1.0) Compound (II): or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof, to provide a compound of formula (I) or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof, Wherein step 1.0 occurs in the presence of a base, and wherein the base is potassium pivalate.

231. The method of any one of claims 179 to 230, further comprising the step of providing the compound of formula (I) or its stereoisomer or mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, in solid form.

232. The method of claim 231, wherein the solid form is a crystalline form.

233. A solid form of a compound of formula (I) or a stereoisomer or mixture of stereoisomers or a pharmaceutically acceptable salt thereof, prepared by a process as claimed in any one of claims 179 to 232.

234. A solid form of a compound of formula (I) or a stereoisomer or mixture of stereoisomers or a pharmaceutically acceptable salt thereof as described in claim 233, wherein the solid form is a crystalline form.

235. A compound of formula (I): It meets one or more of the following purity standards: (i) has less than about 1%, about 0.5%, about 0.1% or about 0.05% impurities; (ii) has a chiral purity of greater than about 99%, about 99.5% or 99.9%, or about 100% chiral purity; (iii) has a water content of less than about 1%, about 0.5% or about 0.1%; and (iv) has less than about 100 ppm, about 50 ppm, about 20 ppm or about 10 ppm palladium.

236. The compound of claim 235, which (i) has less than about 0.05% impurities; (ii) has about 100% chiral purity; (iii) has less than about 0.1% water content; and (iv) has less than about 10 ppm palladium.

237. A compound of formula (III) or (IV): or a stereoisomer or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof.

238. A compound of formula (SP-1), (SP-2), (SP-3), (SP-4), (SP-5), (SP-6), (SP-7) or (SP-8), or a stereoisomer or mixture of stereoisomers or a pharmaceutically acceptable salt thereof.

239. A pharmaceutical composition comprising Compound 1: or its stereoisomers or stereoisomer mixtures or pharmaceutically acceptable salts thereof, diluents, disintegrants, glidants, binders and lubricants.

240. The pharmaceutical composition of claim 239, wherein Compound 1 or a stereoisomer or mixture of stereoisomers thereof or a pharmaceutically acceptable salt thereof is a free base of Compound 1.

241. The pharmaceutical composition of claim 240, wherein the free base of Compound 1 is a crystalline free base of Compound 1.

242. The pharmaceutical composition of claim 240, wherein the free base of Compound 1 is characterized by an XRPD pattern comprising peaks at approximately 12.4, 18.9, and 21.1 ° 2θ (± 0.2°).

243. The pharmaceutical composition of claims 239 to 242, wherein the amount of Compound 1 or its stereoisomer or mixture of stereoisomers or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is from about 1% to about 30% w / w.

244. The pharmaceutical composition of claim 243, wherein the amount of Compound 1 or its stereoisomer or mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, in the pharmaceutical composition is from about 5% to about 20% w / w.

245. The pharmaceutical composition of any one of claims 239 to 244, wherein the diluent is microcrystalline cellulose.

246. The pharmaceutical composition of any one of claims 239 to 245, wherein the amount of the diluent in the pharmaceutical composition is about 50% to about 95% w / w.

247. The pharmaceutical composition of claim 246, wherein the amount of the diluent in the pharmaceutical composition is about 68% to about 83.5% w / w.

248. The pharmaceutical composition of any one of claims 239 to 247, wherein the disintegrant is croscarmellose sodium.

249. The pharmaceutical composition of any one of claims 239 to 248, wherein the amount of the disintegrant in the pharmaceutical composition is about 1% to about 10% w / w.

250. The pharmaceutical composition of claim 249, wherein the amount of the disintegrant in the pharmaceutical composition is about 5% w / w.

251. The pharmaceutical composition of any one of claims 239 to 250, wherein the glidant is colloidal silicon dioxide.

252. The pharmaceutical composition of any one of claims 239 to 251, wherein the amount of the glidant in the pharmaceutical composition is about 1% to about 5% w / w.

253. The pharmaceutical composition of claim 252, wherein the amount of the glidant in the pharmaceutical composition is about 2.5% w / w.

254. A pharmaceutical composition as described in any one of claims 239 to 253, wherein the binder is hydroxypropyl cellulose (HPC).

255. The pharmaceutical composition of any one of claims 239 to 254, wherein the amount of the binder in the pharmaceutical composition is about 1% to about 5% w / w.

256. The pharmaceutical composition of claim 255, wherein the amount of the binder in the pharmaceutical composition is about 2.5% w / w.

257. The pharmaceutical composition of any one of claims 239 to 256, wherein the lubricant is magnesium stearate.

258. The pharmaceutical composition of any one of claims 239 to 257, wherein the amount of the lubricant in the pharmaceutical composition is about 0.5% to about 4% w / w.

259. The pharmaceutical composition of claim 258, wherein the amount of the lubricant in the pharmaceutical composition is about 1.5% to about 2% w / w.

260. The pharmaceutical composition of claim 239, comprising: Compound 1 or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof, in an amount of about 2.5% to about 7.5% w / w of the total weight of the pharmaceutical composition; a diluent in an amount of about 75% to about 90% w / w of the total weight of the pharmaceutical composition; a disintegrant in an amount of about 2.5% to about 7.5% w / w of the total weight of the pharmaceutical composition; a glidant in an amount of about 1% to about 4% w / w of the total weight of the pharmaceutical composition; a binder in an amount of about 1% to about 4% w / w of the total weight of the pharmaceutical composition; and A lubricant in an amount of about 1% to about 2% w / w of the total weight of the pharmaceutical composition.

261. The pharmaceutical composition of claim 239, comprising: Compound 1, in an amount of about 5% w / w of the total weight of the pharmaceutical composition; Microcrystalline cellulose in an amount of about 83.5% w / w of the total weight of the pharmaceutical composition; Cross-linked carboxymethylcellulose sodium in an amount of about 5% w / w of the total weight of the pharmaceutical composition; colloidal silicon dioxide in an amount of about 2.5% w / w of the total weight of the pharmaceutical composition; Hydroxypropyl cellulose in an amount of about 2.5% w / w of the total weight of the pharmaceutical composition; and Magnesium stearate in an amount of about 1.5% w / w of the total weight of the pharmaceutical composition.

262. The pharmaceutical composition of claim 260 or 261, having a total weight of about 100 mg.

263. The pharmaceutical composition of claim 239, comprising: Compound 1 or a stereoisomer or a mixture of stereoisomers or a pharmaceutically acceptable salt thereof, in an amount of about 15% to about 25% w / w of the total weight of the pharmaceutical composition; a diluent in an amount of about 60% to about 75% w / w of the total weight of the pharmaceutical composition; a disintegrant in an amount of about 2.5% to about 7.5% w / w of the total weight of the pharmaceutical composition; a glidant in an amount of about 1% to about 4% w / w of the total weight of the pharmaceutical composition; a binder in an amount of about 1% to about 4% w / w of the total weight of the pharmaceutical composition; and A lubricant in an amount of about 1% to about 3% w / w of the total weight of the pharmaceutical composition.

264. The pharmaceutical composition of claim 239, comprising: Compound 1, in an amount of about 20% w / w of the total weight of the pharmaceutical composition; Microcrystalline cellulose in an amount of about 68% w / w of the total weight of the pharmaceutical composition; Cross-linked carboxymethylcellulose sodium in an amount of about 5% w / w of the total weight of the pharmaceutical composition; colloidal silicon dioxide in an amount of about 2.5% w / w of the total weight of the pharmaceutical composition; Hydroxypropyl cellulose in an amount of about 2.5% w / w of the total weight of the pharmaceutical composition; and Magnesium stearate in an amount of about 2% w / w of the total weight of the pharmaceutical composition.

265. The pharmaceutical composition of claim 263 or 264, having a total weight of about 125, about 250, about 375, about 500, about 625, or about 750 mg.

266. The pharmaceutical composition of any one of claims 239 to 265, which is in oral dosage form.

267. The pharmaceutical composition of claim 266, wherein the oral dosage form is a tablet.

268. A method of treating cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition as described in any one of claims 239 to 267 to a subject in need thereof.

Citation Information

Patent Citations

  • Inhibition of irritating side effects associated with use of a topical ophthalmic medication

    US20050004074A1

  • Compositions for delivery of therapeutics into the eyes and methods for making and using same

    US20050031697A1

  • Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions

    US20050059744A1

  • Ophthalmic formulations including selective alpha 1 antagonists

    US20050080056A1

  • Membrane Oxygenator with Gas Exchange Fiber Lumen Access Based on Fiber Effective Length

    US20210030940A1

Cited By

  • Large heterocyclic ALK inhibitor and pharmaceutical use thereof

    WO2026219300A1